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Abstract 
Prion diseases are fatal neurodegenerative disorders of both humans and other 
animals. The cause of prion-mediated neurodegeneration by conversion of the normal 
cellular  prion  protein  (PrP
C)  to  the  disease-related  isoform  (PrP
Sc)  remains  unknown. 
Increasing evidence suggests a role for the ubiquitin proteasome system (UPS) in prion 
disease. PrP
C and PrP
Sc isoforms have been shown to accumulate in cells after proteasome 
inhibition, leading to increased cell death. The aim of this thesis was to investigate the role 
of cellular degradation systems, such as the UPS and autophagy, in prion-mediated cell 
death.  
In UPS-mediated degradation poly-ubiquitinated substrates get degraded by the 
26S proteasome, which comprises a 20S hydrolytic core and a 19S regulatory particle. 
Using a variety of biochemical methods, I report that abnormal -sheet-rich PrP isoforms 
inhibit the catalytic activity of the 26S proteasome, by specifically inhibiting its 1 and 5 
proteolytic subunits. Pre-incubating these PrP isoforms with an antibody raised against 
aggregation  intermediates  abrogates  the  inhibitory  effect  seen,  consistent  with  an 
‘oligomeric’  inhibitory  species.  Using  open-gated  yeast  20S  proteasome  mutants  and 
conserved 19S ATPase C-terminal peptides containing an essential motif for gate-opening, 
this thesis describes findings supporting an inhibitory effect on proteasomal gating rather 
than a direct inhibitory effect on the active sites of the 20S proteasome. These C-terminal 
peptides open the gate in a ‘key in a lock’ fashion by docking into inter-subunit pockets in 
the -ring of the 20S proteasome. In this system, the inhibitory effect of the -sheet-rich 
PrP isoforms may be due to abnormal PrP competing with the C-terminal peptides for the 
inter-subunit pockets, thereby preventing gate-opening.  
Proteins  are  also  degraded by  autophagy,  a  degradation  pathway  that  has  not 
been adequately characterised in prion disease. This thesis investigates potential roles 
autophagy  may  play  in prion disease. Data presented  here  suggest  that  a)  prions  are 
cleared by autophagy, b) prion-infected cells have higher numbers of autophagosomes 
compared to uninfected controls, c) induction of autophagy ameliorates cell death after 6 | P a g e  
 
proteasome  inhibition,  indicating  cross-talk  between  the  two  protein-degradation 
pathways, and d) it is up-regulated in vivo at end-stage prion disease. 
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1 INTRODUCTION 
Prion  diseases,  also  known  as  transmissible  spongiform  encephalopathies  (TSEs), 
comprise a family of fatal neurodegenerative disorders. They affect both humans (i.e., 
Creutzfeldt-Jakob  disease;  CJD)  and  other  animals  (i.e.,  bovine  spongiform 
encephalopathy; BSE), and can be transmitted within or between mammalian species by 
inoculation with, or dietary exposure to infected tissues. Although they are relatively rare 
- it is estimated that they affect one person per million worldwide annually - they remain 
in the spotlight due to the unique biology of the transmissible agent. According to the 
protein-only hypothesis, the main pathogenic event in prion disease is associated with a 
conformational re-arrangement of the normal cellular prion protein, PrP
C (C for cellular), 
to an abnormal isoform, PrP
Sc (Sc for scrapie). At the microscopic level, prion diseases 
share  four  principal  neuropathological  features,  specifically  spongiform  vacuolation, 
marked neuronal loss, astrocytic and microglial proliferation, as well as an accumulation of 
the disease-associated isoform of the prion protein in the brain, sometimes accompanied 
by  the  formation  of  amyloid  deposits.  To  date,  the  exact  cause  of  prion-mediated 
neurodegeneration remains unclear and a major gap exists in the understanding of how 
the conversion of PrP
C to PrP
Sc ultimately kills neurones.  
 
 
1.1  Animal prion diseases 
The  first  prion  disease,  scrapie,  was  described  in  the  18
th  century  in  Europe. 
Although it was not shown to be transmissible until 200 years later, it was believed that 
flocks  of  sheep  could  be  infected  by  this  disease.  Descriptions  of  other  animal  prion 
diseases  include  chronic  wasting  disease  of  deer  and  elk,  transmissible  mink 
encephalopathy, BSE in cattle, and feline transmissible encephalopathies. 19 | P a g e  
 
1.1.1  Scrapie 
Scrapie  is  a  naturally-occurring,  common  disease  of  sheep  and  goats,  and  is 
present worldwide. Its name is derived from the predominant clinical symptom, whereby 
the animal will scrape its fleece off due to an itching sensation caused by the disease. 
Symptoms include gait disorders and wool loss; death usually occurs between 6 weeks to 
6 months after symptom onset. At present, its routes of transmission remain unclear; 
however, a hereditary link has been suspected because of a strong genetic element (Parry, 
1979).  In  the  19
th  century,  it  was  demonstrated  that  neuronal  vacuolation  was  a 
characteristic neuropathological feature of the disease, but initial transmissibility studies 
of scrapie infection were negative. The failure to recognise the long incubation times of 
the disease was overcome by the inoculation of scrapie into goats  (Cuillé and Chelle, 
1936). The transmissibility of the infectious agent was further confirmed after scrapie was 
accidentally transmitted into sheep when a Scottish herd was inoculated against a virus 
with a brain, spleen and spinal cord extract from an infected animal (Gordon, 1946). Since 
then, scrapie has effectively been transmitted experimentally into other species including 
laboratory mice (Chandler, 1961), demonstrating that it can cross the ‘species barrier‘ 
(Section 1.4.6). Scrapie has never been shown to pose a threat to human health (Brown 
and Bradley, 1998). 
 
1.1.2  Chronic wasting disease 
Chronic wasting disease (CWD) is a TSE affecting mule deer and elk, predominantly 
in the USA (Sigurdson and Aguzzi, 2007). It is the only TSE of free-ranging wildlife, affecting 
white deer, white-tailed deer, Rocky Mountain elk (Williams and Miller, 2002) and moose 
(Williams,  2005).  Symptoms  include  weight  loss  and  excessive  drinking,  and  disease 
duration ranges from days  to  months.  Experimental evidence  has  confirmed  neuronal 
vacuolation (Williams and Young, 1980), the accumulation of aggregated prion protein 
(Spraker et al., 2002) and prion infectivity in the brain (Browning et al., 2004). Moreover, 
prion protein aggregates are not only found in the central nervous system (CNS), but also 
in  lymphoid  tissues,  skeletal  muscles  and  other  organs.  The  origin  and  routes  of 20 | P a g e  
 
transmission are unclear (Miller and Williams, 2003; Mathiason et al., 2006). As yet, there 
is no evidence for CWD transmission to humans.  
 
1.1.3  Transmissible mink encephalopathy 
Transmissible mink encephalopathy (TME) has been described in captive animals 
mainly  in  the  USA  and  is  believed  to  be  an  acquired  prion  disease  (Marsh,  1992). 
Symptoms include aggression and loss of muscle coordination; following symptom onset 
animals die within 6 weeks. TME epidemics have occurred infrequently among ranched 
mink and it is thought they originated from scrapie-infected sheep or TSE-infected cattle 
in  feeds  (Marsh  et  al.,  1991).  TME  has  been  experimentally  transmitted  to  hamsters 
(Kimberlin and Marsh, 1975) and although not thought to be related to BSE in cattle 
(Section 1.1.4), a study by Baron and colleagues noted similarities between TME and BSE 
in a mouse model (Baron et al., 2007). 
 
1.1.4  Bovine spongiform encephalopathy 
BSE is a fatal neurodegenerative disorder in cattle. ‘Mad cow disease’, as it is also 
colloquially known, first appeared in the UK in the mid 1980s and evolved into a major 
epidemic (Wilesmith et al., 1988; Anderson et al., 1996). Since then, BSE cases have been 
recognised  in  many  European  countries,  the  US,  Canada,  Israel  and  Japan 
(www.BSEreview.org.uk). Epidemiological studies identified meat-and-bone-meal (MBM), 
a high protein supplement, which originates from tissue waste from various species, as 
the  linking  feature  in  all  UK  farms  with  BSE-positive  cattle.  Clinical  symptoms  include 
changes in temperament and movement disorders. Since 1986, approximately 180,000 
cattle have developed the disease, with a one to three million thought to be infected prior 
to slaughter for human consumption (Anderson et al., 1996; Donnelly et al., 2002).  
Two  hypotheses  have  been  put  forward  regarding  the  origin  of  BSE.  First, 
neuropathological findings in BSE are similar to those seen in scrapie, so BSE may have 
arisen from either a scrapie-like agent from sheep or from cattle infected with a scrapie-21 | P a g e  
 
like  agent  (Wilesmith  et  al.,  1988;  Wilesmith  et  al.,  1991;  Smith  and  Bradley,  2003). 
However,  the  BSE  strain  is  molecularly  and  biologically  different to  the  strain  causing 
scrapie,  arguing  against  this  hypothesis  (Bruce  et  al.,  1994).  Alternatively,  perhaps  a 
sporadic case of BSE arose by chance and was incorporated in MBM, which could have 
then seeded the epidemic (Weissmann and Aguzzi, 1997). Control measures, which were 
applied in 1988, but that were not always properly enforced, resulted in a steady decline 
of BSE in the UK. Nonetheless, BSE cases were still identified after the 1988 ban, and 
following the emergence of variant CJD in 1996 (Will et al., 1996; Collinge and Rossor, 
1996), the ban was re-enforced. The route of BSE transmission is thought to be oral. 
European countries enforced the 1996 UK ban in 2001 and due to the long incubation 
time of the disease (usually 5 years), further cases are likely to be identified.   
 
1.1.5  Other animal prion diseases 
In addition to the animal TSEs described above, prion diseases with links to BSE have 
been described in other species, such as in domestic and captive exotic cats. Feline TSE 
was  first  reported  in  domestic  cats  in the  UK  (Leggett  et  al.,  1990).  Reports of  prion 
disease  have  also  been  described  in  greater  kudu,  tiger,  and  cheetah.  These  TSEs 
appeared during or after the emergence of BSE, and studies have confirmed that some are 
caused by a BSE-like strain (Bruce et al., 1994; Collinge et al., 1996a). 
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1.2  Human prion diseases 
Human prion diseases are rare and fatal disorders, and include CJD, Gerstmann-
Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI) and kuru (Wadsworth and 
Collinge,  2007).  Uniquely,  they  may  arise  spontaneously,  be  genetically  inherited,  or 
acquired via infection, and they all have the potential to be transmissible. Clinical features 
comprise rapidly progressive dementia accompanied by cerebellar ataxia and myoclonus. 
Definitive diagnosis can be made from post-mortem examination of brain tissue showing 
the classical histopathological triad: spongiform change, severe neuronal loss and marked 
astrogliosis;  these  are  sometimes  accompanied  by  PrP
Sc-containing  amyloid  plaque 
deposits. Inherited forms of prion disease support the protein-only hypothesis of prion 
propagation (Section 1.4) and highlight the importance of PrP
C in disease. A polymorphism 
at amino acid residue 129 of the prion protein [which encodes methionine (M) or valine 
(V)] confers genetic susceptibility for development of prion disease. Thirty-eight per cent 
of Europeans are homozygous for M at codon 129, 51% are heterozygous and 11% are 
homozygous for V (Palmer et al., 1991). Methionine homozygotes (codon 129MM) are at a 
higher  risk  of  developing  prion  disease,  which  may  be  explained  by  the  increased 
propensity of PrP to form PrP
Sc-like structures in vitro (Tahiri-Alaoui et al., 2004), whereas 
heterozygosity (codon 129MV) is thought to confer resistance to disease by inhibiting 
homologous PrP protein-protein interactions (Palmer et al., 1991). 
 
1.2.1  Sporadic prion disease 
Sporadic  CJD  (sCJD)  affects  one  per  million  population  per  year  worldwide 
(Caramelli et al., 2006). It is a rapidly progressive multifocal dementia with an age of onset 
between 45-75 years and a mean duration of 5 months (Brown et al., 1984; Collins et al., 
2006). Individuals initially experience insomnia, depression and ill-defined pain sensations, 
as well as manifesting movement disorders. Definitive diagnosis of sCJD is by post-mortem 
or  brain  biopsy.  PrP  amyloid  plaques  are  not  typically  present  in  sCJD,  but  PrP 
immunohistochemistry is nearly always positive (Budka, 2003). sCJD accounts for 85% of 
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history of prion disease and no known exposure to prions. Therefore, although a genetic 
or infectious cause cannot be excluded in all cases, the aetiology of sCJD is uncertain. The 
two main possible causes are either spontaneous somatic PRNP mutation (Brown et al., 
1987; Collinge, 1997; Wadsworth et al., 2006), or spontaneous conversion of PrP
C to PrP
Sc 
as a rare stochastic event (Collinge, 1997). Interestingly, two case-control studies have 
reported prior surgery as a risk factor for sCJD and therefore raise the possibility that sCJD 
may be an acquired illness (Collins et al., 1999; Ward et al., 2002). As aforementioned, 
susceptibility to human prion disease is influenced by a polymorphism at residue 129 of 
human PrP (Mead, 2006), and homozygosity predisposes to sporadic and acquired forms 
of CJD. Moreover, genetic studies have revealed polymorphisms upstream of exon 1 of 
the PRNP gene (Mead et al., 2001) and an 129MV independent polymorphism in the 5’ un-
translated region (UTR) of the PRNP gene (Vollmert et al., 2006), both of which have been 
associated with sCJD.  
 
1.2.2  Inherited prion disease 
Around  15%  of  human  prion  disease  cases  are  associated  with  autosomal 
dominant  mutations  of  the  PRNP  gene  (Masters  et  al.,  1981b;  Windl  et  al.,  1999). 
Inherited  prion  diseases  comprise  GSS,  FFI  and  familial  CJD  (fCJD),  and  confer  strong 
evidence  for  the  protein-only  hypothesis  of  prion  propagation  (Section  1.4).  The  first 
reports of PRNP mutations described insertion and missense mutations in families with 
dominantly inherited neurodegenerative diseases (Owen et al., 1989; Hsiao et al., 1989). 
There  are  three  types  of  PRNP  mutation:  point  mutations  leading  to  amino  acid 
substitutions or premature stop codons, or octapeptide repeat insertions (OPRI). Over 
thirty distinct mutation types have been documented (Mead, 2006) (Figure 1.1) and PRNP 
analysis allows for pre-symptomatic diagnosis of inherited prion disease (Collinge, 2005). 
Clinical symptoms and neuropathology differ depending on the type of mutation involved, 
and occasionally variation occurs even within the same PrP mutation (Chapman et al., 
1993; Barbanti et al., 1996; Wadsworth et al., 2006). The fact that a single PRNP mutation 
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epigenetic factors in prion disease pathogenesis. So far, it is unclear how PRNP mutations 
cause disease. It has been hypothesised that they may favour the tendency of the normal 
prion protein, PrP
C, to form abnormal infectious isoforms (PrP
Sc). Nonetheless, studies 
have reported that pathogenesis in inherited prion diseases may not only be due to a 
decreased thermodynamic stability of mutated PrP
C and indicated that subtle structural 
differences in the mutant proteins may affect inter-molecular signalling in various ways 
(Riek et al., 1998; Swietnicki et al., 1998). Moreover, spontaneous disease without any 
detectable protease-resistant PrP in experimental models with PRNP mutations has been 
described (Muramoto et al., 1997; Hegde et al., 1998). 
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Figure 1.1 The human prion protein and pathogenic mutations
1 
Human PrP comprises two signal peptides (white), an octapeptide repeat region (OPR) (orange), a 
hydrophobic  domain  (HD)  (green),  three  -helices (pink),  one  di-sulphide  bond  (S-S)  between 
cysteine residues 179 and 214, and two potential N-glycosylation sites. Included in this figure are 
point  mutations  and  insertions  found  in  PRNP  in  patients  with  prion  disease.  The  associated 
polymorphisms at codon 129 are indicated in italics for methionine and bold for valine. ** denotes 
a stop codon, which results in truncated PrP. 
                                                      
1 Adapted and reprinted, with permission from Ann. Rev. Neurosci. Aguzzi, A., et al., The Prion’s elusive 
reason for being, Vol 31, pp 439-477, © 2008 by Annual Reviews http://www.annualreviews.org 26 | P a g e  
 
1.2.3  Acquired prion disease 
Kuru 
Kuru was the first known human acquired prion disease, which emerged as a major 
epidemic in the 1950s as a result of endo-cannibalism in the Fore linguistic tribe of the 
Eastern Highlands of Papua New Guinea (Mead et al., 2003). Kuru represents the only 
known  example  of  a  human  prion  disease  epidemic  and  has  provided  much  of  the 
knowledge  we  have  regarding  acquired  human  prion  disease.  Kuru  predominantly 
affected  women  and  children  who  practised  cannibalism  as  a  sign  of  respect  and 
mourning for deceased relatives (Alpers M, 1987). The epidemic is thought to have started 
when an individual with sCJD was consumed at one of these ritual feasts. Thereafter, prion 
recycling is the most likely reason for the extent of the epidemic. Following the ban of 
cannibalism by the Australian government in the late 1950s, there have been no new kuru 
cases  (Lindenbaum,  1979).  Clinically,  kuru  is  a  cerebellar  syndrome  with  an  almost 
complete absence of dementia (Alpers M, 1987). Disease onset ranges from 5->60 years, 
whilst its duration can last from 3 months to 3 years. Kuru incubation periods vary, from 
as little as 4.5 years to over 50 years (Collinge et al., 2006). The residue 129 genotype has 
a profound effect on incubation period and susceptibility to kuru, with the MM genotype 
having the shortest incubation period (Lee et al., 2001a), followed by VV homozygotes; 
MV heterozygotes (the most resistant genotype) have been reported to show incubation 
times >50 years (Collinge et al., 2006). Strikingly, 129 homozygotes have been essentially 
eliminated as kuru imposed a strong balancing selection on the Fore population. Elderly 
women survivors of the kuru epidemic, who were previously exposed to mortuary feasts, 
are predominantly PRNP 129 heterozygotes (Lee et al., 2001a; Mead et al., 2003).  
 
Iatrogenic CJD 
  Although transmissible in the laboratory, human prion disease is not contagious. 
Cases of acquired prion disease are limited to cannibalism (kuru) and accidental exposure 
to  human  prions.  Routes  of  unintentional  inoculation  documented  include:  a)  use  of 
inappropriately  sterilised  surgical  instruments  or  intra-cerebral  electroencephalogram 27 | P a g e  
 
(EEG) electrodes, b) dura mater grafts, c) corneal grafting, and d) use of human cadaveric 
pituitary-derived growth hormone or gonadotrophin. The two most frequent causes of 
iatrogenic CJD (iCJD) are from dura mater grafts and hormone administration (Brown et 
al., 1992; Brown et al., 2000). Interestingly, cases in which prion disease was acquired via 
an intra-cerebral or optic route clinically present with a rapidly progressive dementia, 
similar to sCJD (Heath et al., 2006). In contrast, cases from peripheral inoculation manifest 
with progressive ataxia as a prominent early symptom, rather than dementia, in a manner 
similar to kuru (Wadsworth and Collinge, 2007). 
 
Variant CJD 
A novel human prion disease, variant CJD (vCJD), emerged in 1995 in the UK (Will 
et al., 1996; Collinge and Rossor, 1996) and has affected ~ 170 individuals in the UK to 
date (www.cjd.ed.ac.uk/figures.htm). Suspicions of a link between BSE and vCJD were 
raised because they arose at the same time. In agreement, a plethora of experimental 
evidence at the clinical, neuropathological and molecular level  has shown that vCJD is 
caused by the same prion strain as BSE in cattle (Collinge et al., 1996b; Bruce et al., 1997; 
Hill et al., 1997; Asante et al., 2002). This raised the possibility that an epidemic could 
occur in the UK and other countries as a result of dietary or other exposure (Ghani et al., 
1998; Collinge, 1999). Human infection with BSE involves cross-species transmission and 
this may confer a substantial prolongation of incubation time. Therefore, vCJD poses a 
potentially serious threat to public health. Moreover, a considerable number of people 
may have already been infected and are incubating the disease with the potential to pass 
it on via blood transfusion, blood products, organ and tissue transplantation, or other 
iatrogenic routes (Collinge, 1999; Wadsworth et al., 2001; Peden et al., 2005). This has 
already been highlighted by the efficient secondary transmission of infection by blood 
transfusion (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006), and at present 
there is no screening test to ensure the safety of blood products. Furthermore, subclinical 
forms of prion disease have also been recognised in animals that do not develop clinical 
disease during a normal life-span, but have high levels of infectivity and PrP
Sc (Hill and 28 | P a g e  
 
Collinge, 2003a; Hill and Collinge, 2003b). Therefore, although the number of confirmed 
vCJD cases is small in relation to the number of individuals who have been potentially 
exposed,  the  actual  number  of  infected  people  remains  unknown.  Epidemiological 
estimates  of  subclinical  infection,  which  were based  on  archived  surgical  instruments, 
currently predict that a relatively high number of individuals (>1000) may be subclinically 
infected (Hilton et al., 2004).  
Clinically,  vCJD  is  characterised  predominantly  by  behavioural  and  psychiatric 
disturbances (Spencer et al., 2002). Individuals initially present with progressive cerebellar 
symptoms and, unlike sCJD, develop dementia later. Age of onset ranges between 16-51 
years  and  disease  duration  varies  from  9-35  months  (Knight,  2006).  At  the 
neuropathological  level,  vCJD  is  characterised  by  widespread  spongiosis  of  the  brain, 
accompanied by marked gliosis and neuronal loss (Will et al., 1996) (Figure 1.2A). In sharp 
contrast  to  sCJD,  immunohistochemistry  has  shown  that  PrP
Sc-positive  ‘florid  amyloid 
plaques’ are present in high numbers both in the cerebrum and cerebellum (Will et al., 
1996). These florid plaques are reminiscent of those usually seen in scrapie and in kuru 
(Alpers  M,  1987).  Moreover,  unlike  in  other  human  prion  diseases,  PrP
Sc  has  been 
detected  in  non-CNS  tissues  such  as  in  the  lymporeticular  system,  ocular  tissue  and 
skeletal  muscle  (Wadsworth  et  al.,  2001;  Peden  et  al.,  2006).  Recently,  a  study  also 
demonstrated  the  transmission  of  vCJD  from  human  rectal  tissue  to  transgenic  mice 
(Wadsworth et al., 2007). 
As mentioned above, there is very strong evidence that dietary exposure to BSE is 
the cause of vCJD, as vCJD-infected individuals were resident in the UK during the BSE 
epidemic (Will et al., 1996; Collinge and Rossor, 1996). Moreover, transmission studies in 
transgenic mice have demonstrated a close correlation between BSE and vCJD (Bruce et 
al., 1997; Hill et al., 1997). A further line of evidence supporting the link between BSE and 
vCJD comes from molecular strain-typing analysis of the disease-associated prion protein 
(Section  1.4.6).  This  involves  analysis  of  SDS-PAGE  PrP  migration  patterns  following 
proteinase K (PK) digestion, which is used to distinguish the normal cellular isoform from 
the  disease-related  PrP  as  they  display  different  sensitivities  to  enzymatic  digestion 
(Section 1.4.1 and 1.4.4 and Figure 1.3). Such studies have demonstrated that vCJD prions 29 | P a g e  
 
are a distinct prion strain compared to other CJD forms (types 1-3), designated type 4 
(Figure 1.2B; Section 1.4.6). Migration patterns of vCJD show the same migration patterns 
as the BSE strain (Collinge et al., 1996b). Firm diagnosis of vCJD, both ante- and post-
mortem, is achieved by tonsil biopsy (for presence of type 4 PrP
Sc); the presence of PrP
Sc in 
tonsil is only detectable in vCJD, suggestive of a distinct pathogenesis (Figure 1.2B).  
To date, no study has identified unusual occupational or dietary exposure of vCJD-
affected  individuals  to  BSE,  suggesting  that  genetic  susceptibility  factors  may  be 
important. All clinical vCJD cases documented have been homozygous for methionine at 
codon  129  (Collinge  et  al.,  1996a;  Hill  et  al.,  1999).  This  represents  the  strongest 
association of a genotype with a disease, but it is not the only genetic locus shown to be 
associated with prion disease. Mouse quantitative trait locus studies have shown that 
regions  unrelated  to  Prnp  play  a  role  in  the  inconsistent  incubation  periods  in  prion 
disease, including in BSE  (Stephenson et al., 2000; Lloyd et al., 2001; Lloyd et al., 2002). 
Furthermore,  a  genome-wide  association  study  by  Mead  and  colleagues  has  recently 
identified two novel candidate loci, RARB and STMN2, as potential vCJD risk factors (Mead 
et al., 2009). 
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Figure 1.2 Characterisation of disease related prion protein in human prion disease
2 
(A) Brains from patients with sporadic CJD or vCJD show abnormal immunoreactivity following 
immunohistochemistry using anti-PrP monoclonal antibody ICSM35. Abnormal PrP deposition in 
sporadid CJD brain most commonly presents as diffuse, synaptic staining, whereas vCJD brain is 
distinguished by the presence of florid PrP plaques consisting of a round amyloid core of PrP 
surrounded by a ring of spongiform vacuoles (black arrows). (B) Immunoblot of PK-digested tissue 
homogenate with anti-PrP monoclonal antibody 3F4 showing PrP types 1-4 in human brain and 
PrP
Sc type 4t in vCJD tonsil. Types 1-3 PrP
Sc are seen in the brain of classical forms of CJD (either 
sporadic or iatrogenic CJD), while type 4 PrP
Sc and type 4t PrP
Sc are uniquely seen in vCJD brain or 
tonsil, respectively. Scale bars 50 m.  
                                                      
2 Reprinted from BBA Molecular Basis of Disease, Vol. 1772, Wadsworth, J.D.F. and Collinge, J., Update on 
human prion disease, pp 598-609, © 2007 with permission from Elsevier.  
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1.3  Neuropathology and diagnosis of human prion disease 
Prion  disease  is  diagnosed  clinically  and  confirmed  at  post-mortem  by 
histopathological  examination  of  brain  tissue,  with  the  accumulation  of  the 
conformationally abnormal isoform of the prion protein, PrP
Sc, a consistent marker of 
disease (Kubler et al., 2003). To date, there is no diagnostic test to detect prion disease in 
humans,  thus  neuropathological  profiles  are  the  most  significant  tools  for  definitive 
diagnosis  (Budka,  2003).  The  hallmark  of  prion  disease  comprises  the  classical 
histopathological triad, which includes spongiform change, marked neuronal loss and glial 
proliferation. As a rule, samples are collected from various brain areas of a suspected 
case. However, one tissue specimen showing the hallmark histological changes or that 
stains positive for PrP is adequate for diagnosis.  
Grey matter is predominantly affected, but cases where white matter is affected too 
have also been described (Park et al., 1980). Spongiform change is the most characteristic 
change in prion disease, and is distinguished by disperse or clustered vacuoles in the 
cerebellum or subcortical grey matter (Budka, 2001). Spongiform change may be mild, 
moderate or severe, is found rarely in the brainstem and spinal cord (although both stain 
positive for PrP
Sc), and occasionally may not even be present (Almer et al., 1999). Despite 
their  supposed  specificity  to  prion  disease,  such  spongiform  changes  have  also  been 
reported in Alzheimer’s disease (AD) and diffuse Lewy body diseases (Budka et al., 1995). 
Moreover,  spongiform  change  distribution  may  vary  according  to  the  size  of  PrP
Sc 
fragments, PRNP genotype and glycoform ratio (Parchi et al., 1999; Hill et al., 2003).  
In cases where spongiform change is ambiguous or absent, other diagnostic tools, 
such  as  PRNP  genotyping  and  positive  PrP
Sc  immunohistochemistry  are  necessary  to 
confirm a suspected prion disease case. Although immunohistochemistry is an invaluable 
tool for prion disease diagnosis, occasionally prion diseases, such as FFI, may be negative 
for PrP staining (Brown et al., 1994b). It is also important to note that PrP
Sc quantity and 
localisation does not always correlate with the type and severity of local tissue damage, 
and that PrP
Sc does not always associate with infectivity, and vice versa. Crucially, PrP
Sc 
deposition and infectivity are found predominantly in the CNS of sCJD, iatrogenic CJD and 32 | P a g e  
 
genetic prion disease cases, in contrast to vCJD where peripheral tissues are also affected, 
especially in the lymphoid system (Hilton et al., 2002). Neuropathological criteria for the 
diagnosis of human prion disease are summarised in Table 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Table 1.1 Neuropathological criteria for diagnosis of human prion disease
3 
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1.4  Protein-only hypothesis of prion transmission 
1.4.1  Biochemical properties of the infectious agent 
Prion  diseases  have  been  termed  as  ‘transmissible  dementias’  because  of  the 
successful transmission of such disease in laboratory animals. As aforementioned, scrapie 
has been transmitted experimentally in mice and studies by C. Gajdusek in 1966 showed 
transmission of kuru to monkeys (Gajdusek et al., 1966). Subsequently, CJD and GSS have 
also been transmitted to monkeys (Gibbs et al., 1968; Masters et al., 1981a). The nature of 
the causative agent has been the focus of intense research. The isolation of the infectious 
particle has been costly and time consuming, as much of the early work was originally 
done in sheep or goats. Since the development of the mouse/hamster bioassay however, 
there is now ample information about the physico-chemical properties of the infectious 
agent. For example, it has been shown to associate with cellular membranes (Mould et al., 
1965;  Hunter  and  Millson,  1967),  co-purify  with  microsomes  (Semancik  et  al.,  1976), 
detach from membranes following ultracentrifugation regimes (Malone et al., 1978), and 
have different densities in sucrose and NaCl (Siakotos et al., 1976; Brown et al., 1978). The 
infectious  agent  is  also  aggregation-prone  and  hydrophobic  in  nature  (Prusiner  et  al., 
1978; Prusiner et al., 1980a), and has a remarkable resistance to procedures which modify 
nucleic acids, such as ultraviolet and ionizing radiation, nucleases, hydroxylamine and zinc 
ions (Alper et al., 1967; Alper et al., 1978; Prusiner, 1982). Furthermore, conditions that 
are non-denaturing to proteins allow for its separation from other cellular components 
(Prusiner et al., 1977; Prusiner et al., 1980b). These and other studies showing that it has 
partial  resistance  to  nuclease  digestion  and  to  some  forms  of  protease  treatment 
(Prusiner et al., 1980c), formed the basis for further purification methods.  
 
1.4.2  Proteinaceous infectious particle 
Physicist J.S. Griffith first raised the possibility in 1967 that the material responsible 
for prion disease transmission might be a protein able to replicate in the body (Griffith, 
1967).  In  order  to  confirm  a  protein-like  agent,  the  protein  had  to  be  purified  and 34 | P a g e  
 
characterised. Experimental evidence that a protein could also be infectious came from 
the transmission of scrapie into Syrian golden hamsters (Prusiner et al., 1980b; Prusiner et 
al., 1982b). In 1981, Stanley B. Prusiner’s work culminated in a partial purification protocol 
for the infectious agent, which included ultracentrifugation and PK treatments (Prusiner et 
al., 1981). These results provided firm evidence against the pathogen being a slow virus, 
as was originally proposed due to its long incubation period characteristics (Cho, 1976), 
and to date no evidence supports the notion that a nucleic acid is associated with prion 
infection. The term ‘prion’ was first coined by Prusiner in 1982 to distinguish the infectious 
agent in prion disease as a pathogen from bacteria, fungi, parasites and viruses, and refers 
to a ‘small, proteinaceous infectious particle that resists inactivation by procedures which 
modify  nucleic  acids’  (Prusiner,  1982).  Later,  Prusiner  and  colleagues  adapted  their 
previous purification protocols by the addition of a sucrose gradient step and were able to 
isolate  the  major  constituent  of  infective  fractions  from  hamster  brain  homogenates 
(Prusiner et al., 1982a). Subsequent experiments showed that the major constituent was a 
27-30 kDa protease-resistant protein designated PrP
27-30 (Bolton et al., 1982). A protein of 
similar size was identified in uninfected brain, but unlike the disease-associated protein it 
was digested by PK treatment (Bolton et al., 1982). The identity of the disease-associated 
protein as a component of the infectious agent, rather than a product of disease, has been 
confirmed by studies showing a correlation of infectivity and PrP
27-30 concentration (Bolton 
et al., 1982; Prusiner et al., 1982a; Hope et al., 1986; Safar et al., 1990). PrP
27-30 originates 
from a protein with a molecular weight of 33-35 kDa, designated PrP
Sc. Identification of 
the  amino  acid  sequence  of  the  prion  protein  allowed  for  further  analysis  and  the 
production  of  anti-PrP  antibodies  (Bendheim  et  al.,  1984),  which  do  not  however 
distinguish between normal and disease-associated material.  
 
1.4.3  Prion protein gene 
Following purification of the prion protein, the gene encoding PrP was identified. 
Amino acid sequencing of the N-terminus of PrP
27-30 was used to derive a cDNA clone 
encoding a host protein, which subsequently demonstrated that PrP
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single-copy chromosomal gene (Oesch et al., 1985; Basler et al., 1986). The presence of 
PrP  mRNA  in  the  brains  of  both  infected  and  unaffected  animals  (Barry  et  al.,  1986) 
provided evidence that PrP could exist in two different forms: the normal cellular isoform 
termed PrP
C and the disease-associated form, PrP
Sc. To date, there is no proof to support 
the notion that the PrP gene undergoes re-arrangement during disease, and there has 
been no genetic basis for alternative splicing (Basler et al., 1986). Additionally, studies 
have demonstrated that PrP mRNA does not increase during the course of prion disease 
(Oesch et al., 1985). Amino acid sequencing studies of the N-terminus of PrP
C and PrP
Sc 
reported vast similarities between the two and raised the possibility that the observed 
difference(s) are due to post-translationals events (Turk et al., 1988). Sequencing of the 
PrP open reading frames (ORF) from various species has demonstrated that they encode a 
highly conserved protein of about 250 amino acids. Its presence in mammals, but also 
other vertebrates such as birds, marsupials and amphibians, suggests an important role 
that is evolutionary conserved (Windl et al., 1995; Wopfner et al., 1999; Calzolai et al., 
2005).  
 
1.4.4  Biochemical properties of PrP
Sc 
Purified  full-length  PrP
Sc  is  insoluble  in  non-ionic  detergents  and  has  partial 
protease resistance, with only the N-terminal third of the sequence being cleaved leaving 
a protease-resistant core, PrP
27-30, which retains infectivity (Riesner, 2003). The increased 
propensity of PrP
Sc to aggregate correlates with its resistance to PK digestion (Figure 1.3). 
The  C-terminus  of  PrP
Sc  can  be  digested  by  cathepsin  D,  which  liberates  the 
glycosylphosphatidylinositol (GPI) anchor, but retains prion infectivity (Lewis et al., 2006). 
Moreover,  transgenic  mice  expressing  PrP  lacking  a  GPI  anchor  can  propagate  prions 
(Chesebro  et  al.,  2005),  thereby  suggesting  that  the  GPI  anchor  is  not  a  prerequisite 
component  of  the  infectious  prion.  Unlike  PrP
C,  which  can  be  readily  cleaved  from 
membranes by treatment with phosphatidylinositol-specific phospholipase C (PIPLC) (Stahl 
et al., 1987), PrP
Sc is resistant to such treatment (Caughey et al., 1990; Borchelt et al., 
1993)  suggesting  a  conformational  change  prevents  accessibility  of  PIPLC.  Indeed, 36 | P a g e  
 
evidence suggests the conversion of PrP
C to PrP
Sc does not involve a covalent modification 
(Stahl et al., 1993), but is conformational in nature (Pan et al., 1993; Cohen et al., 1994). 
Insight into the native conformation has been hindered by the insolubility and 
aggregation state of PrP
Sc. Nonetheless, Fourier Transform Infrared Spectroscopy (FTIR) 
and circular dichroism studies have demonstrated that unlike PrP
C, which is predominantly 
-helical, PrP
Sc is -sheet-rich dominant (Gasset et al., 1993; Pan et al., 1993). -sheet 
content in PrP
Sc comprises 45% compared to 3% in PrP
C. The protease-resistant core of 
PrP
Sc has been shown to re-arrange into amyloid rods, which stain with Congo red and 
show green-gold birefringence, typical of amyloids (Prusiner et al., 1983). Interestingly, 
PrP
Sc  deposits  of  varying  size  and  morphology,  including  amyloid  plaques,  have  been 
identified  in  scrapie-infected  animal  brain  tissue  (Merz  et  al.,  1981).  Nonetheless,  no 
experimental evidence supports the presence of fibrils in human prion disease (Budka, 
2003),  although  studies  using  synthetic  fibrils  have  provided  some  insight  into  prion 
conformation  (Baskakov  et  al.,  2002;  Tattum  et  al.,  2006).  Furthermore,  although  the 
nature  of  the  self-propagating  infectious  agent  is  unknown,  recent  studies  have 
demonstrated that small PrP oligomers of 14-28 molecules were maximally infective when 
compared to monomeric or fibrillar PrP (Silveira et al., 2005). 
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Figure 1.3 Proteinase K resistance of PrP 
Schematic of a characteristic Western blot of SDS-electrophoresis of PrP
C and PrP
Sc without and 
with PK digestion. The characteristic three PrP bands (with two, one or none glycosyl groups; blue) 
are visible and disappear completely after PK digestion of PrP
C. In the case of PrP
Sc, the bands 
remain nearly undiminished in intensity although shifted to lower molecular weight (red) and 
represent the N-terminally truncated forms of PrP
Sc, called PrP
27-30. 
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1.4.5  Models of PrP
Sc replication 
Following the discovery that PrP is host-encoded, much research has focused on 
elucidating differences between PrP
C and PrP
Sc. Although it is now known that the two 
isoforms share the same amino acid sequence, they have diverse biochemical properties 
(Prusiner, 1998). Therefore, the differences between the two isoforms appear to be due 
to  post-translational  modifications  or  simply  conformational  change.  Research  has 
focused  on  the  refolding  properties  of  recombinant  PrP  to  either  the  normal  or  the 
disease-related isoform.  
The protein-only hypothesis, which postulates that prion propagation results from 
a  change  in  PrP  conformation  whereby  PrP
Sc  recruits  endogenous  PrP
C  in  order  to 
replicate  (Griffith,  1967;  Prusiner,  1982),  is  well  established.  Some  of  the  strongest 
supporting  evidence  comes  from  findings  that  inherited  prion  diseases  are  linked  to 
mutations in the PRNP gene (Collinge, 2001), indicating that a genetic disease may be able 
to propagate in an infectious way. Another important line of evidence comes from PrP
C 
knockout  (KO)  mice,  which  are  resistant  to  scrapie  prions  (Bueler  et  al.,  1993). 
Furthermore, infectious prions have been shown to consist mainly or exclusively of PrP
Sc, 
as indicated by a large body of experimental data. Using an in vitro amplification system 
Kocisko et al. showed de novo PrP
Sc production using radio-labelled PrP
C and a PrP
Sc seed 
(Kocisko et al., 1994).  However, these  in vitro conversion methods were inefficient in 
transmission barrier studies, as large amounts of PrP
Sc seed were required (Bessen et al., 
1995;  Raymond  et  al.,  1997).  The  development  of  the  protein  misfolding  cyclic 
amplification (PMCA) assay (Castilla et al., 2005) has improved such in vitro amplification 
systems both with regards to amplification and infectivity, and has helped demonstrate 
that infectious material can be produced in a cell-free system, which when inoculated into 
mice leads to a scrapie-like disease (Supattapone, 2004; Castilla et al., 2005). Additionally, 
synthetic prions that polymerise into fibrils in vitro have also been shown to be infectious 
in vivo (Legname et al., 2004).  
A protein-only mechanism of replication and inheritance may have wider relevance 
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(Wickner,  1997;  Serio  and  Lindquist,  2000;  Wickner  et  al.,  2007).  However,  the  exact 
molecular events involved in the conversion of PrP
C to PrP
Sc remain unclear. The current 
model of prion replication proposes that PrP fluctuates between a native state, PrP
C, and a 
series of minor conformations, a subset of which can self-associate to form a stable supra-
molecular  structure,  PrP
Sc,  composed  of  misfolded  PrP  monomers.  Studies  using  a 
recombinant protein mimetic of PrP
Sc, -PrP, have shown that -PrP aggregation occurs 
until it reaches a critical size at which a stable ‘seed’ structure is formed. Following this, 
the recruitment of unfolded PrP and/or -PrP monomers can lead to an explosive, auto-
catalytic  formation  of  PrP
Sc  (Figure  1.4).  Such  a  mechanism  could  explain  all  three 
aetiologies (sporadic, inherited and acquired) of human prion disease. Initiation of this 
pathogenic self-propagating conversion reaction, with accumulation of aggregated -PrP, 
may  be  induced  following  exposure  to  a  ‘seed’  of  aggregated  -PrP  following  prion 
inoculation,  as  a  rare  stochastic  conformational  change,  or  as  an  inevitable  result  of 
expression of a pathogenic mutant PrP
C form, which is prone to form -PrP (Collinge, 
2005). Whether such alternative conformational states of the protein are enough to adopt 
PrP
Sc conformation and cause prion disease alone in the absence of a cellular co-factor still 
remains to be seen.  
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Figure 1.4 Possible mechanism for prion propagation
4 
Largely -helical PrP
C proceeds via an unfolded state (A) to re-fold into a largely -sheet form, -
PrP (B). -PrP is prone to aggregation in physiological salt concentrations. Prion replication may 
require a critical ‘seed’ size. Further recruitment of unfolded PrP (C) or -PrP monomers (D) then 
occurs  as  an  essentially  irreversible  process  driven  thermodynamically  by  inter-molecular 
interactions.  
 
                                                      
4 Reproduced from the J. Neurol. Neurosurg. Psychiatry, Collinge, J., Vol 76, pp 906-919, © 2005  with 
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1.4.6  Prion strains and transmission barriers 
The prion strain phenomenon has presented one of the most challenging problems 
for the protein-only hypothesis (Chesebro, 1998; Soto and Castilla, 2004). Prion strains are 
distinct  isolates,  which  when  transmitted  to  susceptible  animals  produce  distinctive 
neuropathology patterns and consistent incubation periods. To comply with the criteria of 
the protein-only hypothesis of prion propagation, PrP
Sc would need to contain all the 
information necessary to encode strain formation. At first it was assumed that the various 
phenotypes found in animals were attributed to genetic information contained within the 
TSE-causing agent. However, unlike virus and bacterial strains, there is no experimental 
support that prion strains are encoded by a nucleic acid genome. The first evidence of 
PrP
Sc-encoded strain specificity came from the serial passage of two different TME strains 
in hamsters, which demonstrated that they are associated with different physico-chemical 
properties of PrP
Sc (Bessen and Marsh, 1992; Bessen and Marsh, 1994). Prion strains can 
be serially propagated in lines of inbred mice with the same Prnp genotype (Scott et al., 
1997), suggesting that strains are not encoded by differences in the primary sequence of 
PrP. At present, the general consensus is that the main disparities between strains arise 
from alternative PrP
Sc conformations and glycosylation patterns (Bartz et al., 2000; Peretz 
et al., 2001a). In vivo, distinct prion strains can be distinguished by differences in clinical 
signs, profile of histological damage, incubation time, and disease length (Morales et al., 
2007). The infectious protein of each prion strain is specifically linked to a precise set of 
biochemical  characteristics:  differential  mobility  on  SDS-PAGE  following  PK-digestion 
(Parchi et al., 1996), glycosylation patterns (Khalili-Shirazi et al., 2005), and the extent of 
PK-resistance (Bessen and Marsh, 1992) (Figure 1.5). Furthermore, distinct ratios of three 
main PrP
Sc glycoforms (di-, mono- and unglycosylated) are also seen with prion strains 
(Collinge et al., 1996b; Hill AF et al., 2003). However, definitive proof for the structural 
nature of differences between prion strains remains obscure.  
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Figure 1.5 Molecular analysis of prion strains 
Molecular prion strain typing is assessed by Western blotting of PK-treated brain homogenates. 
PK-digestion completely digests PrP
C but it only removes ~70 amino acid residues from the N-
terminus of PrP
Sc. Distinct prion strains are represented by different PrP
Sc conformers and have 
different  cleavage  sites,  which  result  in  strain-specific  migration  patterns  on  SDS-PAGE 
electrophoresis. The relative intensities of the three PrP
Sc bands (representing the three different 
PrP glycoforms) are also strain-specific.  
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Particular strains of the infectious agent have a characteristic ability to infect some 
species  but  not  others,  a  phenomenon  recognised  as  the  ‘species  barrier’.  This  is 
manifested in cases where prions from species A are used to infect species B and not all 
animals from species B develop the disease (those that do present with prolonged and 
variable incubation periods) (Moore et al., 2005). Nonetheless, on secondary passage of 
infectivity from species B to other members of the same species all animals succumb to 
disease, displaying short and consistent incubation times. 
Species-specific variations in the primary sequence of PrP have been suggested to 
be the cause of both the species barrier and the existence of different PrP
Sc conformations 
(Palmer et al., 1991; Vanik et al., 2004). Support for the existence of a species barrier 
came  from  studies  in  transgenic  mice,  which  express  human  PrP,  and  which  readily 
succumb to disease after infection with human prion disease, unlike their wild-type (WT) 
counterparts (Collinge et al., 1995). On the contrary, studies in which vCJD was used to 
infect  WT  and  human  PrP-expressing  transgenic  mice  have  demonstrated  that  vCJD 
transmits to both (Hill et al., 1997). BSE has been shown to transmit to a wide range of 
hosts and in doing so maintains its transmission characteristics after passage though an 
intermediate species. Indeed, inter-species transmission from cattle to human is the most 
relevant  problem  in  terms  of  public health  (Smith  and  Bradley,  2003),  with  a  general 
acceptance that vCJD resulted from consumption of BSE-infected material (Bruce et al., 
1997; Hill et al., 1997). Taken together, these findings highlight the fact that the term 
‘transmission-barrier’, rather than ‘species barrier’, may be more appropriate to explain 
the transmissibility of prion strains and various models have been put forward to explain 
the transmission barrier (Hill and Collinge, 2003a; Collinge and Clarke, 2007) (Figure 1.6).  
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Figure 1.6 Conformational selection model of prion transmission barriers
5 
Mammalian PrP genes are highly conserved, and this hypothesis suggests that only a restricted 
number of different PrP
Sc conformations are thermodynamically permissible and constitute the 
range of observed prion strains. Although a significant number of different PrP
Sc conformations 
might be possible across the range of mammalian PrPs, only a subset of these would be allowed 
within a given mammalian species. Substantial overlap between the favoured conformations for 
PrP
Sc derived from species A and species B might therefore result in relatively easy transmission of 
prion  diseases  between  these  two  species,  whereas  two  species  with  no  preferred  PrP
Sc 
conformations in common would have a large barrier to transmission. According to this model of a 
prion  transmission  barrier,  BSE  would  represent  a  thermodynamically  highly  favoured  PrP
Sc 
conformation that is permissive for PrP expressed in a wide range of different species, accounting 
for the remarkable promiscuity of this strain in mammals. In this Figure, there is overlap between 
the  allowable  PrP
Sc  conformers  between  species  A  and  species  B.  This  overlap  facilitates 
transmission between these species involving the ‘green’ and ‘red’ strains. However, inoculation 
with the ‘blue’ or ‘yellow’ strains would only result in propagation if a strain switch to red or green 
occurred.  There  is  no  overlap  or  allowed  conformers  between  species  A  or B  with  species  C 
resulting in a substantial transmission barrier between species C and A, or C and B. Passage of 
strains through an intermediate host might allow the adaptation of a particular strain to a new 
host.  
                                                      
5 Reprinted from Trends Microbiol., Vol 11, Hill A.F. and Collinge J., Subclinical prion infection, pp 578-584, 
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1.5  Cell biology of prion disease 
1.5.1  Prion protein: structure 
The  normal  cellular  isoform  of  the  prion  protein,  PrP
C,  is  a  highly  conserved, 
approximately 250 amino acid glycoprotein that is widely expressed in the body. This 30-
35 kDa protein is abundant in the neurones and glia of the CNS, and can also be found in 
several  peripheral  tissues  and  leukocytes  (Dodelet  and  Cashman,  1998;  Aguzzi  and 
Polymenidou,  2004).  In  humans,  PrP
C  is  encoded  by  a  single  exon  of  the  PRNP  gene 
located on the short arm of chromosome 20 (20p).  
PrP
C has two N-glycosylation sites and is GPI-anchored to the outer leaflet of the 
plasma membrane (Stahl et al., 1987). Studies on purified hamster PrP
C and PrP
Sc have 
demonstrated that there are at least fifty different sugar chains capable of attaching to 
the glycosylation sites, with differences between the two isoforms  (Endo et al., 1989; 
Somerville and Ritchie, 1990; Rudd et al., 1999; Rudd et al., 2001). The C-terminal domain 
of PrP
C is folded largely into -helices stabilised by a single di-sulphide bond and nuclear 
magnetic  resonance  (NMR)  shows  it  exists  in  a  monomeric  state  (Riek  et  al.,  1996). 
Furthermore, studies into the crystal structure of the C-terminus of PrP reveal that it has 
three -helices and a short anti-parallel -sheet (Knaus et al., 2001; Eghiaian et al., 2004; 
Haire et al., 2004).  
Unlike  the  C-terminus, structural  information  about  the  N-terminal  segment  of 
PrP
C is incomplete. The N-terminus is the most highly conserved PrP region and contains 
an  octapeptide  repeat,  which  may  be  involved  in  the  cellular  function  of  PrP
C.  The 
octapeptide  repeats  have  been  shown  to  have  tight  binding  sites  for  Cu
2+  and  Zn
2+, 
suggesting a possible role in ion regulation/signalling  (Riek et al., 1998; Hosszu et al., 
1999;  Jackson  et  al.,  2001).  Mutations  in  the  N-terminal  segment  of  PrP  have  been 
identified as the cause of some human prion diseases, raising the possibility that it may be 
an important factor in some PrP
Sc conformations and/or disease manifestation (Mead, 
2006; Mead et al., 2006; Hill et al., 2006).  
The highly conserved hydrophobic region in the middle of the protein has been 
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Nonetheless, studies using synthetic systems have demonstrated that peptides from this 
region can span membranes and suggest that this could occur as part of PrP
C function 
during cellular trafficking (Forloni et al., 1993; Glover et al., 2001). Small peptides from 
this  region  that  have  been  refolded  can  adopt  an  apoptosis-inducing  conformation 
suggesting that the hydrophobic domain may be an important part of an infectious prion 
(Gasset et al., 1992; Forloni et al., 1993; Goldfarb et al., 1993). In agreement, PrP mutants 
characterised by a deleted internal hydrophobic domain, PrPHD, cause severe ataxia and 
neuronal death limited to the granular layer of the cerebellum in transgenic mice as early 
as 1-3 months after birth (Shmerling et al., 1998; Baumann et al., 2007; Li et al., 2007b). 
More recent studies have shown that this hydrophobic domain promotes dimer formation 
of PrP and that PrP dimerisation is linked to a stress-protective activity (Rambold et al., 
2008). At present, there is little known about the structure of PrP
Sc, mainly because of its 
highly insoluble and aggregated nature (Section 1.4.4). 
Recombinant  purified  PrP
C  has  been  produced  in  E.  coli.  Original  attempts  to 
achieve this were hindered by low expression levels, low purification efficiency, instability 
and insolubility of the protein and failure to form the di-sulphide bond which is required 
for correct PrP
C folding (Riesner, 2003). These problems were finally overcome, and after 
purification  recombinant  PrP
C  is  re-constituted  by  denaturation  in  8  M  urea  or  5  M 
guanidinium  hydrochloride,  whereas  the  di-sulphide  bond  is  formed  under  oxidising 
conditions. Following this, PrP
C is re-natured by dialysing out the denaturant (Mehlhorn et 
al., 1996). 
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1.5.2  Prion protein: localisation and trafficking 
In  order  to  further  understand  prion  disease  pathogenesis,  insight  into  the 
synthesis,  localisation  and  metabolism  of  both  PrP
C  and  PrP
Sc  is  essential.  PrP
C  is 
synthesised  in  the  endoplasmic  reticulum  (ER)  where  it  undergoes  post-translational 
modifications, which include N-terminal glycosylation, signal peptide removal, sulphide 
bond  formation,  and  GPI  anchor  attachment  (Stahl  et  al.,  1987;  Turk  et  al.,  1988; 
Haraguchi et al., 1989).  
 
Localisation 
Characterising the precise cellular localisation of PrP
C and PrP
Sc is essential in order 
to  identify  the  intracellular  compartment  and  the  mechanisms  that  underlie  prion 
formation. At present, there is conflicting data with regards to the exact localisation of 
PrP
C in neurones, perhaps due to the variety of techniques used. Putative sites of PrP
C 
localisation include: the ER (Sarnataro et al., 2004), the Golgi (Magalhaes et al., 2002), 
endolysosomes  (Magalhaes  et  al.,  2002),  exosomes  (Fevrier  et  al.,  2004),  the  plasma 
membrane  (Sarnataro  et  al.,  2002),  the  nucleus  (Mange  et  al.,  2004)  and  the  cytosol 
(Mironov, Jr. et al., 2003). At present there is a significant gap in our understanding of 
PrP
Sc  localisation  as  there  are  no  PrP
Sc-specific  antibodies.  However,  studies  to  date 
suggest a wide cellular distribution, in particular at the plasma membrane (Caughey and 
Raymond, 1991; Jeffrey et al., 1992a) and in the endolysosomal compartment (McKinley 
et al., 1991; Arnold et al., 1995). Under certain conditions, PrP
Sc-like conformers have 
been reported to accumulate in the cytosol (Ma and Lindquist, 2002) and there is also 
evidence  for  cytosolic  PrP
Sc-containing  aggresomes  in  prion-infected  cells  following 
proteasome inhibition (Kristiansen et al., 2005).  
 
Trafficking: pathways for PrP
C endocytosis 
Following its synthesis in the ER, PrP
C is trafficked via the Golgi to the cell surface, where it 
constitutively cycles between the plasma membrane and early endosomes (Shyng et al., 
1993).  Various  mechanisms  have  been  proposed  to  explain  how  PrP
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(Figure  1.7).  For  example,  PrP
C  has  been  shown  to  recycle  from  the  cell  surface  to 
endosomes via clathrin-coated pits both in primary cultures of sensory neurones, as well 
as in neuroblastoma N2a and SH-SY5Y cells (Shyng et al., 1994; Sunyach et al., 2003; Taylor 
et al., 2005). Furthermore, a basic amino acid motif in the N-terminal region of PrP
C has 
been shown to be required for localisation of PrP
C in clathrin-coated pits and subsequent 
internalisation (Shyng et al., 1993; Lee et al., 2001b; Sunyach et al., 2003). These findings 
suggested that PrP
C may be binding, via its N-terminal region, to a transmembrane protein 
containing  a  localisation  signal  for  coated  pits.  Another  putative  mechanism  of 
internalisation has been proposed following PrP
C localisation studies in various cell models 
that showed that PrP
C clusters in caveolae or caveolae-like domains (Vey et al., 1996; 
Kaneko et al., 1997). Moreover, PrP
C has been found in caveolae, but not in clathrin-
coated pits and vesicles, in Chinese hamster ovary cells, which express caveolin-1 (Peters 
et al., 2003). However, the role of caveolae in prion trafficking on neurones is irrelevant, 
as caveolae have not been shown to occur on adult mammalian neurones (Morris et al., 
2006). A further possible mechanism of PrP
C internalisation involves lipid rafts. In rafts, 
lipids of specific chemistry can associate with one another in a dynamic manner to form 
platforms  that  segregate  various  membrane  proteins,  including  GPI-anchored  proteins 
(Simons and Ikonen, 1997). In neurones, PrP
C is found on lipid rafts that are different both 
chemically and spatially from those containing the major neuronal GPI-anchored protein, 
Thy-1 (Madore et al., 1999; Sunyach et al., 2003; Brugger et al., 2004). In order for a GPI-
anchored protein to be internalised through clathrin-coated pits it needs to translocate 
out of its lipid rafts into non-raft regions of the membrane. Indeed, using primary cultures 
of neurones as well as neuroblastoma N2a cells, Sunyach et al. demonstrated that PrP
C 
leaves  its  rafts  to  traverse  detergent-soluble  (non-raft)  membrane,  following  which  it 
enters coated pits for endocytosis, and  cycles back to the cell surface  via perinuclear 
sorting compartments (Sunyach et al., 2003).  
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Figure 1.7 Pathways of PrP
C internalisation
6 
At  the  plasma  membrane,  PrP
C  can  be  constitutively  internalised  and  its  endocytosis  can  be 
increased by extracellular copper ions (not shown). A chief pathway of PrP
C internalisation in 
neuronal  cells  seems  to  depend  on  clathrin-mediated  endocytosis  (A).  Caveolin-related 
endocytosis and trafficking have been implicated in PrP
C transport in Chinese hamster ovary and 
glial cells (B). Rab5-positive endosomes and recycling endosomes involving Rab4 have also been 
implicated  in  the  endocytic  transport  of  PrP
C.  Finally,  non-clathrin  and  non-caveolin  but  raft-
dependent endocytosis has been proposed to participate in the internalisation and conversion of 
prion protein (C). 
 
                                                      
6 Adapted from Trends Cell Biol., Vol 15, Campana, V., et al., The highways and byways of prion protein 
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Trafficking: endocytic partner(s) 
  Various proteins have been proposed to bind to and act as endocytic partners for 
PrP
C (Morris et al., 2006; Linden et al., 2008). For example, the  
NH2-KKRPKP- amino acid 
residues of the N-terminal domain of PrP
C, which are essential for coated pit endocytosis 
(Morris  et  al.,  2006),  have  been  identified  as  a  major  heparin 
sulphate/glycosoaminoglycan binding site of PrP
C (Pan et al., 2002; Warner et al., 2002). 
These basic residues also serve as binding motifs for extracellular cargo binding to the low 
density  lipoprotein  (LDL)  receptor-related  protein  (LRP1),  which  has  been  shown  to 
require  heparin  sulphate  glycosoaminoglycans  as  co-receptors  (Wang  et  al.,  2004). 
Furthermore,  binding  of  a  GPI-anchored  protein,  urokinase  plasminogen  activator 
receptor, by its basic residues to LRP1 has been shown to allow for its internalisation via 
clathrin-coated  pits  (Horn  et  al.,  1998).  Recently,  Parkyn  et  al.,  showed  that  LRP1 
associates with endogenous PrP
C on the neuronal cell surface to internalise it, and that 
LRP1 binds to PrP
C to facilitate its trafficking to the neuronal surface (Parkyn et al., 2008). 
Cu
2+ has also been demonstrated to draw PrP
C out of its rafts prior to its endocytosis in 
SH-SY5Y cells (Taylor et al., 2005), and more recently it was shown that LRP1 is required 
for Cu
2+-dependent endocytosis of exogenous PrP
C in the same cell model (Taylor and 
Hooper, 2007). The laminin receptor precursor and the laminin receptor have also been 
shown to bind recombinant PrP
C (Rieger et al., 1997; Gauczynski et al., 2001; Hundt et al., 
2001), suggesting these receptors may be acting as cell-surface receptors for PrP
C, but 
more work is needed to assess whether this is also true for endogenously expressed PrP
C. 
 
Trafficking: role in the conversion of PrP
C to PrP
Sc 
  One of the main questions in prion research is where the conversion of PrP
C to 
PrP
Sc occurs, and numerous pathways have been proposed (Campana et al., 2005). First, 
studies suggest that PrP
C mutants, which are associated with familial forms of CJD, are 
retained by chaperones in the ER (Drisaldi et al., 2003; Campana et al., 2006), thereby 
indicating that in inherited prion disease the conversion process could be occurring early 
in the biosynthesis of PrP
C. Furthermore, PrP molecules have been  shown to undergo 
retrograde  transport  toward  the  ER,  and  stimulation  of  this  translocation  leads  to  an 51 | P a g e  
 
accumulation of PrP
Sc (Beranger et al., 2002). Second, direct surface contact has also been 
implicated in the conversion process, as studies have shown it is required for the transfer 
of infection in cell models of scrapie (Kanu et al., 2002). These findings are also supported 
by reports of transfer of infection by adherence to stainless steel wires (Flechsig et al., 
2001).  Third,  exosomes  have  been  implicated  to  carry  infection  when  released  from 
scrapie-infected cells (Fevrier et al., 2004). Fourth, increasing evidence indicates that the 
endocytic pathway could be involved in the conversion of PrP
C to PrP
Sc (Borchelt et al., 
1992; Taraboulos et al., 1992). For example, blocking the endocytosis and internalisation 
of PrP
C inhibits the formation of PrP
Sc (Borchelt et al., 1992), and studies have also shown 
that PrP
Sc is partially digested at its N-terminus in an acidic compartment following its 
synthesis and that it accumulates in late endosomes (McKinley et al., 1991; Taraboulos et 
al., 1992; Arnold et al., 1995). Furthermore, it is also possible that prions use lipid rafts to 
enter cells and to initiate and/or propagate the conversion of PrP
C to PrP
Sc (Campana et 
al.,  2005).  Studies  have  demonstrated  that  both  PrP
C  and  PrP
Sc  are  present  in  rafts 
extracted from prion-infected mouse cells and brain (Taraboulos et al., 1992; Taraboulos 
et al., 1995; Naslavsky et al., 1997; Baron et al., 2002; Baron and Caughey, 2003; Botto et 
al., 2004). Conversely, there is also evidence supporting a protective role of rafts in the 
conversion process. For example, it has been suggested that the GPI anchor stabilises the 
conformation of PrP
C within rafts to block the conversion of PrP
C to PrP
Sc (Baron et al., 
2002;  Baron  and  Caughey,  2003),  whereas  disrupting  lipid  raft  composition  leads  to 
increased scrapie infection in neuroblastoma cells (Naslavsky et al., 1999) and enhanced 
cellular levels of misfolded PrP
C in the ER (Sarnataro et al., 2004; Campana et al., 2006). 
These findings, which indicate a neuroprotective role for rafts, can be explained by density 
gradient studies showing that PrP
C- and PrP
Sc-associated rafts have distinct characteristics 
(Vey et al., 1996; Naslavsky et al., 1997), suggesting that either the rafts associated with 
each isoform are different, or that the membrane association of each isoform has distinct 
characteristics.   
Further work in defining the internalisation pathway of PrP
C and PrP
Sc and their 
endocytic receptor(s) is required to help our understanding of the conversion process. 
Figure 1.8 summarises possible pathways of PrP
Sc formation.  52 | P a g e  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Possible pathways of PrP
Sc formation
7 
After its synthesis and ER quality control, PrP
C is transported through the Golgi apparatus to the 
cell  surface,  where  it  associates  with  rafts  and  is  internalised  by  clathrin-  and/or  caveolin-
dependent mechanisms. Blocking transport of PrP
C to the plasma membrane and rerouting it to 
lysosomes for degradation (A), and releasing nascent PrP
C from the cell surface (B) prevent the 
formation of PrP
Sc. A reduction in PrP
C internalisation (C) also decreases PrP
Sc formation. Both PrP 
isoforms are found in Rab5-positive early endosomes, pass through late endosomes and are totally 
(PrP
C) or partially (PrP
Sc) degraded in acidic lysosomes. Moreover, part of the PrP
C pool is recycled 
back to the plasma membrane in a Rab4-dependent pathway, and both PrP
C and PrP
Sc are found 
associated with exosomal membranes in the extracellular medium of infected cells. Finally, the ER 
has been postulated to have a role in prion conversion by amplifying PrP
Sc formation after the 
Rab6-dependent retrograde transport of PrP
C (D).  
                                                      
7 Adapted from Trends Cell Biol., Vol 15, Campana, V., et al., The highways and byways of prion protein 
trafficking, pp 102-111, © 2005, with permission from Elsevier. 53 | P a g e  
 
1.5.3  Prion protein: function 
The amino acid sequence of mammalian PrP
C is highly conserved between species 
and  implies  an  important  cellular  function.  Loss  of  PrP
C  expression  shows  no  overt 
phenotype in both embryonic PrP
C-null mice and adult-onset knockout models (Bueler et 
al., 1992; Mallucci et al., 2002). However, embryonic PrP
C-null mice have been shown to 
develop  abnormalities  in  synaptic  physiology,  circadian  rhythm  and  sleep  patterns 
(Collinge et al., 1994; Tobler et al., 1996).  
The function of PrP
C remains unknown, although a number of roles have been 
proposed (Westergard et al., 2007) (Table 1.2). Putative functions for PrP
C are based on its 
localisation  (Section  1.5.2)  and  on  molecules  that  interact  with  it,  and  include  cell 
adhesion  (Graner  et  al.,  2000;  Schmitt-Ulms  et  al.,  2001;  Santuccione  et  al.,  2005), 
synaptogenesis (Kanaani et al., 2005), signalling (Mouillet-Richard et al., 2000), copper 
homeostasis (Vassallo and Herms, 2003), and neuroprotection  (Kuwahara  et al., 1999; 
Bounhar et al., 2001; Roucou et al., 2003; Khosravani et al., 2008). PrP
C has also been 
implicated in the self-renewal of hematopoietic stem cells during serial transplantation 
(Zhang et al., 2006). A link between AD and prion disease has also been proposed, as PrP
C 
was shown to regulate neurotoxic Amyloid  (A) production by inhibiting -secretase 
cleavage of the amyloid precursor protein (APP) (Parkin et al., 2007). Endogenous PrP
C 
was reported to associate with LRP1 on the cell surface, which allows for its internalisation 
(Parkyn et al., 2008). Furthermore, the same study showed that PrP
C binds to LRP1 in 
biosynthetic compartments to enable its trafficking to the neuronal surface.  
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Table 1.2 Putative PrP interactors 
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1.6  Prion-mediated neurodegeneration 
The molecular basis of prion-mediated neurotoxicity is poorly understood and a 
major gap exists in the understanding of how the conversion of PrP
C to PrP
Sc ultimately 
leads to neurodegeneration. At present, there is ongoing debate about the nature of the 
neurotoxic species in prion disease.  
 
1.6.1  Loss of function of PrP
C 
Even though the precise function of PrP
C remains unclear (Section 1.5.3), a loss of 
its putative physiological role(s) could lead to the characteristic pathology seen in prion 
disease. It is known that PrP
C is essential for the development of prion disease (Bueler et 
al., 1993), as PrP
C-null mice do not succumb to disease when inoculated with prions; 
prion-infected heterozygous mice show longer incubation times compared to WT mice 
(Bueler  et  al.,  1993).  These  results  suggested  that  PrP
Sc,  incubation  time  and  disease 
progression  are  inversely  related  to  PrP
C  levels.  However,  loss  of  function  of  PrP
C  is 
unlikely to be the cause of pathology because neither embryonic nor adult KO of PrP
C 
results in neurodegeneration (Bueler et al., 1992; Manson et al., 1994; Mallucci et al., 
2002).  
Currently, there is conflicting evidence with respect to the role of abnormal PrP
C 
processing. PrP
C-null primary neurones in vitro have been shown to be more sensitive to 
oxidative stress (Brown et al., 1997; White et al., 1999). Exposure of cells to the synthetic 
peptide PrP106–126, which has been used as a model for PrP
Sc (Forloni et al., 1993), has 
been  shown  to  result  in  microglial  activation  and  the  production  of  reactive  oxygen 
species (ROS) (Combs et al., 1999). Furthermore, the expression of N-terminally truncated 
PrP
C  in  PrP
C-null  mice  has  been  reported  to  lead  to  rapid  degeneration  of  cerebellar 
neurones, which can be rescued by co-expression of WT PrP
C (Shmerling et al., 1998). PrP
C 
has also been reported to confer cytoprotection against the deleterious effects of the pro-
apoptotic protein Bax (Bounhar et al., 2001). N-terminally truncated PrP
C mutants have 
been  shown  to  activate  both  Bax-dependent  and  independent  neurotoxic  pathways, 56 | P a g e  
 
suggesting that this region could be crucial for the putative cytoprotective activity of PrP
C 
(Li et al., 2007a).  
 
1.6.2  PrP
Sc as the neurotoxic entity 
It is widely hypothesised that an unknown toxic gain of function of PrP
Sc, or its 
precursor, is more likely to underlie cell death than a loss of PrP
C function. Studies have 
suggested that both full-length PrP
Sc (Hetz et al., 2003) and shorter PrP peptides are toxic 
to primary neuronal cultures in vitro (Forloni et al., 1993), but their relevance to in vivo 
pathogenesis is under debate. Primary neurones have been shown to undergo apoptosis 
when exposed to low concentrations of PrP106-126 (Forloni et al., 1993). However, as 
there is no evidence for the occurrence of PrP106-126 in vivo, its relevance to the actual 
disease  pathogenesis  is  unclear.  Moreover,  purified  full-length  PrP
Sc  has  also  been 
demonstrated  to  cause  apoptotic  cell  death  in  neuroblastoma  cells  via  caspase  12 
activation and ER stress (Hetz et al., 2003).  
Conversely,  although  PrP
Sc  is  thought  to  be  associated  with  neuropathological 
features and with prion infectivity, strong evidence suggests that PrP
Sc itself may not be 
the toxic entity. For example, PrP
C-null tissue remains healthy and free of pathology when 
exposed to PrP
Sc (Brandner et al., 1996; Mallucci et al., 2003). Brandner and colleagues 
showed that when neural tissue over-expressing WT PrP
C is grafted into PrP
C-null mice, 
prion infection of the mice leads to increased levels of PrP
Sc and neurodegeneration only 
in  the  PrP
C-expressing  graft  (Brandner  et  al.,  1996).  Furthermore,  depletion  of 
endogenous neuronal PrP
C in prion-infected mice has been demonstrated to reverse early 
spongiform change and prevent neuronal loss and progression to clinical disease, despite 
the  presence  of  extra-neuronal  PrP
Sc  (Mallucci  et  al.,  2003).  Another  line  of  evidence 
arguing  against  direct  PrP
Sc  toxicity  comes  from  CJD  cases,  as  no  direct  correlation 
between PrP
Sc plaques and neuronal loss has been demonstrated in the brains of CJD 
patients (Parchi et al., 1996). In addition, prion diseases where PrP
Sc levels are barely 
detectable have been described (Collinge et al., 1995; Lasmezas et al., 1997; Piccardo et 
al., 2007). For example, although mice inoculated with BSE prions exhibit neuronal death, 57 | P a g e  
 
biochemical analysis shows no detectable PrP
Sc (Lasmezas et al., 1997); PrP
Sc levels are 
also barely detectable in brain homogenates from FFI patients and transgenic FFI mice 
(Collinge et al., 1995). Conversely, Piccardo et al. recently showed an accumulation of PrP 
in a GSS patient, and in transgenic mice inoculated with brain homogenate from the same 
case, in the absence of any spongiform degeneration (Piccardo et al., 2007). Furthermore, 
subclinical  infection,  where  high  levels  of  PrP
Sc  accumulate  in  the  absence  of  clinical 
symptoms, has also been described (Hill et al., 2000; Race et al., 2001; Race et al., 2002; 
Hill  and  Collinge,  2003a).  Moreover,  prion-infected  transgenic  mice  expressing  PrP
C 
without  a  GPI  anchor  produce  infectious  prions,  accumulate  extracellular  PrP  amyloid 
plaques, but do not succumb to disease (Chesebro et al., 2005). It has also been suggested 
that PrP
Sc needs to interact with cell surface PrP
C to exert a neurotoxic effect via aberrant 
signalling cascades (Solforosi et al., 2004).  
 
1.6.3  Aberrant PrP
C trafficking 
Studies have suggested that PrP
C may be neuroprotective (Section 1.5.3) and that 
aberrantly processed or atypical topological PrP
C variants perhaps induced by PrP
Sc, might 
be neurotoxic (Hegde et al., 1998; Hegde et al., 1999; Yedidia et al., 2001; Ma et al., 2002). 
Studies in cell-free translation/translocation systems have shown that PrP can be found in 
more  than  one  topologic  forms  (Hay  et  al.,  1987).  Following  translocation  in  the  ER 
(Section  1.5.2),  PrP
C  can  assume  two  different  transmembrane  topologies  (
CtmPrP-  C 
transmembrane PrP with an extracellular C-terminus and 
NtmPrP- N transmembrane PrP 
with  an  extracellular  N-terminus)  (Hegde  et  al.,  1998).  Both  isoforms  are  thought  to 
represent  a  small  amount  of  total  PrP
C  (about  10%),  but  elevated 
CtmPrP  has  been 
associated with neurotoxicity (Hegde et al., 1998; Hegde et al., 1999). Hegde et al. showed 
in vivo that the expression of PrP with the A117V mutation, which is linked to GSS, leads to 
neurodegeneration  with  a  prion  disease  phenotype  (Hegde  et  al.,  1998).  The  authors 
showed increased levels of 
CtmPrP, but low levels of PrP
Sc accumulation, in the transgenic 
mice carrying the A117V mutation, as well as in a patient carrying the same mutation. 
More  recently,  it  has  been  shown  that  neurodegeneration  in 
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depends on the co-expression of endogenous WT PrP
C (Stewart et al., 2005). 
CtmPrP is 
thought  to  be  a  critical  intermediate  in  the  pathway  of  prion-mediated 
neurodegeneration, by means of escaping ER quality control mechanisms (Hegde et al., 
1998; Hegde et al., 1999).  
It has also been suggested that the accumulation of PrP
C in the cytosol may be 
neurotoxic  (Ma  et  al.,  2002).  During  ER-associated  degradation  (ERAD),  ER-resident 
proteins  in  an  unassembled  or  misfolded  form  undergo  retrograde  transport  to  the 
cytosol, where they get ubiquitinated and degraded by the proteasome (Meusser et al., 
2005) (Figure 1.9) and misfolded, mutant and WT forms of PrP have been shown to be 
degraded by ERAD (Zanusso et al., 1999; Jin et al., 2000; Ma and Lindquist, 2001; Yedidia 
et al., 2001; Ma et al., 2002; Cohen and Taraboulos, 2003). Under normal physiological 
conditions, PrP
C in the cytosol would be degraded by the proteasome. However, following 
proteasome  inhibition,  cytosolic  PrP
C  has  been  shown  to  aggregate,  acquire  partial 
resistance to proteases and the ability to self-replicate (Ma and Lindquist, 2001; Ma and 
Lindquist, 2002; Cohen and Taraboulos, 2003). Whilst cytoplasmic PrP
C aggregates have 
not  be  shown  to  be  toxic  themselves  (Ma  and  Lindquist,  2001;  Yedidia  et  al.,  2001), 
expression of a PrP mutant, which lacks signal sequences and the GPI anchor, cyPrP, that 
remains in the cytoplasm leads to neurodegeneration both in vitro and in vivo (Ma et al., 
2002). Recently, evidence of ER stress and decreased translocation into the ER of nascent 
PrP was reported during prion infection (Rane et al., 2008). The authors suggested that 
PrP
Sc accumulation could cause ER stress, forcing nascent PrP
C to retro-translocate to the 
cytosol, where putative toxic PrP molecules accumulate (Rane et al., 2008). At present 
there is debate concerning the role of ERAD in the intracellular trafficking of PrP
C and 
whether  cytoplasmic  PrP
C  is  involved  in  prion-mediated  neurotoxicity  (Section  1.9.1). 
Cytoplasmic PrP
C may be the normal outcome of PrP
C trafficking, which would rapidly be 
degraded  by  the  proteasome.  However,  functional  impairment  of  the  ubiquitin 
proteasome system (UPS) may account for the accumulation of cytoplasmic PrP
C and the 
ensuing toxicity (Section 1.9.1). 
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Figure 1.9 Proteasomal degradation of ERAD targets
8 
Aberrant proteins are recognised in the ER lumen by different quality control mechanisms, which 
escort terminally misfolded polypeptides to a putative channel that facilitates their export from 
the ER. Cytoplasmically exposed lysine residues are ubiquitinated by ubiquitin ligases. Dislocation 
is  completed  with  the  help  of  Cdc48p/p97  complex  and  membrane-extracted  substrates  are 
conveyed to the proteasome by accessory factors such as Rad23p and Dsk2p. 
 
                                                      
8 Reprinted by permission from Macmillan Publishers Ltd. Nat. Cell Biol., Meusser et al., Vol 7, pp 766- 772, 
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1.6.4  Intermediate PrP species 
An alternative explanation for the experimental observation that both PrP
C and 
PrP
Sc are required for toxicity (Sections 1.6.1, 1.6.2, 1.6.3), is that accumulation of high 
intracellular levels of disease-associated PrP, or an intermediate species, is required for 
cytotoxicity. For example, it has been suggested that a neurotoxic intermediate molecule, 
PrP
L (L for lethal), might be formed during the conversion of PrP
C to PrP
Sc (Hill et al., 2000; 
Hill and Collinge, 2003a), with PrP
L adopting a transient structure or conformation in the 
conversion of one to the other. However, the precise nature, or even the existence, of 
such a species remains unclear.  
 
1.6.5  Neuronal death in prion disease 
The exact mechanism of prion-mediated neurotoxicity is poorly understood. Cell 
death is thought to be caused via apoptosis as evidenced by in vitro and in vivo studies, as 
the presence of apoptotic neurones has been confirmed in both naturally-occurring and 
experimental models of prion disease (Dorandeu et al., 1998; Liberski et al., 2008) (Figure 
1.10).  Prion  infection-induced  neuronal  apoptosis  has  been  shown  to  occur  in  prion-
infected primary neurones (Cronier et al., 2004) and treatment of various primary cell 
cultures of brain origin with the peptide PrP106-126 has been shown to induce neuronal 
apoptotic death (Forloni et al., 1993; Brown et al., 1994a; Brown et al., 1996; Jobling et al., 
1999; Thellung et al., 2000); in vivo PrP106-126 injection in mouse retina has also been 
shown to induce apoptosis (Ettaiche et al., 2000). The exact mechanism by which PrP106-
126 treatment leads to apoptosis is unclear. Possibilities include increased production of 
ROS (Brown et al., 1996; Turnbull et al., 2003), or disruption of mitochondrial membranes 
with subsequent release of cytochrome C and caspase activation (O'Donovan et al., 2001). 
Carimalo et al. reported that exposure of primary cultures to PrP106-126 directly induces 
apoptosis, including early production of ROS and late activation of caspase 3, highlighting 
the  involvement  of  the  JNK-c-Jun  pathway  in  PrP106-126-mediated  neuronal  death 
(Carimalo et al., 2005). Caspase-12 activation has been detected in neuroblastoma cells 
treated with nanomolar concentrations of full-length PrP
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induce apoptosis (Hetz et al., 2003). Furthermore, prion-infected neuronal cells have been 
shown  to  become  apoptotic  following  mild  proteasome  inhibition  (Kristiansen  et  al., 
2005). The authors showed that proteasome impairment in prion-infected cells resulted in 
formation of large, cytosolic aggresomes, which was directly associated with activation of 
caspase  3  and  8,  resulting  in  apoptosis  (Kristiansen  et  al.,  2005)  and  implying  the 
possibility that proteasome dysfunction is involved in prion pathogenesis (Section 1.9.1).  
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Figure 1.10 Hypothetical mechanisms for prion neurotoxicity
9 
Misfolded PrP
C can be subject to the ERAD pathway. Under conditions of proteasome inhibition, 
cytoplasmic forms of PrP aggregates have been associated with neurotoxicity (such as PrP
cyto and 
aggresomes). The mechanisms by which these aggregates are generated (for example the retro-
translocation of PK-resistant PrP from the lumen of the endocytic and lysosomal vesicles into 
cytosolic aggresomes, and the cause of proteasome inhibition) are unknown. The release of ROS 
from chemokine-activated microglial cells could contribute to ER stress and/or the ERAD process 
by inactivation of ER chaperones (for example protein disulphibe isomerase (PDI) and GRP58), one 
of which has been shown to protect against prion neurotoxicity. Excessive levels of misfolded 
prion  proteins  in  the  cytosol  might  impair  proteasome  function,  either  directly  or  after 
incorporation into aggresomes.   
                                                      
9 Adapted by permission from Macmillan Publishers Ltd. Nature, Caughey, B., and Baron, G.S., Vol 443, 
Prions and their partners in crime, pp 803-810, © 2006. 63 | P a g e  
 
1.7  Therapeutic strategies in prion disease 
Prion diseases are currently incurable and there are no available effective drugs for 
individuals who are already infected (Mallucci and Collinge, 2005). If prion propagation 
depends on the conversion of PrP
C to PrP
Sc, then the prevention of this conversion should 
prevent  disease  progression  and  early  neuronal  changes  should  be  reversed.  Prion 
therapeutics  should  therefore  aim  for  the  design  of  compounds  that  prevent  disease 
onset  and/or  alter  progression,  or  for  the  use  of  neuronal  precursor  cells.  To  date, 
therapeutic approaches include the use of compounds such as Congo red, polyanionic 
compounds, amphotericin B, porphyrins and quinacrine, each of which has been shown to 
reduce accumulation of PrP
Sc in prion-infected cell models (Trevitt and Collinge, 2006). 
However, such models are not stringent screens and these compounds have produced 
only modest effects in vivo (Aguzzi et al., 2001). Targeting endogenous PrP
C in mice with 
early  prion  infection  reverses  spongiform  change  and  prevents  clinical  symptoms, 
neuronal loss, cognitive and behavioural deficits  (Mallucci et al., 2003; Mallucci et al., 
2007). Strategies to prevent the conversion process may also include the use of antibodies 
to bind and stabilise PrP
C (Enari et al., 2001; Heppner et al., 2001; Peretz et al., 2001b; 
White et al., 2003), but the use of large quantities of anti-PrP antibodies in the CNS is not 
feasible as yet as they have been reported to lead to marked neurodegeneration in mice 
(Solforosi et al., 2004). The use of RNA interference (RNAi) has been demonstrated to 
inhibit PrP
C  expression  in  neuroblastoma  cells  (Tilly  et  al.,  2003)  and to  prevent  PrP
Sc 
accumulation in scrapie-infected cells (Daude et al., 2003). In a recent study using a single 
administration  of  lentivirus-expressing  shRNA  targeting  PrP  into  each  hippocampus  of 
mice  with  established  prion  disease  resulted  in  significantly  prolonged  survival  times 
compared to control mice (White et al., 2008).  
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1.8  Cellular degradation systems  
Protein turnover is critical for the removal of misfolded or damaged proteins and 
in  contributing  to  the  amino  acid  pool  required  for  protein  synthesis,  especially  in 
conditions  in  which  there  are  limited  amounts  of  nutrients.  The  majority  of  cellular 
functions  are  regulated  by  changes  in  cellular  protein  levels,  which  are  obtained  by 
altering  the  delicate  balance  between  protein  synthesis  and  breakdown.  The  role  of 
protein  degradation  systems  in  protecting  cells  from  aberrant,  misfolded  proteins  has 
been in the spotlight due to its emerging relevance to human neurodegenerative disease. 
For the purposes of the work described in this thesis, the two major degradation pathways 
in eukaryotic cells, the UPS and the autophagy-lysosomal system, will be discussed in 
detail.  The  UPS  targets  short-lived  and/or  aberrant  ubiquitinated  proteins,  whereas 
autophagy is responsible for the degradation of long-lived proteins, organelles and for 
maintaining steady amino acid pools when the cell is starved. 
 
1.8.1  The ubiquitin proteasome system 
The UPS is the primary cellular quality control system in eukaryotes for selecting 
and degrading proteins that are either incomplete, missense, or misfolded, and that could 
potentially form toxic aggregates (Goldberg, 2003). In this highly complex and selective 
pathway, proteins destined for degradation are firstly covalently attached to ubiquitin, 
and  subsequently  recognised  and  degraded  by  the  26S  proteasome  in  an  ATP-driven 
process (Hershko and Ciechanover, 1998; Glickman and Ciechanover, 2002). The UPS is 
also responsible for the degradation of a vast number of crucial cellular factors, making it 
an  imperative  regulator  in  cellular  functions  ranging  from  the  cell  cycle  to  organelle 
biogenesis  (Glickman  and  Ciechanover,  2002).  Aberrations  in  the  UPS  have  been 
implicated in the pathogenesis of many diseases, including neurodegenerative diseases 
such  as  Parkinson’s  disease  (PD),  Huntington’s  disease  (HD),  AD  and  prion  disease 
(Ciechanover and Brundin, 2003).   
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The proteolytic process: ubiquitin meets the 26S 
Degradation  of  proteins  by  the  UPS  involves  two  discrete  steps:  a)  covalent 
attachment  of  a  poly-ubiquitin  chain  to  the  substrate,  which  serves  as  a  tag  for  its 
recognition by the 19S regulatory particle, and b) 26S-mediated substrate degradation 
with  the  release  of  free  and  recyclable  ubiquitin  (Hershko  and  Ciechanover,  1998). 
Ubiquitin is a highly conserved 76 amino acid protein ubiquitously expressed in cells of all 
eukaryotes. During ubiquitination an isopeptide bond is formed between a lysine residue 
on the substrate and the carboxyl terminus of ubiquitin (Figure 1.11). The biochemical 
steps in ubiquitination involve three different types of enzyme: E1 (ubiquitin-activating 
enzyme),  E2  (ubiquitin-conjugating  enzyme)  and  E3  (ubiquitin  ligase)  (Hershko  and 
Ciechanover, 1998). The first step activates ubiquitin by its ATP-dependent conjugation to 
an E1 enzyme, followed by its transfer to an E2 enzyme. Ubiquitin is then transferred from 
the E2 to the substrate by the action of an E3 ligase, which can further elongate the 
ubiquitin  chain  by  creating  isopeptide  bonds  between  ubiquitin  moieties.  E3  enzymes 
confer target recognition, through physical interactions with the substrate. Indeed, there 
is a vast number of E3 genes in eukaryotic genomes (Ardley and Robinson, 2005), which 
reflects the precise nature of substrate recognition in UPS-mediated degradation (Semple, 
2003).  Moreover,  mass  spectrometry  studies  have  demonstrated  that  all  seven  lysine 
residues in ubiquitin (lys 6, lys 11, lys 27, lys 29, lys 33, lys 48, lys 63) are used for chain 
elongation (Peng et al., 2003), but currently the importance of different ubiquitination 
patterns is poorly understood (Kuhlbrodt et al., 2005). The most abundant chains are lys 
48-linked and result in 26S-mediated substrate degradation, whereas the less frequent lys 
63-linked  chains  have  been  suggested  to  mediate  other  biological  functions,  such  as 
marking proteins for endocytosis (Tai and Schuman, 2008). 
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Figure 1.11 Overview of ubiquitination in the ubiquitin proteasome system
10 
An isopeptide bond forms between a lysine residue on the target protein and ubiquitin (ub) during 
ubiquitination, which consists of 4 different classes of enzymes: E1–E4. First, ub is covalently 
conjugated  to  the  ub-activating  E1  enzyme  in  an  ATP-dependent  reaction,  and  then  it  is 
transferred to the ub-conjugating E2 enzyme. The E3 ub–protein ligase transfers the ub from the 
E2 to the substrate. After the first ub has been attached, the E3 can elongate the ub chain by 
creating ub–ub isopeptide bonds. The E4 enzymes (chain elongation factors) are a subclass of E3-
like enzymes that only catalyse chain extension. K48 chains lead to 26S proteasome-mediated 
degradation,  whereas  monoubiquitylation  and  K63  chains  do  not  specify  degradation.  Several 
classes  of  UPS  factors  are  involved  in  presenting  substrates  to  the  proteasome  including 
ubiquitylating enzymes (E1–E4) and deubiquitylating enzymes (DUBs). The organization of these 
factors can differ for each substrate, and only one potential configuration is represented. The 
figure shows an example of how a protein’s ubiquitylation pattern can be dynamically edited by 
E3s,  E4s  and  DUBs.  When  K48-polyubiquitylated,  the  protein  can  reach  the  proteasome  by 
diffusion or with the assistance of chaperones and shuttling factors.  
                                                      
10 Adapted by permission from Macmillan Publishers Ltd. Nat. Rev. Neurosci., Tai and Shuman, Vol 9, pp 
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The 26S proteasome 
The 26S proteasome is an essential, 2.4 MDa, ATP-dependent enzyme complex, 
resident in both the nucleus and the cytosol of eukaryotic cells (Coux et al., 1996). It is 
made up of at least thirty-two different subunits and consists of a 20S proteolytic core 
capped at one or both ends by a 19S complex (also known as PA700) (Figure 1.12). The 
20S  is  a  cylinder-shaped  multi-protein  complex  possessing  a  central  cavity  where 
hydrolysis proceeds without interference from the cytosol; the 19S contributes various 
functions to the 26S proteasome. The structural instability of the 26S proteasome makes it 
very  hard  to  conduct  detailed  structural  analyses  and  therefore  insights  into  the  26S 
proteasome structure come from studies on the structure, assembly and function of the 
20S proteasome as well as on properties of the 19S.  
The 20S proteasome has a molecular weight of about 700 kDa, a diameter of 11 
nm and height of 15 nm. 20S proteasomes exist in all pro- and eukaryotes (Dahlmann et 
al., 1992) and it is EM studies of Thermoplasma 20S proteasomes that have shown that 
these  enzymes  are  arranged  as  cylinders  (Puhler  et  al.,  1992).  In  eukaryotes,  20S 
proteasomes are essential and ubiquitously expressed (Zwickl et al., 2000). The eukaryotic 
20S proteasome is composed of fourteen  and fourteen  subunits arranged in four 
stacked  rings.  Immuno-EM  studies  demonstrated  that  the  subunits  form  two  rings, 
which  are  located  between  two  rings  of    subunits  (Zwickl  et  al.,  1992).  X-ray 
crystallography revealed that each ring consists of seven subunits with an overall highly 
conserved architecture arranged as (1-7)(1-7)(1-7)(1-7) (Lowe et al., 1995; Voges et 
al.,  1999).  Like  archaea,  eukaryotic  20S  proteasomes  share  this  common  subunit 
architecture, but eukaryotic 20S have seven different  and  subunits in two copies per 
20S, thereby resulting in a pseudo-seven-fold symmetry (Groll et al., 1997). In reality, the 
20S proteasome has a two-fold axis of symmetry (Groll et al., 1997; Groll et al., 2000). 
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Figure 1.12 Subunit composition of the 26S proteasome
11 
Schematic of the 26S proteasome in Saccharomyces cerevisiae, showing the 20S proteolytic core 
and one 19S regulatory particle. The 19S is made up of two sub-complexes termed lid and base, 
the latter consisting of six homologous members of the ATPase family (Rpt1-6; shown in red) and 
two larger, non-ATPase subunits (Rpn1 and Rpn2). The C-termini of the ATPases dock into inter-
subunit pockets in the rings of the proteasome and open the gate for substrate hydrolysis by the 
20S  subunits. Cross section of the ring reveals the positions of the caspase-like (1), trypsin-like 
(2)  and  chymotrypsin-like  (5)  subunits  (all  shown  in  yellow).  Rpn=  regulatory  particle  non-
ATPase; Rpt= regulatory particle ATPase.  
 
                                                      
11 Reprinted from BBA Molecular Basis of Disease, Vol 1782, Deriziotis P. And Tabrizi S., Prions and the 
proteasome, pp 713-722, © 2008 with permission from Elsevier. 69 | P a g e  
 
The 20S proteasome is where hydrolysis of polypeptides occurs. The proteolytic 
activity of the 20S proteasome resides in its two  β-rings and only three of the seven 
different  subunits  in  eukaryotes  contain  functional  active  sites,  resulting  in  only  six 
active sites per proteasome (Groll et al., 1997). Studies using synthetic peptide substrates 
have demonstrated that the 20S proteasome comprises three distinct catalytic activities 
termed 1 (caspase-like; cleaving after acidic residues), 2 (trypsin-like; cleaving after basic 
residues),  and  5  (chymotrypsin-like;  cleaving  after  hydrophobic  peptides)  (Orlowski, 
1990). Mutational and biochemical studies of the specificity of the proteasomal subunits 
have revealed that all proteolytic activities can be assigned to 1, 2 and 5 subunits, 
rejecting the existence of other active sites (Dick et al., 1998). Moreover, comparisons of 
cleavage of enolase 1 between WT and mutant 20S proteasomes showed that product 
length  is  not  dependent  on  the  number  of  active  sites  (Nussbaum  et  al.,  1998). 
Nonetheless, as there is mutual allosteric regulation of the chymotrypsin-like and caspase-
like sites, it has been suggested that 20S proteolysis proceeds in a ‘bite and chew’ fashion 
(Kisselev et al., 1999). Unfolded polypeptides have been shown to be processively cleaved 
by  the  proteolytic  active  sites  of  the  20S  in  Thermoplasma,  yeast  and  rabbit  muscle 
(Nussbaum et al., 1998; Kisselev et al., 1998; Kisselev et al., 1999). The resulting fragments 
range from 3-30 amino acids in length, with the average peptide comprising 7-8 residues, 
and which may be further degraded by cytosolic endopeptidases and aminopeptidases 
(Kisselev et al., 1999; Venkatraman et al., 2004; Bhutani et al., 2007).  
The use of inhibitor (Fenteany et al., 1995), deletion and mutation (Seemuller et 
al., 1995) studies have confirmed the 20S as a threonine protease, whereby the secondary 
alcohol of the N-terminal threonine of the active  subunit acts as the nucleophilic species 
(Lowe et al., 1995). Only three of the seven eukaryotic subunits have an N-terminal 
threonine, namely 1, 2 and 5, thereby resulting in the six active sites per proteasome 
(Groll  et  al.,  1997).  Interestingly,  mutational  and  crystallographic  studies  in  yeast  20S 
found that the inactive subunits 3, 6 and 7 cannot be rendered active by introducing 
canonically active residues, including Thr1 (Groll et al., 1999; Zwickl et al., 2000).   70 | P a g e  
 
The  precise  structural  organisation  of  the  20S  proteasome  functions  to  isolate 
proteolytic  compartments  from  the  cytoplasm,  thereby  preventing  unwanted 
degradation,  and  more  importantly  to  impose  constraints  on  substrate  entry.  This  is 
achieved by the two -rings, which form gated channels through which substrates enter 
and  peptides  exit  the  20S  proteasome.  Structural  studies  in  free  eukaryotic  20S 
proteasomes  have  shown  that  the  N-termini  of  the  seven    subunits  assume  unique 
conformations while pointing inwards to the centre of the ring (Groll et al., 1997; Groll et 
al., 2000); the N-termini of the  subunits keep the pore, or ‘gate’, of the proteasome in a 
closed state (Figure 1.13). Activation of the 20S reflects the opening of a channel, which 
allows substrate access (Groll et al., 2000). This is achieved by the re-arrangement of the 
N-terminal segments of various subunits, which normally keep the gate sealed. Evidence 
for a gated channel into the proteolytic core came from crystallographic studies by Groll 
and colleagues, who compared WT yeast 20S proteasome with the 3N mutant, which 
lacks the nine N-terminal residues of the 3 subunit. Even though each of the seven tails is 
remarkably conserved, they differ from one another and it is the 3 N-terminal segment 
that projects directly across the pseudo-seven-fold symmetry. The 3N 20S proteasome 
demonstrates increased rates of hydrolysis of small peptides compared to its WT 20S 
counterpart (Groll et al., 2000; Kohler et al., 2001). This is because neighbouring subunit 
tails are significantly disordered (in the absence of the nine N-terminal residues of the 3 
subunit) and the 3N 20S proteasome mutant is constitutively in an open state (Figure 
1.13).   
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Figure 1.13 The gated channel of the 20S proteasome
12 
Electron density maps of the  ring of the yeast core particle from a) WT and b) 3N cells. The N-
terminal segments of the seven  subunits (shown in different colours) seal the central channel in 
the 20S core particle (WT). The deletion of nine residues of the 3 subunit (shown in yellow in a) 
and the loss of order in 20 residues from the other subunits, each of which directly contacts the 3 
tail in the WT complex, results in a loss of electron density in the 3N core particle compared to 
WT. 
 
 
                                                      
12 Reprinted by permission from Macmillan Publishers Ltd. Nat. Struct. Biol., Groll et al., A gated channel into 
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20S activation can be achieved in various ways, the most prominent of which is the 
attachment of regulatory particles (Chu-Ping et al., 1994; Hoffman and Rechsteiner, 1994). 
The 20S proteasome can degrade short or unstructured polypeptides, and it has been 
shown to degrade proteins with misfolded or hydrophobic patches (Orlowski and Wilk, 
2003; Forster and Hill, 2003). In an ATP-driven reaction, the 19S binds substrates, unfolds 
them, removes the poly-ubiquitin chain and translocates the polypeptide into the 20S for 
degradation (Pickart and Cohen, 2004) (Figure 1.14). The C-termini of the six 19S ATPases 
(Rpt1-Rpt6)  (Figure 1.12)  contain  a  conserved HbYX  (hydrophobic  amino  acid residue-
tyrosine-X amino acid residue) motif that docks into the pockets between the adjacent  
subunits of the 20S (Smith et al., 2007). Peptides seven residues or longer that correspond 
to  these  ATPases’  C-termini  and  contain  the  HbYX  motif,  such  as  CtRpt5,  which 
corresponds to the Rpt5 ATPase, dock into the same pockets and induce gate-opening 
(Smith et al., 2007; Gillette et al., 2008). When the ATPases bind a nucleotide, these C-
termini function like a ‘key in a lock’ to open the gate. 
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Figure 1.14 Model depicting the association of PAN with the -ring of the 20S proteasome
13 
(A) The C-termini (yellow) of PAN (orange) dock into the inter-subunit pockets in the top of the 
20S. (B) Schematic model for gate opening in the 20S upon binding of peptides derived from PAN’s 
C-terminus  to  the  inter-subunit  pockets  in  the  20S.  (C)  (Top)  Top  view  of  the  20S  a  ring 
demonstrating  the  inter-subunit  pockets  and  location  of  Lys66  (yellow).  (Bottom)  Ribbon 
representation  of  the    ring.  The  N-terminal  gating  residues  are  not  resolved  in  this  crystal 
structure.  
                                                      
13 Reprinted from Mol. Cell, Vol 27, Smith, D.M. et al., Docking of the proteasomal ATPases’ carboxyl termini 
in the 20S proteasome’s  ring opens the gate for substrate entry, pp 731-744. © 2007 with permission 
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1.8.2  Autophagy 
Autophagy,  which  literally  means  ‘self-eating’,  is  a  process  in  which  cellular 
constituents, such as organelles and proteins, are degraded by the lysosomal system. This 
degradation system is highly conserved from yeast to humans and studies in yeast have 
identified over twenty different autophagy-related genes (Atg) (Reggiori, 2006). Unlike the 
UPS, which targets mostly short-lived proteins (Ciechanover et al., 2000), autophagy is 
primarily responsible for the catabolism of long-lived proteins and for maintaining steady 
amino acid pools during starvation. Apart from its role in protein degradation, autophagy 
is  also  involved  in  various  cellular functions  ranging  from  antigen  presentation to the 
regulation  of  development  and  cell  death  (Mizushima,  2005).  Initially,  autophagy  was 
thought to be associated with the ‘bulk’, non-selective degradation of proteins, but recent 
molecular advances have revealed specialised forms of autophagy that differ in the way 
cytosolic constituents reach the lysosomal compartment.  
The  three  types  of  autophagy  are:  microautophagy,  chaperone-mediated 
autophagy  (CMA)  and  macroautophagy  (Figure  1.15).  The  molecular  mechanism  of 
microautophagy  is  unknown,  but  the  process  itself  involves  the  direct  engulfment  of 
cytosol by lysosomes (Ahlberg et al., 1982). CMA is a regulated, selective process, which 
entails the receptor-mediated translocation of proteins that contain a pentapeptide motif 
into the cytosol (Dice, 1990). Macroautophagy is responsible for the degradation of long-
lived  proteins,  and  requires  the  formation  of  double-membraned  vesicles  called 
autophagosomes  and  their  subsequent  fusion  with  lysosomes  in  which  their  cargo  is 
degraded.  In  mammalian  cells,  autophagosomes  fuse  with  late  endosomes  and 
multivesicular  bodies  to  form  ‘amphisomes’  (Berg  et  al.,  1998),  which  then  fuse  with 
lysosomes. Macroautophagy (hereafter referred to as autophagy) can also be selective; 
autophagic  processes  have  been  shown  to  be  specific  for  mitochondria  (mitophagy), 
peroxisomes  (pexophagy),  ribosomes  (ribophagy),  protein  aggregates  (aggrephagy) 
(Kundu et al., 2003). 
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Figure 1.15  Autophagy, a cellular degradation system
14 
Proteins that are tagged with poly-ubiquitin chains are generally considered to be substrates for 
the UPS, which feeds unfolded proteins through the barrel of the 26S proteasome and generates 
small digested peptides. Recent evidence suggests that some ubiquitinated substrates can also be 
degraded  via  the  autophagy-lysosomal  system.  This  system  comprises  (1)  macroautophagy  in 
which  cytosolic  components  are  engulfed  and  delivered  to  the  lysosome  in  bulk,  (2) 
microautophagy, in which small volumes of cytosol are directly engulfed by lysosomes, and  (3) 
chaperone-mediated  autophagy  (CMA),  in  which  soluble  substrates  associated  with  a  specific 
chaperone complex translocate into the lysosome via the lysosomal-associated membrane protein 
2A (LAMP-2A) lysosomal receptor. Macroautophagy involves a series of maturation steps. First, a 
portion of cytoplasm is surrounded by an expanding isolation membrane or phagophore. Second, 
the phagophore seals to form an autophagosome, which in mammals fuses with late endosomes 
and  multivesicular  bodies  to  form  an  amphisome.  Third,  the  amphisome  then  fuses  with  a 
lysosome to form an autolysosome, in which cytosolic cargo is degraded by lysosomal hydrolases. 
LC3-II is a protein that associates with the inner and outer surfaces of autophagic membranes, and 
provides a marker of autophagic vacuoles.  
                                                      
14 Reprinted from BBA Molecular Basis of Disease, Nedelsky et al., Autophagy and the UPS: Collaborators in 
neuroprotection, Vol 1782, pp 691-699, © 2008 with permission from Elsevier. 76 | P a g e  
 
Autophagy occurs at a basal level during growth and development, but can be up-
regulated in conditions of cellular stress, such as during starvation. Autophagy induction is 
regulated by the target of rapamycin (TOR) kinase, which acts as a sensor for nutrient 
levels.  Inactivation  of  TOR  in  yeast  or  mammalian  cells  leads  to  the  induction  of 
autophagy, even in nutrient-rich growth medium, indicating that TOR negatively controls 
starvation-induced autophagy (Blommaart et al., 1995; Noda and Ohsumi, 1998). Shortly 
after induction, the expansion of an isolation membrane, or phagophore, engulfs a portion 
of the cell and eventually fuses to form the autophagosome (Figure 1.15). The induction, 
selection and packaging of cargo, formation of autophagosomes and completion, recycling 
of  autophagy  regulators,  fusion  of  the  autophagosome  with  the  lysosome  and  cargo 
degradation are all dependent on the function of key Atg genes and two highly conserved 
ubiquitin-like  conjugation  reactions  (Figure  1.16).  One  involves  the  formation  of  the 
Atg12-Atg5  complex,  which  can  additionally  bind  Atg16,  and  the  other  involves  the 
association of Atg8 (microtubule-associated protein 1 light chain in mammals, LC3) with 
phosphatidylethanolamine (PE). The function of the former 300 kDa complex is important 
in autophagosome membrane formation and has been shown to stabilise the Atg8-PE 
complex. The conjugation reaction between LC3 and PE allows for the lipidation of the 
cytosolic LC3I, forming the autophagosome-bound LC3II; LC3II is the only known protein 
that  remains  attached  to  the  autophagosomal  membrane  and  thus  is  a  marker  for 
autophagosome number (Kabeya et al., 2000; Tanida et al., 2005). After they are formed, 
autophagosomes proceed stepwise to eventually fuse with lysosomes. 
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Figure 1.16 Atg conjugation pathways 
In the Atg12-Atg5 pathway, the E1-like Atg7 associates with Atg12, which is then transferred to 
the E2-like Atg10 and finally conjugated to Atg5. In the Atg8-PE pathway, Atg8 associates with the 
E1-like Atg7, is then transferred to the E2-like Atg3, and subsequently conjugated to PE via the E3 
action of the Atg12-Atg5 complex.  78 | P a g e  
 
1.9  Cellular degradation systems and neurodegenerative diseases 
Accumulating  evidence  in  neurodegenerative  diseases  such  as  AD,  PD,  HD, 
amyotrophic lateral sclerosis (ALS) and prion disease suggests that they share cellular and 
molecular  mechanisms  such  as  protein  misfolding  and  aggregation  (Ross  and  Poirier, 
2004). These ‘proteinopathies’ are characterised by the formation of protein aggregates, 
which  usually  include  ubiquitinated  deposits  (Tai  and  Schuman,  2008).  Indeed, 
abnormalities of four proteins, namely TAR DNA binding protein-43 (TDP-43), -synuclein, 
tau and amyloid  have been linked to 90% of dementias (Tai and Schuman, 2008). The 
nature  of  the  neurotoxic  species  in  neurodegenerative  disease  has  been  a  matter  of 
increased debate and ambiguity (Taylor et al., 2002; Ross and Poirier, 2005). Whether 
soluble  monomers,  oligomers,  or  larger  amyloid  fibrils  are  responsible  for  the 
neuropathology  of  neurodegenerative  disease,  the  general  consensus  is  that  it  is  the 
capacity of abnormal proteins to aggregate per se that correlates with toxicity. Genetic 
and  transgenic  studies  support  the  notion  that  mutations  in  the  relevant  proteins  in 
neurodegenerative  disease  confer  a  toxic  gain-of-function,  thereby  causing  disease. 
Therefore,  an  understanding  of  cellular  processes  such  as  protein  degradation,  which 
coupled to protein synthesis regulates protein levels, is critical. Both proteasomes and 
lysosomes have been reported around ubiquitin-positive aggregates, but an unanswered 
question  remains  as  to  how  neurodegeneration  is  linked  to  protein  degradation 
impairment; is degradation impairment responsible for disease (and aggregate formation 
secondary), or is it that protein aggregation is toxic and subsequently interferes with the 
degradation of other proteins? 
 
1.9.1  The UPS and neurodegenerative disease 
Dysfunction  of  the  UPS  and  the  autophagy-lysosomal  pathway  have  been 
implicated  in  neurological  diseases  (Rubinsztein,  2006;  Levine  and  Kroemer,  2008).  In 
sporadic  PD,  studies  have  reported  loss  of    subunits  of  20S/26S  and  reduced  20S 
proteolytic activities (McNaught et al., 2003), but whether this is a cause or late effect of 
the disease is poorly understood. The discovery of UPS mutations associated with familial 79 | P a g e  
 
PD has provided the strongest support for a primary role of the UPS in the pathogenesis of 
neurodegenerative disease. Mutations in the E3 ubiquitin ligase parkin cause one of the 
more common types of familial PD, characterised by early onset, loss of dopaminergic 
neurones in the substantia nigra, usually in the absence of Lewy bodies (Shimura et al., 
2000). Mutations in UCHL1, a de-ubiquitinating enzyme, have also been implicated with 
familial and sporadic PD, but there are conflicting data  (Belin and Westerlund, 2008). 
Recently, studies using novel conditional genetic mouse models showed that targeted 
conditional  disruption  of  Rpt2  (19S  ATPase;  Figure  1.12)  in  the  substantia  nigra  and 
forebrain results in neurodegeneration and Lewy body-like pathology, directly confirming 
that  26S  dysfunction  in  neurones  is  involved  in  the  pathology  of  neurodegenerative 
disease (Bedford et al., 2008).  
A significant subset of proteins that cause proteinopathies are partly dependent on 
the  UPS  for  their  degradation  (Ravikumar  et  al.,  2002;  Webb  et  al.,  2003),  but 
proteasomes cannot efficiently degrade proteins when they are aggregated (Verhoef et 
al.,  2002).  Moreover,  the  proteasome’s  enzymatic  machinery  is  not  able  to  cleave 
between  successive  polyQ  residues,  which  characterise  polyQ  diseases  such  as  HD 
(Venkatraman et al., 2004). In polyQ disease there is conflicting evidence regarding the 
role of the UPS. Studies have shown impaired UPS function in both HD patient brain and 
HD-patient-derived fibroblasts (Seo et al., 2004). However, in a spinocerebellar ataxia 7 
mouse  model,  polyQ  pathogenesis  has  been  described  in  the  absence  of  marked 
proteasome  impairment  (Bowman  et  al.,  2005).  Additionally,  in  the  R6/2  transgenic 
mouse model of HD there was no detectable impairment of proteasome catalytic function 
(Bett et al., 2006). In a recent study, global changes to the UPS were reported in HD, early 
in the disease course in both the R6/2 transgenic mouse model as well as in HD patients 
(Bennett et al., 2007), suggesting that the impairment may be occurring at the level of 
ubiquitin turnover rather than impairment of proteolytic function  per se. Furthermore, 
recent  findings  of  UPS  impairment  in  the  synapses  of  transgenic  HD  mice,  which 
contribute  to  early  synaptic  dysfunction,  underscore  the  importance  of  investigating 
proteasome activity in various sub-cellular regions (Wang et al., 2008). 
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The UPS and prion disease 
Cytosolic PrP
C 
There is increasing data for a role of the UPS in prion disease. The UPS is involved 
in  ERAD  where  ER-resident  proteins,  in  unassembled  or  misfolded  forms,  undergo 
retrograde  transport  to  the  cytosol,  get  ubiquitinated  and  are  degraded  by  the 
proteasome (Meusser et al., 2005) (Figure 1.9). Both WT and misfolded forms of PrP
C 
undergo ERAD (Ma and Lindquist, 2001; Yedidia et al., 2001). A pathogenic PrP
C mutant 
(Y145stop) associated with an inherited prion disease, GSS, is degraded via ERAD (Zanusso 
et al., 1999), whereas another GSS-associated PrP
C mutant (Q217R), remains bound to BiP, 
an ER chaperone, for an unusually long period of time prior to proteasomal degradation 
(Jin  et  al.,  2000).  More  importantly,  WT  PrP
C  molecules  undergoing  ERAD  have  been 
shown to accumulate in the cytosol when the proteasome is inhibited (Ma and Lindquist, 
2001;  Yedidia  et  al.,  2001).  Yedidia  et  al.  showed  that  cells  treated  with  proteasome 
inhibitors accumulate both detergent-soluble and insoluble PrP
C species, with the latter 
containing a protease-resistant core and ubiquitin (Yedidia et al., 2001). In a separate 
study, Ma and Lindquist showed that inhibition of the proteasome in cells leads to a 
significant fraction of endogenous PrP
C accumulation in the cytoplasm (Ma and Lindquist, 
2001). The authors suggest that PrP
C accesses the cytoplasm via retrograde transport from 
the ER. Electron microscopy of mouse brain sections shows that cytosolic PrP
C is localised 
in the neurones of the hippocampus, neo-cortex and thalamus, supporting the fact that 
cytosolic PrP
C occurs in vivo (Mironov, Jr. et al., 2003). It has been reported that UPS 
impairment may allow the conversion of this cytosolic PrP
C to an abnormal, ‘PrP
Sc-like’ 
form, with partial protease resistance and detergent insolubility (Ma and Lindquist, 2002). 
Proteasome inhibition has been shown to cause the accumulation of PrP
C aggregates in 
the cytosol of neurones with some PrP
Sc like properties, such as self-sustaining replication 
and partial PK-resistance (Ma and Lindquist, 2002). It is possible that if the quantity of PrP
C 
exceeds the degradative capacity of the UPS, then some PrP
C may be able to convert to a 
protease-resistant  pathogenic  form  as  removal  of  the  proteasome  inhibitor  does  not 
affect the abnormal PrP generation process once it starts (Ma and Lindquist, 2002).  81 | P a g e  
 
The  relationship  between  UPS  inhibition,  cytosolic  PrP
C  accumulation  and 
neurotoxicity in prion disease has been investigated. Studies indicate that cytosolic PrP
C 
accumulation appears toxic to neurones (Ma et al., 2002; Rane et al., 2004; Rambold et 
al., 2006). Cells with higher levels of PrP
C expression have been shown to be selectively 
killed by treatment with proteasome inhibitors (Ma et al., 2002). In the same study, Ma et 
al. showed that unglycosylated PrP
C lacking a signal peptide, and hence the ability to 
traffic to the ER, accumulates in the cytosol and is neurotoxic. In agreement with these 
findings, it has been shown that cytosolic PrP
C accumulates in cells when the function of 
the PrP
C signal sequence is compromised (Rane et al., 2004). More evidence for a toxic 
role  of  cytosolic  PrP
C  comes  from  a  yeast  model  in  which  during  post-translational 
targeting  of  PrP
C  to  the  ER,  PrP
C  is  mis-sorted  to  the  cytosol  and  interferes  with  cell 
viability  (Heller  et  al.,  2003).  Additionally,  toxicity  has  been  linked  to  cytosolic  PrP
C 
accumulation, when PrP
C co-aggregates with the anti-apoptotic protein Bcl-2 with toxicity 
abrogated after over-expression of heat shock proteins Hsp70 and Hsp40 (Rambold et al., 
2006). In vivo, mice expressing a PrP
C mutant lacking the N-terminal ER targeting signal 
(cytoPrP)  develop  normally,  but  are  severely  ataxic,  with  cerebellar  degeneration  and 
gliosis; they also accumulate an insoluble form of PrP
C (Ma et al., 2002).  
Despite the experimental data described above, the neurotoxic nature of cytosolic 
PrP
C in prion pathogenesis is under debate. The absence of toxicity when cytosolic PrP
C 
accumulates in human primary neurones treated with proteasome inhibitors has been 
reported; paradoxically, it protects against Bax-mediated cell death (Roucou et al., 2003). 
Importantly, it has been observed that neither mutant or WT PrP
C undergo retrograde 
transport prior to proteasome degradation in various cell models (Drisaldi et al., 2003; 
Fioriti et al., 2005). Furthermore, it has been argued that cytosolic PrP
C accumulation may 
be  a  result  of  elevated  levels  of  PrP
C  expression  from  the  cytomegalovirus  (CMV) 
promoter used in many of the experiments. Drisaldi et al. show that proteasome inhibition 
results in the accumulation of unglycosylated cytosolic PrP
C in cells over-expressing PrP
C 
under the CMV promoter, but not in un-transfected or Tg mice-derived primary neurones, 
which express PrP
C from the endogenous promoter (Drisaldi et al., 2003). Similarly, Fioriti 
et  al.  show  that  UPS  inhibition  in  transfected  cells  expressing  mutant  mouse  PrP 82 | P a g e  
 
homologues associated with inherited human prion diseases causes accumulation of an 
unglycosylated, aggregated form of PrP
C in transfected cells that is not toxic (Fioriti et al., 
2005). In agreement with previous findings (Drisaldi et al., 2003), the authors show that 
elevated PrP
C expression leads to cytosolic PrP
C accumulation and suggest this is due to 
impaired  degradation  of  abortively  translocated,  signal  peptide-bearing  molecules 
synthesised from the CMV promoter.  
Furthermore, the occurrence of PrP
C retrograde transport has been challenged, as 
antibodies against the signal peptide show that PrP
C accumulates in the cytosol as a result 
of failed translocation into the ER. In vivo, accumulation of unglycosylated cytosolic PrP
C 
does not cause any overt phenotype in aged, gene-targeted mice (Cancellotti et al., 2005). 
These lines of evidence suggest that some PrP
C undergoes ERAD, but this proportion is 
most likely rapidly broken down and is a short-lived species (Yedidia et al., 2001). Despite 
conflicting data, aberrant PrP
C trafficking to the cytosol, which does appear to occur via 
ERAD (Ma and Lindquist, 2001; Yedidia et al., 2001), may play a role in prion pathogenesis, 
but as yet, is not fully defined.  
 
The UPS and PrP aggresomes 
A correlation between elevated levels of ubiquitin protein conjugates and reduced 
proteasome function in prion-infected mouse brain has been reported (Kang et al., 2004), 
indicating  that  proteasome  impairment  may  indeed  be  important  in  prion  disease 
pathogenesis.  Large,  intracellular,  peri-centrosomal  structures  termed  aggresomes  are 
thought to be a precise
 cellular response when cells try to cope with increased levels of
 
misfolded and aggregated proteins, evidenced by the active recruitment of proteasome 
components and molecular chaperones to these aggregates (Olzmann et al., 2008). 
PrP
C and PrP
Sc aggresome formation has been reported in prion disease models in 
vitro (Cohen and Taraboulos, 2003; Mishra et al., 2003; Kristiansen et al., 2005; Grenier et 
al.,  2006;  Goggin  et  al.,  2008).  WT  cells  treated  with  cyclosporine  A,  an 
immunosuppressant,  accumulate  proteasome-resistant,  ‘prion-like’  PrP  species  in 
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PrP
C  mutants  have  also  been  reported  to  accumulate  in  aggresomes  (Cohen  and 
Taraboulos, 2003). In vitro, green fluorescent protein (GFP)-tagged PrP mutants associated 
with  familial  prion  disease  accumulated  in  cytosolic,  aggresome-like  structures  after 
proteasome  inhibition,  whereas  GFP-tagged  WT  PrP
C  did  not  (Mishra  et  al.,  2003). 
Moreover, the formation of cytosolic PrP
C aggresomes after transient cytoplasmic PrP
C 
expression appears to be toxic in both neuronal and non-neuronal cells (Grenier et al., 
2006). Recently, cytoplasmic PrP
C aggresomes were shown to induce cell death in various 
cell models by modifying the cell stress response via the activation of the RNA-dependent 
protein kinase and the induction of poly(A)
+ RNA aggregation (Goggin et al., 2008).  
Prion-infected mouse neuronal cell lines have been shown to be more susceptible 
to cell death following proteasome inhibition (Kristiansen et al., 2005). In their cell system 
Kristiansen et al. used mild levels of proteasome inhibition, which is suggested to mimic 
the loss of proteasome activity associated
 with either the ageing process (Keller et al., 
2002; Ding et al., 2003), or that may be seen in prion disease in vivo (Kang et al., 2004). 
They  showed  that  mild  proteasome  inhibition  induced  prion-infected  cells  to  form 
cytosolic  aggresomes
  containing  PrP
Sc,  Hsp70,  ubiquitin  and  proteasome
  subunits 
(Kristiansen  et  al.,  2005).  This  work  also  showed  that  PrP
Sc  aggresome  formation  was 
temporally associated with caspase
 3 and 8 activation, and subsequent apoptosis in prion-
infected  cells  and  that  cell  death  was  abrogated  after  treatment  with  microtubule 
inhibitors,  which prevent  aggresome  formation  (Kristiansen  et  al.,  2005).  Evidence  for 
PrP
Sc aggresome-like structures in prion-infected mouse brain was described. Granular 
deposits of disease-related PrP
 have been previously reported in neuronal perikarya from 
post-mortem sporadic CJD cases, suggesting
 intra-neuronal prion aggregates may play a 
role in disease pathogenesis (Kovacs et al., 2005).
  
At  present,  PrP
Sc  trafficking  is  poorly-defined  due  to  the  lack  of  PrP
Sc-specific 
antibodies  and  hence  the  route  by  which  PrP
Sc  may  enter  the  cytoplasm  to  form 
aggresomes has not been established  (Caughey and Baron, 2006). Possibilities include 
retro-translocation  from  the  ER  (Ma  and  Lindquist,  2001;  Yedidia  et  al.,  2001)  or  via 
endolysosomal membrane destabilisation and leakage into the cytosol, as described for 
A1-42 (Ji et al., 2006). Furthermore, a recent paper by Wadia and colleagues reported that 84 | P a g e  
 
some PrP may escape macropinosomes and leak into the cytosol (Wadia et al., 2008). 
Consequently, UPS impairment due to the aging process or during prion infection in vivo, 
may allow for PrP
Sc accumulation
 into toxic aggresomes. These aggresomes could further 
inhibit the proteasome leading to impairment of PrP
C degradation and accumulation of 
PrP
C in the cytosol, in agreement with previous observations, underscoring that ERAD may 
contribute to neurodegeneration in prion diseases.  
Although UPS impairment appears to cause accumulation of PrP
C in the cytosol, 
PrP
Sc-aggresome formation and lead to ER stress and subsequent cell death (Ma et al., 
2002; Hetz et al., 2003; Kristiansen et al., 2005), several unanswered questions remain. 
For example, does prion infection cause proteasome impairment in vivo, and if so, what is 
the  mechanistic  link  between  the  two?  Furthermore,  the  nature  of  the  prion  protein 
species  responsible  for  proteasome  inhibition  and  subsequent  cellular  stress  is  still 
unclear.   
 
1.9.2  Autophagy and neurodegenerative disease 
Autophagy  has  been  implicated  in  the  pathogenesis  of  a  number  of  diseases, 
including  cancer,  myopathies,  infectious  disease  and  neurodegeneration  (Kundu  and 
Thompson, 2008). As neurones are highly active, post-mitotic cells, they are especially 
vulnerable to the intracellular accumulation of aberrant proteins, explaining the frequency 
with which proteopathies affect the nervous system (Nedelsky et al., 2008).  
The suggestion that autophagy plays a role in neurodegenerative disease initiation 
or progression resulted from increasing observations of autophagic vacuoles in affected 
brain regions of AD, PD, polyQ diseases and prion diseases (McCray and Taylor, 2008). In 
AD,  autophagic  vacuoles  have  been  observed  in  neocortical  and  pyramidal  neurones 
(Nixon et al., 2005), whereas in HD, remnants of polyQ-expanded huntingtin have been 
shown to accumulate in cathepsin D positive vacuoles in patient-derived lymphoblasts 
(Sapp et al., 1997). In PD, autophagic vacuoles have been described in melanised neurones 
of the substantia nigra (Anglade et al., 1997). These observations at the histopathological 
level  have  been  corroborated  in  respective  disease  models.  Interestingly,  exogenous 85 | P a g e  
 
expression  of  polyQ-expanded  disease-related  proteins  results  in  an  augmentation  in 
biochemical and morphological markers of autophagy both in vitro (Taylor et al., 2003; 
Ravikumar et al., 2004) and in vivo in fly and mouse models of polyQ diseases (Petersen et 
al., 2001; Pandey et al., 2007).  
It is possible that the increased frequency of autophagic vacuoles in the diseased 
brain is due to the induction of autophagy as a response to cell stress or death, or due to 
impaired autophagy flux. In other words, the accumulation of autophagic vacuoles may be 
caused  by  either  the  induction  of  autophagosome  formation,  or  a  defect  in 
autophagosome  clearance  when  fusion  of  autophagosome  to  lysosome  is  impaired. 
Furthermore,  the  accumulation  of  autophagosomes  in  dying  neurones  has  raised  a 
number of important questions (Kundu and Thompson, 2008). For example, is autophagy 
cytoprotective or does it mediate cell death? Is it induced as a secondary effect in cells 
already  committed  to  dying?  Insight  into  the  role  of  autophagy  in  neurodegenerative 
disease has come from studies which have collectively shown that a) aberrant proteins are 
degraded by autophagy, b) autophagy impairment leads to neurodegeneration in animal 
models and human disease, and c) manipulating autophagy alters the disease phenotype 
in animal models (Kundu and Thompson, 2008).  
Accumulating evidence supports the degradation of some disease-related proteins 
by autophagy. In vitro studies in which autophagy was either pharmacologically induced or 
impaired  have  demonstrated  changes  in  the  turnover  rate  of  mutant  polyQ  protein, 
mutant  polyA  protein,  as  well  as  WT  and  mutant  -synuclein  (Webb  et  al.,  2003; 
Ravikumar et al., 2004). At the ultra-structural level, immuno-electron microscopy has 
revealed  that  disease-related  proteins,  such  as  expanded  polyQ,  are  delivered  to 
autophagosomes (Kegel et al., 2000; Taylor et al., 2003). Moreover, some Atg proteins, 
such as LC3 and the Atg5/Atg12/Atg16 complex, have been shown to be recruited into 
mutant huntingtin aggregates suggesting that autophagy is taking place close to protein 
inclusions (Iwata et al., 2005b; Yamamoto et al., 2006).  
A neuroprotective role conferred by autophagy in the context of proteopathies is 
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leads to neurodegeneration. Specifically, cathepsin D KO mice and  Drosophila mutants 
show a neurodegenerative phenotype coupled with the accumulation of autophagosomes 
and lysosomes (Koike et al., 2000; Koike et al., 2005; Myllykangas et al., 2005; Shacka et 
al.,  2007).  Moreover,  conditional  Atg-null  mice  die  prematurely  as  a  result  of 
neurodegeneration  and  exhibit  extensive  ubiquitin  staining  (Hara  et  al.,  2006),  and 
induction of autophagy by rapamycin treatment in fly and mouse models of HD has been 
shown to ameliorate the phenotype of the disease (Ravikumar et al., 2004; Berger et al., 
2006; Pandey et al., 2007). TOR independent methods of autophagy induction such as the 
use of lithium (Sarkar et al., 2008) or trehalose (Tanaka et al., 2004; Davies et al., 2006; 
Sarkar et al., 2007) also ameliorate neurodegeneration in fly and mouse models of HD 
(Tanaka et al., 2004; Sarkar et al., 2008) and clear aggregate-prone protein in vitro (Sarkar 
et al., 2007).  
Data  on  the  role  of  autophagy  in  prion  disease  are  confined  to  a  number  of 
electron  microscopy  studies,  which  show  the  presence  of  autophagic  vacuoles  in  the 
neurones of experimental models of human and animal prion disease (Boellaard et al., 
1989; Boellaard et al., 1991; Liberski et al., 1992a), as well as in naturally occurring BSE 
(Liberski et al., 1992b). However, unlike in other neurodegenerative diseases, the role of 
autophagy in prion disease has not been investigated using molecular and/or biochemical 
approaches. Therefore, it is unclear whether increases in autophagosome numbers, by 
PrP
Sc formation, correlate with increased levels of autophagy or impaired autophagosome 
turnover.  Furthermore,  it  is  yet  unclear  how  this  relates,  if  at  all,  to  prion  disease 
pathogenesis.  
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1.10 Aims of the thesis 
 
A.  Role of the UPS in prion disease pathogenesis 
  To evaluate the role of the UPS in prion disease pathogenesis and investigate the 
relationship between the two 
  To test whether disease-related, -sheet-rich prion protein directly and specifically 
impairs neuronal cellular function by inhibiting the 26S proteasome in vitro as well 
as in prion-infected mouse brain 
  To  examine  the  nature  of  the  PrP
Sc  species  responsible  for  neurotoxicity  using 
recombinant prion protein species 
  To  define  the  biochemical  mechanism  by  which  aggregated  -sheet-rich  prion 
protein could be inhibiting the proteasome  
  To  investigate  whether  there  is  a  physical  interaction  between  the  aggregated 
prion species and the proteasome 
 
B.  Role of autophagy in prion disease pathogenesis 
  To investigate the role of autophagy in prion disease by biochemical analysis, both 
in vitro and in prion-infected mouse brain 
  To evaluate whether autophagy is acting as a compensatory protein degradation 
system when the proteasome is impaired 
  To test whether induction of autophagy can ameliorate the deleterious effects 
seen in prion-infected cells where the proteasome is inhibited  
  To examine whether induction of autophagy clears PK-resistant prion protein 
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2  MATERIALS AND METHODS 
All chemicals were purchased from Sigma-Aldrich Ltd unless otherwise specified. 
2.1  Cell culture 
Work with mouse cell lines was carried out in a designated tissue culture facility using 
strict aseptic technique. All media and solutions were bought pre-sterilised and sterile 
plastic-ware was used. All procedures, including preparation of media, were performed in 
a tissue culture hood with a laminar flow unit. All solutions and media were pre-warmed 
to 37C prior to use. 
 
2.1.1  Cell lines 
N2a 
N2a  mouse  neuroblastoma  cells  were  purchased  from  the  American  Type  Tissue 
Collection (ATCC CCL131). The N2aPK-1 cell line was a kind gift from Dr Peter Klöhn (MRC 
Prion Unit, Institute of Neurology, UCL).  
GT-1-7 
GT-1-7 cells are a subcloned cell line of immortalized mouse hypothalamic GT-1 cells. They 
were  a  kind  gift  from  Professor  Hermann  Schatzl  (Institute  of  Virology,  Technical 
University, Munich) and from Dr Andrew Hill (University of Melbourne, Australia).  
Cerebellar granule neurones 
Murine cerebellar granule neurones (CGN) were prepared by Ms Heike Naumann from 6 
day old Friend Virus B-type (FVB) mice as previously described (Schousboe and Pasantes-
Morales, 1989). 
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2.1.2  Propagation of cell lines 
Cell growth 
N2aPK-1  and  GT-1  cells  grew  in  Opti-MEM  standard  growth  medium  (Invitrogen) 
supplemented with 50 U/ml penicillin (Invitrogen), 50 g/ml streptomycin (Invitrogen) 
and 10 % v/v foetal calf serum (FCS; Invitrogen). Cell lines were maintained in sterile 10 
cm tissue culture plates (VWR) in a humidified CO2 incubator, in an atmosphere of 5-7 % 
CO2  at  37C.  Growth  medium  was  regularly  changed  2-3  times  weekly.  Prior  to  the 
addition of fresh medium, cells were washed with sterile phosphate buffered saline (PBS; 
Invitrogen) (137.9 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4) to 
remove debris. All cell work was carried out in a Class II microbiological safety cabinet. 
Cell harvesting 
When cells reached confluence they were harvested and sub-cultured. First, cells were 
washed with PBS and subsequently incubated for 3-5 min at 37°C with 1 ml trypsin (25 g/L 
trypsin, 8.5 g/L NaCl; Invitrogen). Cells were then dislodged by gently tapping the plate. 
Following this, 6 ml of fresh Opti-MEM supplemented with FCS were added to the plate to 
stop the enzymatic action. The medium was then lightly triturated to ensure equal cell 
dispersal. The  cells  were  then  split  into numerous  plates  ranging  from  1:3 to 1:10  to 
continue growing.  
Cryopreservation of cell lines 
Confluent plates of cells were harvested in blue Falcon™ tubes and spun for 5 min at 160 x 
g at 22°C. They were then washed with ice-cold sterile PBS and spun for 5 min at 160 x g 
at  22°C.  The  resulting  pellet  was  re-suspended  in  1  ml  of  sterile  freezing  medium 
consisting of 50% FCS and 8 % sterile dimethyl sulfoxide (DMSO) and transferred to a cryo-
vial. Cryo-vials were then placed in Nalgene® freezing boxes and subsequently into the -
70°C freezer to gradually bring down cell temperature. The following day cryo-vials were 
placed in liquid nitrogen for long term storage and their location was noted in the tissue 
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Defrosting of cell lines 
Cells were rapidly defrosted by thawing the cryo-vial in a 37°C water bath for 30 seconds. 
The cell suspension was then transferred to 9 ml of pre-warmed growth medium in a blue 
Falcon™  tube  and  spun  for  5  min  at  160  x  g  at  4°C.  Following  centrifugation,  the 
supernatant was discarded and the pellet was re-suspended in 1 ml fresh pre-warmed 
growth medium. The cell suspension was then transferred to a 10 cm plastic tissue culture 
plate and topped up to 7 ml with growth medium. The next day cells were washed with 
sterile PBS and fresh medium was added.  
Prion infection of cell lines 
Mouse-adapted  Rocky  Mountain  laboratory  (RML)  prions  or  WT  CD-1  mouse  brain 
homogenate were used to infect N2aPK-1 and GT-1 neuronal cells. The brains of scrapie-
sick mice infected with RML mouse adapted prions or of WT CD-1 mice were homogenized 
by passing eight times each through a 21-gauge needle and adjusted to 10 % (w/v) with 
PBS. Following a 5 min centrifugation at 800 x g at RT, supernatants were removed and 
stored at -70°C. 5000 or 15000 cells were seeded into 96-well plates and maintained in 
culture for 24 hours (h) prior to being exposed to either 0.1 % RML-infected mouse brain 
in  standard  growth  medium  or  to  0.1  %  WT  CD-1  mouse  brain  in  standard  growth 
medium. Three days later the inoculum was removed and cells split 1:8; cells were split 
1:8 twice more in 3 day intervals. The presence of PrP
Sc was then tested by the scrapie cell 
assay (SCA). Cells were maintained in standard growth medium at 37°C in 5 % CO2.  
Curing cells of prion infection 
Both ScN2aPK-1 and
 ScGT-1 cells were cured of PrP
Sc with 0.5 µg/ml anti-PrP
 antibody 
ICSM18 (D-Gen Ltd., London, UK) in standard growth medium for 14 days.  
 
2.1.3  Scrapie cell assay 
A sterile Elispot plate (MultiScreen Immobilon®-P 96-well Filtration Plates, Millipore) was 
activated by suctioning through with 70 % ethanol and then washing twice with PBS (by 
suction). Following cell counting, 5000 cells were plated in each of 12 wells (in 200 l 91 | P a g e  
 
standard  growth  medium).  The  plate  was  dried  for  1  h  at  50°C.  Elispot  plates  were 
incubated at 37°C for 90 min with 50 l proteinase K (PK; Roche) in 1 X lysis buffer (50 mM 
Tris.HCl, pH 8.0, 150 mM NaCl, 0.5 % Na deoxycholate, 0.5 % Triton-X); the liquid was then 
removed by suctioning, and wells washed twice with PBS (by suction). Following a 10 min 
RT exposure to phenylmethylsuphonyl fluoride (PMSF; 2 mM) to stop PK action, each well 
was incubated with 160 l 3M guanidinium thiocyanate (GSCN) in 10 mM Tris.HCl (pH 8) 
at RT for 10 min to expose PrP
Sc epitopes. After discarding the supernatant, the plate was 
washed four times with PBS and the wells were incubated for 1 h at 37°C with 160 l 
Superblock blocking buffer (Pierce). After suctioning the liquid off, wells were incubated 
with 50 l anti-PrP antibody (ICSM-18; 1:5000) in 1 X TBST (10 mM Tris.HCl, pH 8.0, 150 
mM NaCl, 0.1 % Tween-20) and 1 % milk powder (Marvel) for 1 h at RT. Following this, 
wells were washed 7 times with 160 l 1 X TBST by suctioning and then incubated with 50 
l  anti-IgG1  alkaline  phosphatase  (1:4500  in  1  X  TBST/  1  %  milk  powder;  Southern 
Biotechnology; AP) for 1 h at RT. Wells were washed seven times with 160 l 1 X TBST by 
suction. After being left to dry, wells were incubated with 50 l AP conjugate substrate 
(prepared as recommended by BIORAD) and incubated until a clear colour change was 
seen in positive controls. Following this wells were washed twice with double distilled 
water and stored at -20°C until analysis.   
 
2.1.4  Semi-purification of PrP
Sc 
From RML prion-infected mouse brain 
One whole RML-infected mouse brain was homogenised in 9 X volumes of lysis buffer (100 
mM Tris.HCl, pH 7.4, 300 mM NaCl, 4 mM EDTA, 1 % Triton-X-100, 1 % deoxycholate) and 
later  spun  at  500  x  g  for  10  min  at  4°C.  Supernatants  were  incubated  with  50  U/ml 
benzonase (Merck) for 20 min on ice and subsequently with PK (5 g/ml protein) at 37°C 
for 30 min. PK activity was stopped by incubating lysates with AEBSF (8 mM; Merck) for 10 
min at 37 °C. Lysates were then centrifuged at 100,000 x g for 45 min and sonicated (three 92 | P a g e  
 
cycles of 10 x 0.5 second pulses). Protein content was measured using the BCA™ assay. 
After being snap-frozen, semi-purified PrP
Sc was kept at -70°C. 
From RML prion-infected GT-1-7 cells 
Ten  10  cm  plates  of  ScGT-1  cells  were  pre-treated  for  24  h  with  1  M  lactacystin 
(Calbiochem) at 37°C. Cells were then harvested and gently washed in ice-cold PBS before 
being freeze-thawed three times in liquid nitrogen and centrifuged at 1000 x g for 10 min 
at 4°C to remove cellular debris. The supernatant was then collected and adjusted with an 
equal volume of 2 X lysis buffer (100 mM Tris, pH 7.4, 300 mM NaCl, 4 mM EDTA, 1 % 
Triton-X-100, 1 % deoxycholate) followed by incubation with benzonase (50 U/ml) for 20 
min  on  ice.  Lysates  were  then  incubated  with  PK  at  1  g/mg  protein  (37°C,  90  min) 
followed by treatment with AEBSF (8 mM) to stop action of PK for 10 min at 37°C. Lysates 
were centrifuged at 100,000 x g for 45 min and then sonicated (3 cycles of 10 x 0.5 second 
pulses). Protein content was measured using the BCA™ assay. The pellet was diluted to a 
final concentration of 1 mg/ml; after being snap-frozen, semi-purified PrP
Sc aggresomes 
were kept at -70°C. 
 
2.2  Methods for the detection of proteins 
2.2.1  Western blotting of proteins 
Preparation of lysates (no proteinase K digestion required) 
Cells were harvested on ice and spun twice at 4°C (160 x g, 5 min) in ice-cold PBS to 
eliminate any FCS. The resulting pellet was then re-suspended in minimal volume of ice-
cold PBS on ice. Cells were lysed by freeze-thawing in liquid nitrogen (3 times). Lysates 
were  benzonase-treated  for  20  min  on  ice  (50  U/ml).  Ice-cold  PBS  was  added  to 
acceptable  viscosity  and  an  aliquot  was  taken  off  for  protein  assay  to  ensure  equal 
loading. The remaining supernatant was frozen at –70°C.  93 | P a g e  
 
Preparation of lysates (proteinase K digestion required) 
Cells were harvested on ice and spun twice at 4°C (160 x g, 5 min) in ice-cold PBS to 
eliminate FCS. The resulting pellet was then re-suspended in minimal volume of ice-cold 
PBS on ice. Cells were lysed by freeze-thawing in liquid nitrogen (3 times). Lysates were 
benzonase-treated for 20 min on ice. Ice-cold PBS was added to acceptable viscosity and 
an  aliquot  was  taken  off  for  protein  assay  to  ensure  equal  loading.  The  remaining 
supernatant was frozen at –70°C. Upon thawing cells were treated by adding PK to a final 
concentration of 50 g/ml for 30 min at 37°C. Samples were then centrifuged at 16,000 x 
g for 1 min to pellet cellular debris; digestion was ended in samples by adding 8 mM 
AEBSF in an equal volume of 2 X reducing sample buffer (125 mM Tris, pH 6.8, 20 % 
glycerol, 0.05 % bromophenol blue, 4 % SDS).  
Quantification of protein by BCA 
The  bicinchoninic  acid  (BCA™)  protein  assay  reagent  kit  (Pierce)  was  used  for  the 
detection and quantitation of total protein in lysates. This method is based on the ability 
of proteins to reduce Cu
+2 to Cu
+1 in an alkaline environment. The purple reaction product 
is  water  soluble  and  readily  detected  at  562  nm.  To  conserve  lysates,  the  microplate 
procedure was used. A fresh set of protein standards was prepared for each assay by 
using bovine serum albumin (BSA) in the same diluent as the unknown sample. The range 
of standards was 0, 25, 125, 250, 500, 750, 1000, 1500 and 2000 g. Preparation of BCA 
working  reagent  (WR)  was  according  to  manufacturer’s  instructions.  25  l  of  each 
standard or unknown sample was pipetted into 96 well plates. This was done in duplicate 
for standards and triplicate for unknown samples. 200 l WR was then added to each well 
and the plate was mixed thoroughly on a plate shaker for 30 seconds. The plate was then 
covered and incubated at 37°C for 30 min. After briefly cooling down, the plate was read 
at 570 nm on a Tecan plate reader (Sunrise). A standard curve was prepared and unknown 
protein concentrations calculated using a statistical analysis program (GraphPad Instat 
Version 3.02, GraphPad Software).  94 | P a g e  
 
SDS –polyacrylamide gel electrophoresis (SDS-PAGE) 
Reducing sample buffer was added to 1 X concentration and samples were boiled at 100°C 
for 10 min. Samples were then spun at 16,000 x g for 1 min, briefly vortexed and finally 
spun at 16,000 x g for 1 min before loading onto 16% Tris-Glycine mini gels (Invitrogen). 
Gels  were  electrophoresed  vertically  in  Tris/Glycine  SDS  running  buffer  (National 
Diagnostics) in a X-Cell SureLock™ Mini-Cell system (Invitrogen) for 80 min at 200V (or 
until the dye front run off at the end of the gel). Pre-stained Seeblue® Protein Standard 
(Invitrogen) was used as a molecular weight marker. 
Coomassie staining of gels 
After electrophoresis, gels were soaked in fixing solution (40 % v/v methanol, 10 % v/v 
acetic acid) for 20 min at RT with gentle agitation to fix proteins onto the gels. The gels 
were then covered with 0.02 % w/v R-250 Coommassie stain (in 40 % v/v methanol, 10 % 
v/v acetic acid) and incubated overnight with gentle agitation. Gels were de-stained using 
8 % v/v acetic acid for 3-4 h, changing the de-stain solution every 30 min. When the 
protein bands were visible without background staining, a photograph of the gels was 
taken. 
Electroblotting of gels 
Protein was transferred onto PVDF membranes (Millipore). PVDF membrane was pre-cut 
at the same size as the gels and pre-soaked in 100 % methanol for 2 min to ensure even 
hydration  prior  to  transfer  into  blotting  buffer  (National  Diagnostics).  Protein  was 
transferred from the gel to the membrane in Novex X-Cell II™ Blot modules (Invitrogen) at 
either 35V for 90 min, or 14V overnight.  
Immunoblotting of gels 
After electroblotting, membranes were transferred to square tissue culture petri dishes 
and washed in PBS containing 0.05 % v/v Tween-20 (1 X PBST). Blots were then blocked 
for 1 h at RT with gentle agitation using either 5 % BSA or 5 % non-fat milk powder 
(Marvel). Blocking solution was made in 1 X PBST.  Membranes were washed briefly with 1 
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gentle agitation. The membranes were then washed in 1 X PBST for a minimum of 45 min 
changing  buffer  5  times.  Secondary  detection  was  performed  by  incubating  with  the 
appropriate secondary antibody (diluted in 1 X PBST) for 45 min at RT. Detection of bound 
antibody  was  performed  with  SuperSignal®  West  Pico  chemiluminescent  substrate 
(Pierce) according to manufacturer’s instructions. Excess reagents were poured off and 
the membranes were placed between acetate films and transferred to a photographic 
cassette.  Biomax®  MR  films  (Kodak™  from  Anachem)  were  developed  using  Kodak™ 
developer and fixer by hand or by using a Xograph imaging machine (Xograph Imaging 
Systems). Developed films were scanned using an Epson scanner for electronic format and 
densitometry of digital images was achieved by using a Kodak Image Station 440 CF.  
Determination of equal protein loading 
The Re-Blot™ Plus Western Blot Strong Antibody Stripping Solution (Chemicon) consists of 
specially  formulated  solutions  that  quickly  and  effectively  remove  antibodies  from 
Western blots without significantly having an effect on the immobilized proteins. Blots 
were washed in 1 X PBST buffer for 10 min before being incubated for 15 min with 1 X Re-
Blot™ Plus Strong Antibody Stripping solution. Following this, blots were briefly washed 
with 1 X PBST and subsequently blocked with 5 % milk powder in 1 X PBST for 1 h. Mouse 
monoclonal anti--actin antibody (1:10,000; Sigma) was used to probe for the control 
loading protein.  
Densitometry 
Densitometry on immunoblots was performed using the Kodak™ Digital Science Image 
station  440CF  (IS440CF)  system  and  analysed  using  the  Kodak™  ID  Image  Analysis 
Software (PerkinElmer Life Sciences). 
 
2.2.2  Co-Immunoprecipitation experiments 
Magnetic tosyl-activated
 beads (Dynal) were coated with mouse monoclonal antibody to 
PrP  (ICSM35;  D-GEN;  at  24  g/reaction).  Five  g  of  human  20S  proteasome  were 
incubated with 3 g aggregated -PrP (Section 2.3) or 3 g aggregated -PrP (Section 2.3) 96 | P a g e  
 
for 1h at 37°C. Samples were incubated with either ICSM35- or uncoated-coated beads 
overnight on a rotator at 4°C. Beads
 were concentrated, washed with PBS, re-suspended 
in  SDS  sample  buffer  and  boiled.  The  supernatant  was  analyzed  by
  SDS-PAGE  and 
immunoblotted with a rabbit polyclonal antibody to the ‘core’ 20S subunits (BIOMOL; 
1:2,000).  
 
2.3  Preparation of recombinant proteins 
Full-length (23-231aa) recombinant mouse PrP in either the oxidised form (-PrP) or the 
reduced form (-PrP) was prepared by a modification of the method as described (Jackson 
et  al.,  1999)  and  was  prepared by  Mr  Mark  Batchelor  (MRC  Prion  Unit,  London,  UK). 
Protein  concentration  was  determined  by  UV  absorption  using  a  calculated  molar 
extinction coefficient of 56,120 M
-1 cm
-1 at 280 nm. Both - and -PrP underwent buffer 
exchange, i.e. from their mother buffer to water. Like -PrP, -PrP was buffer exchanged 
in water by ultra-filtration.  
Aggregation methods for recombinant PrP 
Aggregation of -PrP was initiated by the addition of NaCl to a final concentration of 150 
mM. The reaction was allowed to proceed for 1 h at 37°C until aggregation was visible. 
Aggregation of -PrP was achieved by thermal denaturation (heating at 70°C for 10 min). 
Moreover,  NaCl  was  added  to  a  sample  of  -PrP  at  a  similar  final  concentration  to 
aggregated -PrP (150 mM) as a control for salt-aggregated -PrP.  
Denaturation of recombinant PrP 
Denaturation of recombinant -PrP was achieved by 10 cycles of freeze (liquid nitrogen)-
boiling.  
PrP amyloid fibrils 
Amyloid fibrils of recombinant murine PrP were prepared by Dr Howard Tattum (MRC 
Prion Unit, London, UK) using a protocol adapted from that of Baskakov et al. and were a 
kind gift from Dr Graham Jackson (MRC Prion Unit, London, UK) (Baskakov et al., 2002). 97 | P a g e  
 
Briefly, recombinant -PrP was transferred into 20 mM sodium acetate, pH 3.7, and was 
denatured by the addition of 10 M urea. Recombinant protein was then dialysed in 1.3 M 
urea and 1 M GuHCl pH 6.0. 800 l of 0.8 mg/ml protein was aliquoted into a 1.5 ml 
microcentrifuge  tube  and  shaken  at  600  rpm  (Eppedorf  Thermomixer™)  at  37°C  to 
stimulate assembly of -PrP monomers. Amyloidogenesis was complete after a reaction 
time of 10 h. The presence of fibrils was confirmed by electron microscopy performed by 
Dr  Howard  Tattum  (MRC  Prion  Unit,  London,  UK).  Fibrils  were  assayed  at  a  final 
concentration of 1 mg/ml.  
Preparation of aggregated non-prion recombinant proteins 
Lysozyme was aggregated by the addition of 50 mM DTT and the reaction was allowed to 
proceed for 1 h; it was assayed at a final concentration of 1 mg/ml. Amyloid 1-40 (A1-40) 
was aggregated immediately by the addition of water and assayed at a final concentration 
of 100 g/ml. SOD1 WT and SOD1 mutant recombinant proteins were prepared by Dr 
Ruth Chia; they were aggregated in PBS and assayed at a final concentration of 1 mg/ml. 
Carboxy-methylated  -lactalbumin  was  prepared  in  water  and  assayed  at  a  final 
concentration of 1 mg/ml.  
 
2.4  Ubiquitin-proteasome system activity assays 
2.4.1  Proteasomal  subunit activity probes 
In their 2005 paper in Nature Methods, Berkers et al. described novel  subunit activity 
probes  that  were  used  to  define  the  in  vivo  specificities  of  the  proteasome  inhibitor 
bortezomib (Berkers et al., 2005). This dansylAhx3LVS activity probe was a kind gift from 
Dr Huib Ovaa (Netherlands Cancer Institute, Netherlands).  
Protein extraction from cells and mouse brain 
Confluent 10 cm plates of N2aPK-1 cells were washed with ice-cold sterile PBS and cells 
were harvested by trituration. The cell pellet was then washed twice at 160 x g for 5 min 
at 4°C with ice-cold sterile PBS and then lysed by vortexing for 30 min at 4°C at 1,400 rpm 98 | P a g e  
 
(Eppendorf Thermomixer®) in an equal volume of freshly-made homogenisation buffer (50 
mM Tris.HCl, pH 7.4, 250 mM sucrose, 5 mM MgCl2, 2 mM ATP) and glass beads (<106 
microns, acid washed). 1 mM DTT was added fresh to the lysates after a small aliquot was 
taken for protein determination by the BCA™ assay. The lysates were further centrifuged 
for 5 min at 4°C at 16,000 x g to remove beads, nuclei, membrane fractions and cellular 
debris.  Subsequently  100  g  of  protein  were  incubated  with  1  M  of  the  dansyl-
sulfonamidohexanoyl  activity  probe  for  1  h  at  37°C  at  1,400  rpm  (Eppendorf 
Thermomixer®) before assaying by immunoblotting. For GT-1 cells, the activity probe was 
used at a concentration of 10 M in culture for 1 h at 37°C; cells were then harvested as 
described above. 
Immunoblotting to assay specific subunit activities 
To  assay  for  specific    subunit  activities  equal  amounts  of  protein  (100  g)  were 
denatured in reducing sample buffer for 10 min at 100°C and then separated by SDS PAGE 
on 12 % Tris Glycine mini gels for 80 min at 200V. Protein was transferred onto PVDF 
membranes at 35V for 90 min. Membranes were then blocked using 5 % BSA in 1 X PBST 
for  1  h  at  RT  and  then  immunoblotted  using  a  rabbit  antibody  against  the  dansyl-
sulfonamidohexanoyl  hapten  tag  (1:1,000  in  1  X  PBST;  Molecular  Probes)  incubated 
overnight at RT. Secondary detection was performed by incubating with a donkey anti 
rabbit horse radish peroxidase (1:5,000 in 1 X PBST; HRP; Amersham Biosciences) for 45 
min at RT followed by enhanced chemiluminescence. To ensure equal protein loading 
PVDF  membranes  were  stripped  using  Re-Blot™  Plus  Western  Blot  Strong  Antibody 
Stripping  Solution  and  re-probed  with  a  mouse  monoclonal  anti--actin  antibody 
(1:10,000 in 1 X PBST).  
Incubation  of  disease-related  PrP  isoforms  with  aggregation  intermediates-specific 
antibody 
Either 500 ng/ml aggregated -PrP or 500 ng/ml PrP
Sc was incubated for 1 h at RT with 5 
g/ml  or  150  g/ml  of  a  rabbit  polyclonal  antibody  raised  against  oligomeric  protein 
species (Kayed et al., 2003) (kind gift from Dr. Glabe, Department of Molecular Biology 99 | P a g e  
 
and Biochemistry, University of California) or 150 g/ml of mouse monoclonal anti-PrP 
antibodies (ICSM18, ICSM4, or ICSM35; these antibodies were a kind gift from Dr Azy 
Khalili-Shirazi,  MRC  Prion  Unit,  Institute  of  Neurology,  UCL).  These  mixtures  were 
incubated with 100 g of cytosolic fraction from N2aPK-1 cell lysates for 1 h at 37°C with 2 
mM  ATP  on  a  shaker  before  addition  of  1  M  probe  (1  h  at  37°C).  Samples  were 
denatured in reducing sample buffer by boiling for 10 min and then separated by SDS 
PAGE on 12 % Tris Glycine mini gels for 80 min at 200V. Protein was transferred onto PVDF 
membranes at 35V for 90 min. Membranes were then blocked using 5 % BSA in 1 X PBST 
for  1  h  at  RT  and  then  immunoblotted  using  a  rabbit  antibody  against  the  dansyl-
sulfonamidohexanoyl  hapten  tag  (1:1,000  in  1  X  PBST)  incubated  overnight  at  RT. 
Secondary detection was performed by incubating with a donkey anti rabbit HRP (1:5,000 
in 1 X PBST;) for 45 min at RT followed by enhanced chemiluminescence. To ensure equal 
protein loading PVDF membranes were stripped using Re-Blot™ Plus Western Blot Strong 
Antibody Stripping Solution and re-probed with a mouse monoclonal anti--actin antibody 
(1:10,000 in 1 X PBST). 
 
2.4.2  Fluorogenic assays for proteasome activity 
Proteasome catalytic activities in cell and mouse brain lysates 
Minor modifications were made to protocols already described (Dantuma et al., 2000; 
Kisselev and Goldberg, 2005; Berkers et al., 2005). Cells were washed twice with ice-cold 
PBS at 4°C for 5 min at 160 x g and then pelleted and lysed in an equal volume of glass 
beads  (<106  microns,  acid  washed)  and  freshly-made  homogenization  buffer  (50  mM 
Tris.HCl, pH 7.4, 2 mM ATP, 5mM MgCl2, 250 mM sucrose). 1 mM DTT was added to the 
lysates after a small aliquot was taken for protein content determination using the BCA™ 
assay. Following this lysates were vortexed for 30 min at 4°C at 1,400 rpm (Eppendorf 
Thermomixer®) and further spun at 16,000 x g for 5 min at 4°C to remove beads, nuclei, 
membrane fractions and cellular debris from the supernatant. To measure the rate of 
hydrolysis  10  g  of  protein  was  incubated  with  100  M  of  either  of  the  following 100 | P a g e  
 
fluorogenic substrates: Ac-nLPnLD-AMC (assays caspase-like activity; Bachem), Suc-LLVY-
AMC (assays chymotrypsin-like activity; Biomol) Boc-LRR-AMC (assays trypsin-like activity; 
Biomol) in 100 l reaction buffer (50 mM Tris.HCl, pH 7.4, 5 mM MgCl2, 2 mM ATP, 1 mM 
DTT).  Samples  were  incubated  for  30  min  at  37°C  and  the  release  of  7-amino-4-
methylcoumarin  (AMC)  was  monitored  continuously  every  minute  for  30  min  using  a 
TECAN 96-well reader at 360nm excitation and 465nm emission.  
Proteasome activities in pure proteasome preparations 
Human 26S and 20S assays 
Minor modifications were made to protocols already described (Dantuma et al., 2000; 
Kisselev and Goldberg, 2005; Berkers et al., 2005). 0.1 g of pure human 26S proteasome 
(BIOMOL)  or  0.1  g  of  pure  human  20S  proteasome  (BIOMOL)  activated  with  32  ng 
PA28 activator (BIOMOL) or CtRpt5 (250M) were added to 100 l reaction buffer (50 
mM  Tris.HCl,  pH  7.4,  10  mM  MgCl2,  1  mM  DTT;  plus  2mM  ATP  for  26S  assays)  and 
incubated with 100 M of either of the following fluorogenic substrates: Ac-nLPnLD-AMC 
(assays caspase-like activity), Suc-LLVY-AMC (assays chymotrypsin-like activity); Boc-LRR-
AMC  (assays  trypsin-like  activity)  to  measure  the  rate  of  hydrolysis.  Samples  were 
incubated at 37°C and the release of 7-amino-4-methylcoumarin (AMC) was monitored 
continuously every minute for 60 min using a TECAN 96-well reader at 360nm excitation 
and 465nm emission. 
Yeast 26S and 20S assays 
625 ng of WT yeast 20S proteasome or 0.1 g of WT yeast 26S proteasome (both kind gifts 
from Dr Michael Glickman, The Technion, Israel) were added to 100 l reaction buffer (50 
mM  Tris.HCl,  pH  7.4,  10mM  MgCl2,    1  mM  DTT;  plus  2mM  ATP  for  26S  assays)  and 
incubated with 100 M of either of the following fluorogenic substrates: Ac-nLPnLD-AMC 
(assays caspase-like activity), Suc-LLVY-AMC (assays chymotrypsin-like activity); Boc-LRR-
AMC (assays trypsin-like activity) to measure the rate of hydrolysis. 625 ng of 3N yeast 
20S  proteasome  (kind  gift  from  Dr  Alexei  Kisselev,  Dartmouth  Medical  School,  New 
Hampshire, USA) were added to 100 l reaction buffer (50 mM Tris.HCl, pH 7.4, 10mM 101 | P a g e  
 
MgCl2,  1 mM DTT) and incubated with 100 M of either of the following fluorogenic 
substrates:  Ac-nLPnLD-AMC  (assays  caspase-like  activity),  Suc-LLVY-AMC  (assays 
chymotrypsin-like activity); Boc-LRR-AMC (assays trypsin-like activity) to measure the rate 
of hydrolysis. 625 ng of 3/7N yeast 20S proteasome or 0.1 g of 3/7 N yeast 26S 
proteasome (both kind gifts from Dr Michael Glickman, The Technion, Israel) were added 
to 100 l reaction buffer (50 mM Tris.HCl, pH 7.4, 10mM MgCl2,  1 mM DTT; plus 2mM 
ATP for 26S assays) and incubated with 100 M of either of the following fluorogenic 
substrates:  Ac-nLPnLD-AMC  (assays  caspase-like  activity),  Suc-LLVY-AMC  (assays 
chymotrypsin-like activity); Boc-LRR-AMC (assays trypsin-like activity) to measure the rate 
of hydrolysis. Samples were incubated for 60 min at 30°C and the release of 7-amino-4-
methylcoumarin (AMC) was monitored continuously every minute using a TECAN 96-well 
reader at 360nm excitation and 465nm emission.  
 
2.4.3  Native- polyacrylamide gel electrophoresis (Native-PAGE™) 
Chymotrypsin substrate overlay 
Pure 26S proteasome samples were topped up to 25 l with 4 X NativePAGE™ sample 
buffer (final concentration 1 X; Invitrogen) and loading buffer (30 mM Tris.HCl, pH 7.4, 5 
mM MgCl2, 2 mM ATP) and run on 3-12 % NativePAGE™ Bis-Tris gels (Invitrogen) in 1 X 
NativePAGE™ running buffer (50 mM Bis.Tris, 50 mM Tricine, pH 6.8; Invitrogen) for 1 h at 
150V before changing to 200V and running for another hour. Gels were then incubated at 
4°C for 15 min in developing buffer (50 mM Tris.HCl, pH 7.4, 5 mM MgCl2, 2 mM ATP). 
Following  this,  gels  were  overlaid  with  100  M  Suc-LLVY-AMC  and  visualized  on  the 
BIORAD Gel Doc 1000 using the Quantity One 4.5.1 (Basic) software.  
Immunoblotting 
Cell  lysates  or  pure  26S  proteasome  samples  were  topped  up  to  25  l  with  4  X 
NativePAGE™ sample buffer (final concentration 1 X; Invitrogen) and loading buffer (30 
mM  Tris.HCl,  pH  7.4,  5  mM  MgCl2, 250  mM  sucrose, 2  mM  ATP)  and  run on  3-12  % 
NativePAGE™ Bis-Tris gels in 1 X NativePAGE™ running buffer (50 mM Bis.Tris, 50 mM 102 | P a g e  
 
Tricine, pH 6.8) for 1 h at 150V before changing to 200V and running for another hour. 
Gels were immunoblotted onto PVDF membranes at 25 V for 1 h in 1X NativePAGE™ 
transfer  buffer  (Invitrogen)  in  the  blotting  chamber  and  double  distilled  water  in  the 
outside chamber. Following transfer, PVDF membranes were incubated for 20 min with 8 
% acetic acid (WVR) to fix the proteins and then blocked with 5 % marvel in 1 X PBST for 1 
h  before  overnight  incubation  with  mouse  monoclonal  4  subunit  antibody  (1:1,000; 
BIOMOL)  and  mouse  monoclonal  Rpt1  (S7)  subunit  antibody  (1:5,000;  BIOMOL)  in  1X 
PBST. The following day blots were washed in 1X PBST and incubated with secondary 
antibody (goat anti mouse AP 1:10,000 in 1X PBST; BIOSOURCE) for 45 min before washing 
in 1X PBST for 1 h changing buffer every 5 min. Blots were developed using the CDP-Star® 
(Tropix) system.  
 
2.4.4  Assaying proteasome subunit levels by immunoblotting 
To assay levels of proteasome subunits, immunoblotting was performed using antibodies 
against  the  4,  2  or  5  subunits  of  the  proteasome.  All  three  mouse  monoclonal 
antibodies were from BIOMOL and were used at a concentration of 1:10,000 in 1 X PBST; 
antibodies  were  incubated  with  blots  overnight  at  RT.  Goat  anti-mouse  alkaline 
phosphatase  was  used  as  a  secondary  antibody  (Biosource)  at  1:10,000  in  1  X  PBST. 
Secondary antibody was incubated with blots for 45 min at RT. This was followed by 
enhanced chemiluminescence (Pierce) and visualisation on Biomax MR film (Kodak™).  
 
2.4.5  Methods to measure protein degradation by the proteasome 
Fluorimetric assays of fluorescently-labelled casein  
The SensoLyte™ Green Protease Assay Kit (Anaspec) is extensively used for the detection 
of generic cellular protease activities. It uses a casein derivative, which is greatly labelled 
with  a  rhodamine  derivative,  resulting  in  almost  total  quenching  of  the  conjugate's 
fluorescence.  Protease-catalysed  hydrolysis  relieves  this  quenching  conjugate,  yielding 
brightly green fluorescent dye-labelled peptides. The increase in fluorescence intensity is 103 | P a g e  
 
directly proportional to protease activity. WT yeast 20S or 26S (20 g) proteasome was 
incubated with or without aggregated -PrP
 or aggregated -PrP
 for 1 h at 30°C. HiLyte™-
488 casein conjugate was then added to each reaction as per manufacturer’s instructions. 
Fluorescence  was  measured  every  five  minutes  for  60  min  on  a  TECAN  96-well  plate 
reader (ex/em= 492:535).  
2.4.6  Ub
G76V-GFP reporter assays  
N2aPK-1 transfection with Ub
G76V-GFP 
The Ub
G76V-GFP construct was a kind gift from Dr Nico Dantuma (Department of Cell and 
Molecular Biology, Karolinska Institutet, Sweden), made as described previously (Dantuma 
et al., 2000). The ubiquitin ORF was amplified by PCR from the Ub-Pro-bGal plasmid with 
the  sense  primer  5’-GCGGAATTCACCATGCAGATCTTCGTGAAGACT-3’  and  the  anti-sense 
primer  5’-GCGGGATCCTGTCGACCAAGCTTCCCCACCACACCTCTGAGACGGAGTAC-3’  for 
Ub
G76V-GFP  and  was  cloned  in  the  EcoR1  and  BamH1  sites  of  the  EGFP-N1  vector 
(Clontech). Restriction sites are shown in bold. Transfection of this vector into N2aPK-1 
cells  was  carried  out  using  Genejammer  lipofection  transfection  reagent  (Stratagene). 
Cells were seeded at 30-50 % density in 6 well plates in standard growth medium. The 
DNA transfection reagent was prepared by mixing 100 l Opti-MEM (un-supplemented) 
and 18 l Genejammer. Following a 10 min incubation at RT, 3  g plasmid DNA were 
added to the mixture and incubated for a further 10 min at RT. Nine hundred microliters 
of fresh, pre-warmed Opti-MEM supplemented with 10% v/v FCS replaced the standard 
growth  medium  and  the  Genejammer/DNA  mixture  was  added  drop  wise.  Cells  were 
incubated  with  the  Genejammer/DNA  mixture  for  8  h  at  37°C,  following  which  fresh 
medium was added in replacement. Stably-transfected cell lines were isolated by selection 
in 600 g/ml gentamicin (G418).  
Prion infection of GFP-proteasome reporter mice 
Two lines of transgenic UPS-reporter mice, Ub
G76V-GFP1/ and 2 (Lindsten et al., 2003) 
were used. Mice heterozygous for the transgene were bred to C57BL/6 mice, and the 
offspring were inoculated intra-cerebrally with 50 l 1% w/v brain homogenates from 22L 104 | P a g e  
 
prion-infected or un-inoculated mice. The mice were followed by visual observation and 
sacrificed at the time when clear signs of clinical disease were manifested (i.e. rocking 
gait, ruffled fur, and immobility). Mice were sacrificed under deep isoflurane anaesthesia 
by cardiac perfusion with ice-cold PBS through the left ventricle. The brains removed and 
processed  either  for  histology  or  for  RNA  isolation  and  real-time  PCR  (Section  2.6.1). 
Briefly, RNA was isolated using the RNeasy mini kit (Qiagen) and prior to real time PCR, the 
integrity of RNA was evaluated with an RNA 6000 nano assay kit and Bioanalyser 2100 
(Agilent) to visualise and compare 18S and 28S rRNA bands.  
Immunohistochemisty on GFP-reporter mice 
Following removal, brains were fixed in 3.7% formaldehyde in PBS for 24 h at RT. Sagittal 
blocks were subjected to processing for dehydration and were embedded in paraffin. Six-
micrometer paraffin sagittal sections to be stained for GFP, ubiquitin, and PrP were first 
subjected to pre-treatment at 120°C for 20 min in citrate buffer (pH 6). Sections for GFAP 
staining were not pre-treated. Rabbit anti-GFP (Molecular Probes), mouse monoclonal 
anti-GFP  (Roche  Applied  Science),  mouse  monoclonal  anti-ubiquitin  (Stressgen),  rabbit 
anti-GFAP  (DAKO)  and  rabbit  anti-mouse  PrP  residues  89-103  (R30)  (Raymond  et  al., 
1997). Staining procedures for all, but GFP, were performed as described (Dimcheff et al., 
2003) by using either biotinylated secondary antisera followed by horseradish peroxidise-
conjugated streptavidin and amino-ethyl-carbazol as substrate. GFP was detected by using 
diaminobenzidine as substrate. A total of 20 UbG76V-GFP
+/- and 11 UbG76V-GFP
-/- scrapie-
inoculated  mice  and  ten  UbG76V-GFP
+/-  and  two  UbG76V-GFP
-/-  mice  inoculated  with 
normal brain homogenate were examined microscopically. Data presented in this thesis 
are from line 1 mice. 
  
2.5  Cell biology 
2.5.1  Lactate dehydrogenase assays for the measurement of cell death 
The lactate dehydrogenase (LDH) assay measures cell death by detecting LDH, a stable 
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lysis.  All  LDH  assays  were  carried  out  using  the  LDH  assay  kit  available  from  Alexis, 
Nottingham, UK. Briefly, the principle of this method involves two steps: firstly NAD
+ is 
reduced  to  NADH/H
+  as  lactate  is  converted  to  pyruvate.  Secondly,  the  catalyst 
(diaphorase) transfers a proton from NADH/H
+ to the tetrazolium salt INT (yellow) which is 
reduced to formazan (red). Cells were seeded onto 96 microwell plates. They were then 
centrifuged for 10 min at 250 x g at RT. Cell free supernatants were transferred to clear 
flat bottomed 96 microwell plates. Reaction mixture containing the catalyst was prepared 
according to manufacturer’s instructions and added to each well. Plates were read at 
492nm following a 30 min incubation at RT (in the dark).  
 
2.5.2  Immunofluorescence 
Preparation of coverslips 
For immunofluorescence experiments, 22 mm autoclaved glass coverslips were coated 
using  poly-L-lysine  (1  mg/ml)  and  incubating  at  RT  for  10  min.  Coverslips  were 
subsequently washed three times with sterile, double-distilled water and left to dry. Poly-
L-lysine enhances electrostatic interaction between negatively-charged ions of the cell 
membrane  and  positively-charged  surface  ions  of  attachment  factors  on  the  culture 
surface.  When  adsorbed  to  the  culture  surface  it  enhances  the  number  of  positively-
charged sites available for cell binding.  
Dual-labelling immunofluorescence for the detection of PrP
Sc aggresomes 
Approximately 100,000 GT-1, ScGT-1, N2aPK-1 and ScN2APK-1 cells plated on poly-L-lysine 
coated 22 mm glass coverslips were treated for 24 h with 1 M lactacystin at 37°C. Cells 
were fixed onto the coverslips with 4 % PFA for 20 min at RT. Coverslips were incubated 
with 98% formic acid for 5 min to acid-hydrolyse PrP
C and expose PrP
Sc and then washed 
three times with PBS and permeabilised at -20°C with pre-cooled 100 % methanol for 15 
min. After washing three times with PBS coverslips were blocked with 10 % normal goat 
serum (NGS) in PBS for 30 min at 37°C and again washed three times with PBS. Coverslips 
were incubated for 1 h at 37°C with appropriate primary antibodies that were diluted to 106 | P a g e  
 
suitable concentrations in 1 % NGS and 1 h at 37°C. After washing, cells were incubated 
for 45 min at 37°C with secondary antibodies (diluted to suitable concentrations in 1 % 
NGS). Following washing in PBS, 1 g/ml DAPI was added to each coverslip; coverslips 
were mounted on glass slides in 10 l anti-fade (DAKO). Slides were left to dry and placed 
at 4°C until analysis.  
 
Confocal image acquisition 
Confocal microscopy was used to obtain fluorescence images. The confocal microscope 
(Zeiss microscope LSM510 META) was equipped with ‘plan-Apochromat’ 63 x/1.40 Oil DIC 
objective at RT and was controlled by Zeiss LSM software. Fluorescence was recorded at 
488 nm using 30 mW Ar-laser for excitation or at 543 nm using 1 mW HeNE-laser for 
excitation. Zeiss Imersol™ was used as imaging medium.  
 
2.6  Molecular biology 
2.6.1  Quantitative real time polymerase chain reaction (PCR) 
Extraction of total RNA 
Total RNA was extracted from mock-infected GT-1 and ScGT-1 (that had been treated with 
or without 1 M lactacystin for 24 h at 37°C) cells using the TRIZOL™ (Invitrogen) method. 
Briefly, cells were harvested at a consistent confluency (~80 %) and washed in PBS. 1.5 ml 
TRIZOL™ reagent was then added directly to a 10 cm plate which was subsequently placed 
on a shaker for 5 min at RT. TRIZOL™-lysed cells were transferred to 1.5 ml RNase-free 
tubes (Sarstedt) and were shook for 15 seconds. After being left to stand at RT for 5 min, 
200 l chloroform (VWR) was added to each eppendorf in a fume hood. Following shaking 
for 15 seconds, samples were left at RT for 5 min. Lysates were centrifuged at 12,000 x g 
at 4°C for 10 min to separate phases; the upper (aqueous) phase was pipetted into a fresh 
tube and 750 l of isopropanol (VWR) was added to each reaction tube. After a 15 second 
shake and a RT incubation of 10 min, samples were centrifuged at 12,000 x g at 4°C for 15 107 | P a g e  
 
min and then immediately placed on ice. Following the addition of 180 l of 100% ethanol 
(VWR) samples were centrifuged at 13,000  x g at 4°C for 5  min. After discarding the 
ethanol, the RNA pellet was left to air dry for 10 min before dissolving RNA in DEPC-
treated water (AMBION) and storing at -70°C.  
Agarose gel electrophoresis RNA 
1 % agarose mini-gels were made by heating 1.5 g agarose (AMBION) in 150 ml of 1 X 
NorthernMAX glyoxyl based gel pre/running buffer (AMBION) in a microwave oven until 
the agarose was fully dissolved. Gels were then cooled to approximately 50°C by stirring 
and were poured into a gel tray fitted with the appropriate comb(s) and left to set at RT. 
RNA samples were adjusted to 50 ng/l with DEPC-treated water in a final volume of 5 l. 
Following this, samples were incubated at 50°C for 30 min with an equal volume of glyoxyl 
loading dye (containing ethidium bromide; AMBION). 10 l of sample were loaded into 
each lane and 5 l of RNA ladder (AMBION). Gels run for 90 min at 100 mV. RNA was 
visualized by examining the gel on a BIORAD Gel Doc 1000 imaging system under UV light 
to evaluate sample integrity. Gels were photographed and analyzed using the Quantity 
One software (version 4.5.1, BIORAD). 
cDNA synthesis 
1 g RNA was combined with 2.5 l random primers (Invitrogen) and topped to 11 l with 
DEPC-treated water in an RNase-free 0.5 ml eppendorf tube (Advanced Biotechnologies) 
on ice. The RNA was denatured at 70 °C for 10 min and then cooled immediately on ice. 
After a quick spin the reaction mixture was incubated with 4 l 5 X First Strand Buffer 
(Invitrogen), 2 l DTT (Invitrogen), 1 l dNTPs (10mM stock; Invitrogen) and 1 l RNase 
Out  at  25  °C  for  10  min.  Following  this  1  l  of  SuperScript®  II  Reverse  Transcriptase 
(Invitrogen) was added to the mix; the mix was incubated for 10 min at 25 °C, then at 42 
°C for 1 h and finally at 70 °C for 10 min. 80 l of DEPC-treated water were then added to 
20 l cDNA and stored at -70 °C.  108 | P a g e  
 
Primer design 
Primers were designed using the Primer Express™ software (Applied Biosystems) (Table 
2.1).  
 
 
 
 
Table 2.1 Primer sets 
 
 
 
 
 109 | P a g e  
 
Real time reverse transcriptase PCR 
SYBR Green 
Reactions took place in 96 well plates. Total RNA samples were reverse transcribed (See 
cDNA synthesis). As a negative control, 1 μg of RNA was processed without addition of 
reverse transcriptase. Quantitative real-time PCR analysis (Applied Biosystems Sequence 
Detection  System  7500)  using  SYBR  Green  (Qiagen)  was  performed  according  to  the 
manufacturer's instructions. Briefly, reactions consisted of 12.5 μl of Sybr Green master 
mix, 1.2 μl of cDNA, sense and anti-sense primers (Table 2.2), topped up to 25 l with 
DEPC-treated water. Default PCR conditions: a) 40 cycles of 15 min at 95°C, 15 seconds at 
95°C, 1 min annealing at 60°C, b) dissociation step of 15 seconds at 95°C, 1 min at 60°C 
and  15  seconds  at  95°C.  All  primers  were  assessed  for  efficiency  using  SYBR  Green 
conditions prior to being utilized. Gene expression levels were assessed in three biological 
replicate samples (and three technical replicates of each) from each group using the ΔΔCT 
method and normalization to Gapdh or Actb. Standard deviations were calculated using 
the values of the biological replicates of mock-infected and RML-infected cells.  
 
 
Gene  Sense/Anti-sense primer (nM)  Volume in reaction (l) 
Gapdh  400/400  1.67/1.67 
Actb  300/300  1.5/1.5 
Becn1  300/300  1.5/1.5 
Atg12  300/300  1.5/1.5 
Atg16L  300/300  1.5/1.5 
 
 
Table 2.2 Primer concentrations in SYBR Green PCR 
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2.7  Statistical analysis 
Data  were  expressed  as  mean  plus  standard  error  of  mean  (SEM;  sd√n).  Data  were 
compared by 2-tailed t-tests and considered significantly different when P<0.05. Degree of 
significance was expressed as follows: P<0.05*; P<0.01**; P<0.001***, unless otherwise 
specified. 
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3  DISEASE-ASSOCIATED  PRION  PROTEIN  OLIGOMERS  INHIBIT 
THE CATALYTIC  SUBUNITS OF THE 26S PROTEASOME 
3.1  Background 
Increasing evidence suggests a possible role for the UPS in prion disease (Section 
1.9). Studies in prion-infected mouse brain have shown a correlation between elevated 
levels of ubiquitin conjugates and reduced proteasome function (Kang et al., 2004). WT 
PrP
C molecules undergoing ERAD have been shown to accumulate in the cytosol of cells 
when  the  proteasome  is  inhibited  (Ma  and  Lindquist,  2001;  Yedidia  et  al.,  2001). 
Therefore,  UPS  inhibition  may  allow  for  the  conversion  of  PrP
C  in  the  cytosol  to  an 
abnormal PrP
Sc-like form, especially if PrP
C accumulation exceeds the degradative capacity 
of the UPS (Ma and Lindquist, 2002) (Section 1.9.1). However, there is conflicting evidence 
concerning the neurotoxicity of PrP
C. Accumulation of cytosolic PrP
C in human primary 
neurones treated with proteasome inhibitors is not toxic, indeed conferring protection 
against Bax-mediated cell death (Roucou et al., 2003). Importantly, studies in various cell 
models have challenged the occurrence of retrograde transport of both mutant and WT 
PrP
C  prior  to  proteasome  degradation  and  have  suggested  that  cytosolic  PrP
C 
accumulation  may  be  a  result  of  elevated  levels  of  PrP
C  expression  from  the  CMV 
promoter used in many of the experiments (Drisaldi et al., 2003; Fioriti et al., 2005).  
Large, intracellular peri-centrosomal structures termed ‘aggresomes’ are thought 
to be a precise response when cells try to cope with increased levels of misfolded and 
aggregated proteins, evidenced by the active recruitment of proteasome components and 
molecular chaperones to these aggregates (Olzmann et al., 2008). Proteasome inhibition 
has been shown to lead to the formation of both PrP
C and PrP
Sc aggresomes (Cohen and 
Taraboulos, 2003; Mishra et al., 2003; Kristiansen et al., 2005; Grenier et al., 2006; Goggin 
et al., 2008). The formation of cytosolic PrP
C aggresomes appears to be toxic in both 
neuronal and non-neuronal cells (Grenier et al., 2006; Goggin et al., 2008). Kristiansen et 
al. reported that following mild proteasome inhibition, prion-infected cells form PrP
Sc-
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and  8  activation  and  subsequent  apoptosis  (Kristiansen  et  al.,  2005).  They  also 
demonstrated PrP
Sc-containing aggresome-like structures in prion-infected mouse brain. 
Granular  deposits  of  disease-related  PrP  have  been  previously  reported  in  neuronal 
perikarya  from  post-mortem  sporadic  CJD  cases,  suggesting  intra-neuronal  prion 
aggregates may play a role in disease pathogenesis (Kovacs et al., 2005).  
 
3.1.1  Aims 
The  aims  of  this  study  were  to  evaluate  the  role  of  the  UPS  in  prion  disease 
pathogenesis  and  to  examine  whether  there  is  a  direct  mechanistic  link  between 
aggregated prion protein species and UPS function.  
 
3.1.2  Methods 
Western blotting was used for the detection of protein levels (Section 2.2.1). A 
proteasomal  subunit activity probe was used to assay specific   subunit proteolytic 
activity by Western blotting (Section 2.4.1), whereas the three peptidase activities of the 
20S  proteasome  were  monitored  using  fluorogenic  substrates  (Section  2.4.2).  Dual-
labelling  immunofluorescence  was  undertaken  for  all  co-localisation  studies  (Section 
2.5.2). The Ub
G76V-GFP proteasome reporter monitored the functional status of the UPS 
(Section 2.4.6) and the experiment was performed by Dr Mark Kristiansen, MRC Prion 
Unit,  UCL  Institute  of  Neurology.  NativePAGE™  immunoblotting  and  substrate  overlay 
methods  assayed  26S  proteasome  dissociation  (Section  2.4.3).  Experiments  were 
performed in collaboration with Dr Mark Kristiansen, MRC Prion Unit, UCL Institute of 
Neurology. Ub
G76V-GFP mouse experiments (Section 2.4.6), including an RT-PCR on the 
mouse brain lysates, were performed by Dr Derek Dimcheff and Dr John Portis, at Rocky 
Mountain Laboratories, USA.  
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3.2  Results 
3.2.1  Prion  infection  in  cells  impairs  the  proteolytic  activity  of  the  26S 
proteasome 
Mouse  hypothalamic  neuronal  GT-1  (Schatzl  et  al.,  1997)  and  neuroblastoma 
N2aPK-1 cells (Klohn et al., 2003) were infected with either 0.1 % RML prion-infected or 
mock-infected control (CD-1) mouse brain homogenate. Prion infection was demonstrated 
by immunoblotting with an anti-PrP antibody (ICSM18), which confirmed PK-resistant PrP 
species in prion-infected cells (ScGT-1 and ScN2aPK-1) (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Prion infection of N2aPK-1 and GT-1 cells 
Cell lysates of uninfected (GT-1 and N2aPK-1) and prion-infected cells (ScGT-1 and ScN2aPK-1) 
were immunoblotted using an anti-PrP antibody, ICSM18. 25 g from cell lysates was loaded per 
lane.  PrP
C  runs  between  50-30  kDa  in  its  three  glycosylation  states  (di-,  mono-  and 
unglycosylated). These three bands disappear completely after PK digestion in uninfected cells. In 
PK-treated  ScGT-1  and  ScN2aPK-1  cells  these  bands  remain  nearly  undiminished  in  intensity, 
although they shift to lower molecular weight (arrows). 
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The  three  peptidase  activities  of  the  20S  proteasome  are  routinely  monitored 
using  specific  fluorogenic  peptides  as  a  measure  of  proteasomal  activity  in  vitro. 
Chymotrypsin-like, caspase-like and trypsin-like proteolytic activities were measured in 
prion-infected (ScGT-1), mock infected, and uninfected GT-1 cell lysates. Significant loss of 
chymotrypsin-like, caspase-like and trypsin-like activities was seen in ScGT-1 cells, but not 
in mock-infected cells or cells cured of prion infection using anti-PrP (ICSM18) antibody 
treatment (Enari et al., 2001), as compared to uninfected controls (Figure 3.2). Specific 
proteolytic  activity  of  the  ATP-dependent  26S  proteasome  was  confirmed  by  a  near-
complete lack of activity in the absence of ATP. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Prion infection in cells impairs the proteolytic activity of the 26S  
Prion infection of GT-1 cells (ScGT-1) significantly reduces their (i) chymotrypsin-like, (ii) caspase-
like,  and  (iii)  trypsin-like  proteolytic  activities.  Peptidase  activities  of  cell  lysates  (10  g  per 
reaction) were monitored using fluorogenic substrates specific for each activity: 100 M Suc-LLVY-
AMC  (chymotrypsin-like),  100  M  Ac-nLPnLD-AMC  (caspase-like)  and  100  M  Boc-LLR-AMC 
(trypsin-like). Lysates were incubated with the fluorogenic substrate for 30 min, following which 
fluorescence was measured over time at 360 nm excitation and 465 nm emission. Proteolytic 
activity is nearly abolished in the absence of ATP. Suffix -18 denotes cells cured of prion infection 
by incubation with the anti-PrP (ICSM18) antibody. Data are from ten independent experiments 
+SEM. ***p<0.001, **p<0.01 (versus uninfected controls).  115 | P a g e  
 
3.2.2  Prion infection impairs the 26S proteasome in mouse brain 
To see if the loss of proteolytic activity seen in prion-infected cells was mirrored in 
mouse brain, chymotrypsin-like and caspase-like proteolytic activities were measured in 
control (CD-1) and RML prion-infected mouse brain homogenates. This demonstrated a 
significant reduction in chymotrypsin-like and caspase-like activities in RML prion-infected 
mouse brain compared with control brain (Figure 3.3). Of note, assaying proteasomal 
function in prion-infected brain tissue may be complicated by the presence of marked glial 
proliferation,  which  is  characteristic  of  prion  neuropathology  and  may  result  in  an 
overestimation of proteolytic function. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Prion infection impairs the 26S in mouse brain 
Scrapie infection significantly reduces chymotrypsin-like and caspase-like proteolytic activities in 
prion-infected mouse brain (RML) compared to control brain (CD-1). Peptidase activities of mouse 
brain homogenates (10 g per reaction) were monitored using fluorogenic substrates specific for 
each activity: 100 M Suc-LLVY-AMC (chymotrypsin-like), 100 M and Ac-nLPnLD-AMC (caspase-
like). Homogenates were incubated with the fluorogenic substrate for 30 min, following which 
fluorescence was measured over time at 360 nm excitation and 465 nm emission. Chymotrypsin-
like activity data are means of five independent experiments +SEM, whereas caspase-like activity 
data are means of ten independent experiments +SEM. ***p<0.001 (versus uninfected controls).  
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3.2.3  Prion infection impairs the catalytic  subunits of the 26S proteasome 
To further investigate prion-induced loss of proteasome proteolytic activities, a 
specific proteasome  subunit activity probe was used (Berkers et al., 2005). This is a cell-
permeant  peptide  vinyl  sulfone-based  competitive  inhibitor,  which  modifies  the 
catalytically active N-terminal threonine residues of the  subunits, forming a covalent -
sulfonyl  ether  linkage  (dansylAhx3L3VS).  This  probe  has  a  dansyl-sulfonamidohexanoyl 
hapten tag, which allows accurate monitoring of  subunit activities in live cells and cell 
lysates. 
 
GT-1 and N2aPK-1 cells were infected with either RML prion-infected or mock-
infected (CD-1) mouse brain homogenates. Lysates from prion-infected (ScN2aPK-1), mock 
infected and uninfected N2aPK1 cells  were incubated with the dansylAhx3L3VS activity 
probe  and  immunoblotted  with  an  anti-dansyl  antibody.  Modification  of    subunits, 
indicating a loss of activity, was clearly seen in ScN2aPK-1 cells compared to uninfected, 
mock-infected  and  anti-PrP  (ICSM18)  antibody-cured  controls  (Figure  3.4A).  As  the   
subunit activity probe is cell permeant, it was also used to assay live cells; live ScGT-1 cells 
demonstrated a significant loss of  subunit activity again as compared to controls (Figure 
3.4B). Lactacystin, a cell-permeable irreversible proteasome inhibitor (Lee and Goldberg, 
1998),  completely  abrogated    subunit  proteolytic  activity  in  N2aPK-1  and  GT-1  cells 
(Figure 3.4A and B). 
 
 
 
 
 
 
 
 
 117 | P a g e  
 
 
 
A 
 
 
 
 
 
B 
 
 
 
 
 
 
Figure  3.4  Prion  infection  impairs  the  proteasome  by  specifically  inhibiting  the  catalytic   
subunit activities 
(A)  Cell  lysates  from  uninfected  (N2aPK-1),  prion-infected  (ScN2aPK-1),  mock-infected  and 
ScN2aPK-1  cells  cured  of  prion  infection  by  treatment  with  an  anti-PrP  antibody  (ICSM18) 
(ScN2aPK-1-18)  were incubated with the  subunit activity probe (dansylAhx3L3VS; 1 M) and 
immunoblotted with  a  rabbit  polyclonal  anti-dansyl  antibody.  Prion  infection  of  N2aPK-1  cells 
resulted in a loss of proteolytic  subunit activities. No loss of  subunit proteolytic activities was 
seen in N2aPK-1, mock-infected, or ScN2aPK-1-18 cells. (B) Live GT-1 cells were incubated with the 
cell permeant activity probe in culture, lysed and immunoblotted with an anti-dansyl antibody. A 
significant reduction in proteolytic  subunit activities was demonstrated in prion-infected GT-1 
(ScGT-1)  cells  but  not  in  mock-infected  or  ScGT-1  cells  cured  of  prion  infection  (ScGT-1-18). 
Lactacystin (50 M) was used as a positive control for proteasome inhibition. 100 g of protein 
from cell lysates was loaded per lane. Levels of an endogenous mouse protein, -actin (-act), 
were assessed by immunoblotting to confirm equal protein loading.  118 | P a g e  
 
3.2.4  Decreased  26S  proteasome    subunit  proteolytic  activity  is  not  due  to 
decreased  subunit expression 
Decreased  proteolytic  activities  in  aged  cells  of  different  origins  have  been 
associated with reductions in levels of proteasome subunits (Ding et al., 2006; Powell, 
2006; Hwang et al., 2007). Therefore, it was important to ensure that the decrease in 
proteolytic activity seen in prion-infected mouse cells and brain was not due to reduced 
expression  of    subunits.  Protein  levels  of  4,  2  and  5  subunits  were  measured  by 
immunoblotting with antibodies to each of these subunits. This demonstrated no loss of 
expression  in  any  of  the  three  subunits  (Figure  3.5),  indicating  that  the  reduced 
proteolytic activity seen in prion-infected mouse cells and brain results from a specific 
inhibitory effect.  
 
 
 
 
 
 
 
 
Figure 3.5 Decreased proteolytic activity is not due to decreased  subunit expression 
GT-1 and N2aPK-1 cells were infected with RML prions, lysed and immunoblotted for proteasome 
subunits. (i) There was no reduction in 4, 2 or 5 subunit levels in ScGT-1 cell lysates compared 
to uninfected controls. (ii) There was no reduction in 4, 2 or 5 subunit levels in ScN2aPK-1 cell 
lysates compared to uninfected controls. (iii) There was no reduction in 4, 2 or 5 subunit levels 
in RML-infected mouse brain homogenates compared to uninfected (CD-1). 100 g protein from 
cell lysates or mouse brain homogenates was loaded per lane and mouse monoclonal antibodies 
to 4, 2, or 5 proteasome subunits were used for immunoblotting. Each lane represents an 
independent  experiment.  Levels  of  an  endogenous  mouse  protein,  -actin,  were  assessed  by 
immunoblotting to confirm equal protein loading.  119 | P a g e  
 
3.2.5  PrP
Sc is localised in the cytosol in prion-infected cells 
The 26S proteasome is localised in the cell to both the nucleus and cytosol (Tanaka 
et al., 1986). It was therefore interesting to investigate whether PrP
Sc can gain access to 
these compartments in prion-infected cells. The sub-cellular distribution of PrP
Sc is difficult 
to assess due to the lack of PrP
Sc-specific antibodies. Nonetheless, studies have shown its 
localisation at the plasma membrane and the endolysosomal compartment (Caughey and 
Baron, 2006), and it has been recently shown that some PrP can escape macropinosomes 
and leak into the cytosol (Wadia et al., 2008). Formic acid (FA) was used to pre-treat 
ScN2aPK-1 cells in order to acid-hydrolyse PrP
C and expose PrP
Sc (Kristiansen et al., 2005). 
These  ScN2aPK-1  cells  were  then  stained  with  the  anti-PrP  (ICSM18)  antibody  and 
visualised using confocal fluorescent microscopy. Following FA treatment, PrP
Sc was found 
to be localised on both the cell surface and intracellularly (Figure 3.6). 
 
To  determine  whether  PrP
Sc  is  present  in  the  cytosol  of  ScN2aPK-1  cells,  co- 
immunostaining  for  endolysosomal  and  cytosolic  markers  was  undertaken.  Confocal 
microscopy showed that PrP
Sc partially co-localised with the endolysosomal marker LAMP-
1, but that it also exists outside this compartment (Figure 3.7A); a proportion of PrP
Sc co-
localised with the cytosolic marker Hsc70 as shown in Figure 3.7B. Furthermore, true co-
localisation  between  Hsc70  and  PrP
Sc  was  revealed  by  an  intensity  scatter  plot  and 
subtraction  of  the  confocal  images  (Figure  3.8).  Indeed  this  finding  suggests  that  a 
proportion  of  PrP
Sc  is  localised  in  the  cytosolic  compartment  is  supported  by  studies 
describing neurotoxic PrP
Sc aggresomes (Kristiansen et al., 2005). Taken together, these 
results show that a limited amount of PrP
Sc is found in the cytosol of prion-infected cells. 
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Figure 3.6 Formic acid exposes PrP
Sc in ScN2aPK-1 cells 
ScN2aPK-1 cells were treated with 98 % formic acid (FA) for 5 min and immunostained with an 
anti-PrP  antibody  (green;  mouse  monoclonal  ICSM  18;  10  g/ml;  D-Gen)  to  reveal  PrP
Sc.  In 
uninfected  N2aPK-1  cells,  FA  removed  all  detectable  PrP
C  after  5  min  (top  right);  PrP
Sc  was 
localised to the cell surface and intracellularly in ScN2aPK-1 cells (bottom right). DAPI nuclear 
staining= blue. Scale bar= 20 m.   
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Figure 3.7 PrP
Sc is localised in the cytosol in prion-infected cells 
ScN2aPK-1 cells were exposed to 98 % formic acid (FA) for 5 min prior to co-immunostaining. (A) 
PrP
Sc (green; mouse monoclonal ICSM18; 10 g/ml; D-Gen) in ScN2aPK1 cells not only partially co-
localises with LAMP-1 (red; rat polyclonal; 1:500; Santa-Cruz), but also exists outside this structure. 
(B) A proportion of PrP
Sc (green; ICSM18) in ScN2aPK-1 cells co-localises with cytosolic Hsc70 (red; 
mouse monoclonal IgG2a; 1:500; Santa-Cruz). PrP
Sc is also seen abundantly on the cell surface 
(green). Scale bar= 20 m; DAPI nuclear staining= blue.  
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Figure 3.8 A proportion of PrP
Sc colocalises with Hsc70 
(i) The intensity scatter plots the intensity of the pixels stained either for PrP
Sc (x-axis) or Hsc70 (y-
axis). Segment 1 reveals pixels with intense PrP
Sc staining; segment 2 reveals pixels with intense 
Hsc70 staining; segment 3 reveals the co-localisation of pixels with both intense PrP
Sc and intense 
Hsc70  staining.  (ii)  Demonstrates  a  subtraction  image  revealing  true  co-localisation  (yellow) 
between Hsc70 and PrP
Sc (image corresponds to the intensity scatter segment 3). Scale bar = 20 
µm. 
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3.2.6  Prion infection causes UPS dysfunction in live cells 
To test whether the proteolytic dysfunction observed in preparations from prion-
infected cells results in real, functionally-significant impairment of the UPS in live cells, 
N2aPK-1 cells stably expressing the fluorescent proteasome reporter substrate Ub
G76V-GFP 
(Dantuma et al., 2000) were infected with RML prions. Prion infection caused an increase 
in the steady-state levels of the GFP-tagged reporter indicating functional impairment of 
the  UPS  (Figure  3.9).  Curing  prion-infected  cells  with  an  anti-PrP  antibody  (ICSM18) 
resulted in normal UPS function (Figure 3.9). The proteasome inhibitor lactacystin was 
used as positive control, resulting in an increase in Ub
G76V-GFP steady-state levels. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Prion infection causes UPS dysfunction in live cells 
N2aPK-1 cells expressing the fluorescent UPS reporter (Ub
G76V-GFP; green), were infected with 
RML prions (ScN2aPK-1). Accumulation of the UPS reporter occurred only in prion-infected cells or 
lactacystin-treated (50M) N2aPK-1 cells (positive control). Uninfected cells did not accumulate 
Ub
G76V-GFP and cells cured of prion infection by treatment with an anti-PrP antibody (ICSM18) did 
not stain significantly for the UPS reporter. This experiment was performed by Dr Mark Kristiansen, 
MRC Prion Unit, UCL Institute of Neurology. 
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3.2.7  Disease-related PrP isoforms directly inhibit the catalytic  subunit activity 
of the 26S proteasome  
To directly assess how prion infection inhibits the catalytic  subunit activity of the 
26S  proteasome,  an  in  vitro  assay  system  was  developed  to  measure  the  effects  of 
different  conformations  and  aggregation  states  of  PrP  on  26S  proteasome  activity  in 
neuronal  cell  lysates.  Specifically,  recombinant  mouse  PrP  (full  length;  23-231aa)  was 
used, which had been folded into one of two forms: an -helical structure, representative 
of native PrP
C (-PrP) or a predominantly -sheet species termed -PrP, which has similar 
physico-chemical  properties  to  PrP
Sc  (Jackson  et  al.,  1999).  Their  effects  on  26S 
proteasome  subunit activity in N2aPK-1 cells and cerebellar granule neurones (CGN) 
were assayed using the dansylAhx3L3VS activity probe.  
Five different PrP species were made: aggregated -PrP (by heating at 70 °C for 10 
min), aggregated -PrP (by addition of NaCl to a final concentration of 150 mM), which 
forms small spherical particles 5-10 nm in diameter (Jackson et al., 1999), acidified -PrP-
derived amyloid fibrils (Baskakov et al., 2002), and NaCl-treated -PrP. Semi-purified PrP
Sc 
was obtained from RML-infected mouse brain and ScGT-1 cells (Kristiansen et al., 2005). 
Both aggregated -PrP and PrP
Sc (from ScGT-1 cells) inhibited the  subunit activities of 
N2aPK-1 cells, whereas -PrP, aggregated -PrP and amyloid fibrils had no effect (Figure 
3.10A). Carboxy-methylated -lactalbumin, a soluble unfolded protein molecule used in 
protein folding studies as a mimetic of the molten globule state (Kuwajima, 1996), had no 
inhibitory effect on the  subunit activities (Figure 3.10A). A marked inhibition on the  
subunit activities of N2aPK-1 cells was also observed by PrP
Sc derived from RML prion-
infected  mouse  brain  (Figure  3.10B).  Lactacystin  pre-treatment  of  N2aPK-1  cells 
completely abrogated their  subunit proteolytic activity (positive control).  
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Figure 3.10 PrP
Sc and aggregated -PrP inhibit the catalytic  subunit activity of the 26S  
N2aPK-1 cell lysates were incubated with recombinant prion proteins or semi-purified PrP
Sc before 
treatment with the  subunit activity probe (dansylAhx3L3VS; 1 M) and immunoblotting with an 
anti-dansyl antibody. (A) Only aggregated -PrP (lane 4), PrP
Sc (lane 6; from ScGT-1 cells) or 50 M 
lactacystin (lane 7; positive control) resulted in a loss of  subunit activity in N2aPK-1 cell lysates. 
(B) PrP
Sc from RML prion-infected mouse brain (lane 2) or 50 M lactacystin (lane 3; positive 
control) incubated with N2aPK-1 cell lysates resulted in a loss of  subunit activity. Proteins were 
assayed at 1 mg/ml (final concentration). 100 g protein from cell lysates was loaded per lane. 
Levels of an endogenous mouse protein, -actin, were assessed by immunoblotting to confirm 
equal protein loading. 
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Cytosolic fractions from mouse CGN cultures were also incubated with the various PrP 
species. Figure 3.11 shows that only aggregated -PrP and PrP
Sc (from ScGT-1 cells) caused 
a loss in  subunit, predominantly 1 and 5, activities in these cells.  Lactacystin (positive 
control) pre-treatment resulted in complete inhibition of subunit activities.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Aggregated -PrP and PrP
Sc inhibit the  subunit proteolytic activities of the 26S in 
primary neurones 
CGN cell lysates were incubated with recombinant prion proteins or semi-purified PrP
Sc before 
treatment with the  subunit activity probe (dansylAhx3L3VS; 1 M) and immunoblotting with an 
anti-dansyl  antibody.  Aggregated  -PrP  (lane  4),  PrP
Sc  (lane  6;  from  ScGT-1  cells)  or  50  M 
lactacystin (lane 9; positive control) resulted in a loss of 1 and 5 subunit activity in CGN cell 
lysates. Proteins were assayed at 1 mg/ml (final concentration). 100 g of protein from cell lysates 
was  loaded  per  lane.  Levels  of  an  endogenous  mouse  protein,  -actin,  were  assessed  by 
immunoblotting to confirm equal protein loading. Primary cerebellar granule neuronal cultures 
were prepared by Ms Heike Naumann, MRC Prion Unit, UCL Institute of Neurology. 
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3.2.8  Denaturation of -PrP
 and PrP
Sc abolishes their inhibitory effect on 26S 
proteasome  subunit activity 
To confirm that the inhibitory effect of -PrP and PrP
Sc on the  subunits of the 
proteasome was dependent on their specific conformation, they were denatured by serial 
freeze-boiling.  Denaturation  of  aggregated  -PrP  and  PrP
Sc  completely  removed  their 
inhibitory activity (Figure 3.12A).  subunit activities were restored after denaturation of 
the  prion  species,  indicating  that  a  specific  conformation  of  the  inhibitory  species  in 
aggregated  -PrP  and  PrP
Sc  is  necessary  for  inhibition  of  the  catalytic    subunits. 
Moreover, an aggregated state was necessary for an inhibitory effect, as non-aggregated 
-PrP showed no effect on  subunit proteolytic activities when incubated with N2aPK-1 
cells (Figure 3.12B). The proteasome inhibitor lactacystin completely abolished  subunit 
proteolytic activity and was used as a positive control. 
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Figure 3.12 The inhibitory effect of PrP
Sc and aggregated -PrP
 is conformation specific 
N2aPK-1 cell lysates were incubated with the prion species in an aggregated or denatured state 
before treatment with the  subunit activity probe (dansylAhx3L3VS; 1 M) and immunoblotting 
with  an  anti-dansyl  antibody.  (A)  Complete  denaturation of  aggregated -PrP
  and  PrP
Sc (from 
ScGT-1 cells) by 10 cycles of freeze/boiling restored  subunit catalytic activities (lanes 3 and 6, 
respectively). (B) Only aggregated -PrP (lane 2) and 50 M lactacystin (lane 4; positive control) 
inhibited  subunit activities in N2aPK-1 cell lysates. Proteins were assayed at 1 mg/ml (final 
concentration). 100 g protein from cell lysates was loaded per lane. Levels of an endogenous 
mouse protein, -actin, were assessed by immunoblotting to confirm equal protein loading. 
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3.2.9  Other  aggregated  proteins  do  not  inhibit  26S  proteasome    subunit 
activity 
To assess if inhibitory effects on proteolytic activity are specific to PrP
Sc and PrP
Sc-
like species, the effect of other non-prion recombinant aggregated proteins on  subunit 
activities  was  investigated.  In  particular  the  effects  of  A1-40  amyloid  fibrils,  WT  and 
mutant SOD1 (G37R) fibrils, as well as lysozyme amyloid fibrils were studied. Figure 3.13 
shows  that  the  inhibitory  effect  on  the  26S    subunits  was  specific  to  aggregated 
conformational  isoforms  of  PrP,  as  none  of  the  other  proteins  was  inhibitory.  The 
proteasome inhibitor lactacystin was used as positive control.  
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Inhibition of the proteasome is specific to conformational isoforms of PrP 
N2aPK-1  cell  lysates  were  incubated  with  recombinant  proteins  before  treatment  with  the   
subunit activity probe (dansylAhx3L3VS; 1 M) and immunoblotting with an anti-dansyl antibody. 
Non-prion recombinant aggregated protein species had no effect on 26S proteasome  subunit 
activities in N2aPK-1 cell lysates. Proteins were assayed at 1 mg/ml (final concentration), with the 
exception  of  A1-40,  which  was  assayed  at  100  g/ml.  For  details  on  recombinant  protein 
preparation see Section 2.3. 100 g protein from cell lysates was loaded per lane. Levels of an 
endogenous mouse protein, -actin, were assessed by immunoblotting to confirm equal protein 
loading. 
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3.2.10 -PrP
 is a potent inhibitor of 26S proteasome  subunit activity 
Serial dilutions of aggregated -PrPwere prepared and incubated with cytosolic 
cell fractions prior to assaying  subunit activity in order to determine the potency of -
PrP
 in inhibiting the 26S  subunit activities. Concentrations of aggregated -PrP above 75 
ng/ml completely inhibited  subunit proteolytic activity, whereas activity was observed at 
normal levels using 50 ng/ml aggregated -PrP
 (Figure 3.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Aggregated -PrP is a potent inhibitor of 26S  subunit activity (cells) 
Serial dilutions of aggregated -PrP
 (10 ng/ml, 25 ng/ml, 50 ng/ml, 75 ng/ml, 100 ng/ml, 500 
ng/ml, 1 g/ml, or 1 mg/ml) were incubated with 100 g cytosolic N2aPK-1 cell fractions before 
incubation with 1 M activity probe (dansylAhx3L3VS) and immunoblotting with an anti-dansyl 
antibody.  Concentrations of  aggregated -PrP  above  75  ng/ml  completely  inhibited   subunit 
proteolytic activity, whereas activity was observed at normal levels using 50 ng/ml aggregated -
PrP.  Levels  of  an  endogenous  mouse  protein,  -actin,  were  assessed  by  immunoblotting  to 
confirm equal protein loading. 
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To  determine  the  molar  ratio  of  aggregated  -PrP
  sufficient  to  inhibit  the 
proteasome, known concentrations of pure human 26S proteasome were incubated with 
various molar concentrations of aggregated -PrP. The concentration of aggregated -PrP 
sufficient to inhibit the 26S proteasome was essentially stoichiometric.  1.5 ng -PrP (2.15 
nM) was sufficient to inhibit 100 ng final concentration (fc) 26S (1.39 nM) (Figure 3.15A), 3 
ng -PrP (4.3 nM) was sufficient to inhibit 300 ng fc 26S (4.16 nM) (Figure 3.15B), and 7.5 
ng -PrP (10.75 nM) was sufficient to inhibit 900 fc ng 26S (12.49 nM) (Figure 3.15C). 
Taken  together,  these  results  demonstrated  that  aggregated  -PrP  is  a  highly  potent 
inhibitor of  subunit proteolytic activity and suggest that it is small aggregated -sheet-
rich PrP isoform(s) that is the inhibitory species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 132 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Aggregated -PrP is a potent inhibitor of 26S  subunit activity (pure 26S) 
Serial dilutions of aggregated -PrP were pre-incubated with three different concentrations of 
pure human 26S proteasome before incubation with the  subunit activity probe (dansylAhx3L3VS; 
1 M) and immunoblotting with an anti-dansyl antibody. (i) 1.5 ng -PrP (2.15 nM) was sufficient 
to inhibit 100 ng final concentration (fc) 26S (1.39 nM), (ii) 3 ng -PrP (4.3 nM) was sufficient to 
inhibit 300 ng fc 26S (4.16 nM), and (iii) 7.5 ng -PrP (10.75 nM) was sufficient to inhibit 900 fc ng 
26S (12.49 nM). This experiment was performed by Dr Mark Kristiansen, MRC Prion Unit, UCL 
Institute of Neurology. 133 | P a g e  
 
3.2.11 Pre-incubation  with  an  antibody  raised  against  aggregation  intermediates 
abrogates the inhibition of the 26S proteasome  subunit activity by aggregated 
-PrP
 and PrP
Sc 
To  investigate  whether  the  PrP  species  responsible  for  inhibition  of    subunit 
activity was oligomeric, the ability of an antibody raised against aggregation intermediates 
(Kayed et al., 2003) to prevent inhibition was tested. Pre-incubation of either 0.5 g/ml 
aggregated -PrP or PrP
Sc (Figure 3.16) with molar excess of anti-oligomer antibody (150 
g/ml) abolished their inhibitory effect on the  subunits. This effect was specific, as pre-
incubating  both  aggregated  -PrP
  and  PrP
Sc  with  a  rabbit  polyclonal  antibody  raised 
against -actin had no effect.  
 
Moreover,  the  inhibitory  effect  of  the  PrP  species  was  not  diminished  when 
aggregated -PrP and PrP
Sc were pre-incubated with the same concentration (150 g/ml) 
of three anti-PrP antibodies raised against different regions of the prion protein (Figure 
3.17), confirming the specificity of the action of the antibody raised against aggregation 
intermediates. These results are consistent with an oligomeric PrP species in aggregated 
-PrP
 and PrP
Sc inhibiting the 26S  subunit activity. The proteasome inhibitor lactacystin 
completely abolished  subunit proteolytic activity and was used as a positive control. 
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Figure 3.16 Inhibition of the  subunit proteolytic activities of the 26S proteasome is abrogated 
by pre-incubation with an anti-oligomer antibody 
Pre-incubating  aggregated  -PrP
  (lane  4)  or  PrP
Sc  (lane  8;  from  ScGT-1  cells)  with  high 
concentrations (150 g/ml) of an antibody raised against aggregation intermediates abolished 
their inhibitory effect on  subunit activities in N2aPK-1 cell lysates. An unrelated protein (-actin) 
had no effect on preventing inhibitory action of -PrP
 (lane5) and PrP
Sc (lane 9). All proteins were 
assayed at 500 ng/ml (final concentration). 100 g of protein from cell lysates was loaded per lane. 
Levels of an endogenous mouse protein, -actin, were assessed by immunoblotting to confirm 
equal protein loading.This experiment was performed by Dr Mark Kristiansen, MRC Prion Unit, UCL 
Institute of Neurology. 
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Figure 3.17 Pre-incubation with anti-PrP antibodies does not prevent  subunit inhibition 
Pre-incubating PrP
Sc (top blot) or aggregated -PrP
 (bottom blot) with high concentrations (150 
g/ml) of mouse monoclonal anti-PrP antibodies (ICSM4, 18 or 35) raised against different regions 
of PrP did not abolish their inhibitory effect on  subunit activities in N2aPK-1 cells. All proteins 
were assayed at 500 ng/ml (final concentration). 100 g of protein from cell lysates was loaded 
per lane. Levels of an endogenous mouse protein, -actin, were assessed by immunoblotting to 
confirm equal protein loading. 
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3.2.12 Aggregated -sheet-rich prion species inhibit the 20S proteasome catalytic 
core, but not via dissociation of the 26S proteasome 
Dissociation of the 26S proteasome into the 20S core particle and 19S regulatory 
particle  causes  inhibition  of  proteolysis  (Elsasser  et  al.,  2005).  To  probe  whether  the 
inhibitory effect of aggregated -PrP and PrP
Sc could be explained by dissociation of the 
26S proteasome, native gels were used to assess the effect of aggregated -PrP and PrP
Sc 
on pure human 26S proteasome. NativePAGE™ using 19S and 20S antibodies showed that 
the prion species did not cause dissociation of the 26S proteasome (Figure 3.18).  
 
 
 
 
 
 
 
 
 
 
 
Figure  3.18  Aggregated  -sheet-rich  PrP  species  inhibit  the  20S  catalytic  core,  but  not  via 
dissociation of the 26S (immunoblot) 
Native gel immunoblotting using anti-19S and -20S antibodies demonstrated aggregated -PrP
 and 
PrP
Sc do not cause dissociation of the 26S proteasome into its 19S and 20S components. Three 
micrograms of pure human 26S proteasome were incubated with aggregated -PrP or with PrP
Sc 
(from RML infected mouse brain), run on NativePAGE™ and immunoblotted using an anti-4 (20S) 
and an anti-Rpt1 (19S) subunit antibody, both at 1:1000. Proteins were assayed at 30 g/reaction 
(final concentration). 19S/20S/19S represents doubly-capped 26S proteasome, whereas 19S/20S 
represents singly-capped 26S. 137 | P a g e  
 
That the inhibition of the 20S catalytic core was inhibited, but not by dissociation of the 
26S  proteasome,  was  confirmed  by  native  gel  activity-staining  using  the  fluorogenic 
substrate overlay for chymotrypsin-like activity (Figure 3.19). Both aggregated -PrP
 and 
PrP
Sc inhibited chymotrypsin-like activity in pure human 26S proteasome compared to 
untreated 26S proteasome alone. To test whether the 26S inhibition in prion-infected 
mouse cells and brain (Figure 3.2; 3.3) was independent of 26S dissociation into 20S and 
19S,  lysates  were  run  on  NativePAGE™.  Immunoblotting  for  20S  and  19S  proteasome 
subunits  demonstrated  no  dissociation  of  the  26S  proteasome  in  prion-infected  GT-1 
(ScGT-1) cells and prion-infected CD-1 mouse brain (RML) (Figure 3.20).   
 
 
The effect of oligomeric PrP species on the 20S core particle independent of the 
19S regulatory cap was also investigated. The 19S particle was substituted with the PA28 
activator (Whitby et al., 2000), which activates the proteasome core particle but does not 
mediate ubiquitin-dependent proteolysis and many other activities mediated by the 19S 
regulatory  particle  (Voges  et  al.,  1999).  Assaying  PA28-activated  20S  showed  that 
aggregated  -PrP
  and  PrP
Sc  significantly  inhibited  chymotrypsin-like  and  caspase  like 
activity,  with  a  lesser  effect  on  trypsin-like  activity  (Figure  3.21).  This  was  the  same 
pattern of inhibition as seen in prion-infected cell lysates (Figure 3.2), although with a less 
profound  inhibitory  effect.  Collectively,  these  results  suggest  that  the  ‘oligomeric’ 
inhibitory species exerts its inhibitory effect directly on the 20S core particle, independent 
of the 19S complex. 
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Figure  3.19  Aggregated  -sheet-rich  PrP  species  inhibit  the  20S  catalytic  core,  but  not  via 
dissociation of the 26S (substrate overlay) 
(A) Aggregated -PrP
 (lanes 2 and 5) and PrP
Sc (lanes 1 and 6; from RML-infected mouse brain) 
significantly inhibited the chymotrypsin-like activity of the 26S proteasome. Three micrograms of 
pure human 26S proteasome incubated with the prion species were run on a native gel, which was 
overlaid with 100 M Suc-LLVY-AMC to detect chymotrypsin-like activity. (B) Coomassie-staining 
on the native gel from A confirmed equal protein loading in all lanes. Proteins were assayed at 30 
g/reaction  (final  concentration).  19S/20S/19S  represents  doubly-capped  26S  proteasome, 
whereas 19S/20S represents singly-capped 26S. 
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Figure 3.20 Prion infection does not cause dissociation of the 26S 
Native gel immunoblotting of prion-infected ScGT-1 cells (lane 3) and prion-infected mouse brain 
(RML;  lane  5)  showed  no  dissociation  of  26S  proteasome  into  its  19S  and  20S  components 
compared with uninfected GT-1 cell lysates (lane 2) or uninfected CD-1 mouse brain (lane 4). 30 g 
of cell lysates and 70 g of brain homogenate were run on NativePAGE™ and immunoblotted 
using  an  anti-4  (20S)  and  an  anti-Rpt1  (19S)  subunit  antibody,  both  at  1:1000.  19S/20S/19S 
represents doubly-capped 26S proteasome, whereas 19S/20S represents singly-capped 26S. 
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Figure 3.21 Aggregated -PrP
 and PrP
Sc inhibit the proteolytic activities of PA28-activated 20S 
Only aggregated -PrP
 and PrP
Sc, but not aggregated conformational isoforms of PrP, decrease 
proteolytic activities of PA28-activated 20S proteasome. Peptidase activities of pure human 20S 
proteasome (10 ng per reaction) activated by PA28 (32 ng per reaction) were monitored using 
fluorogenic substrates specific for each activity: 100 M Suc-LLVY-AMC (chymotrypsin-like), 100 
M Ac-nLPnLD-AMC (caspase-like) and 100 M Boc-LLR-AMC (trypsin-like). 20S/PA28 preparations 
were incubated with the recombinant proteins before incubation with the fluorogenic substrate 
for 30 min. Fluorescence was measured over time at 360 nm excitation and 465 nm emission. Data 
are from ten independent experiments +SEM. ***p<0.001, **p<0.01, *p<0.05 (versus untreated 
20S/PA28 control). This experiment was performed by Dr Mark Kristiansen, MRC Prion Unit, UCL 
Insittute of Neurology. 141 | P a g e  
 
3.2.13 Prion  infection  inhibits  the  UPS  in  vivo  in  GFP-proteasome  reporter 
transgenic mice  
To  assess  whether  UPS  impairment  also  occurs  in  prion-mediated 
neurodegeneration in vivo, a transgenic mouse model that allows the functional status of 
the UPS to be monitored was used (Lindsten et al., 2003). These mice express a Ub
G76V-
GFP reporter, under the control of the CMV-immediate early enhancer and the chicken -
actin  promoter,  with  constitutive  and  ubiquitous  expression  throughout  the  body, 
including  the  brain.  Accumulation  of  GFP  then  indicates  dysfunction  of  UPS  activity. 
Detection of the Ub
G76V-GFP reporter was observed only in the 22L (prion strain)-infected 
transgenic mouse brains, whereas no Ub
G76V-GFP accumulation in mice inoculated with 
normal brain or in 22L prion-infected non-transgenic littermates was seen (Figure 3.22). 
This accumulation was seen in regions of the brain with the most intense neuropathology, 
consisting of spongiosis, gliosis, and PrP
Sc deposition (Figure 3.22). Similar results were 
obtained  with  the  two  available  reporter  mouse  strains  established  from  different 
founders (Lindsten et al., 2003). Quantitative PCR confirmed that the accumulation of 
Ub
G76V-GFP was not due to transcriptional upregulation (Figure 3.23). 
 
Furthermore, also observed was accumulation of intraneuronal, granular, ubiquitin 
deposits in the brains of 22L prion-infected Ub
G76V-GFP mice (Figure 3.24). These were 
occasionally observed in the control mice, but with lower frequency and intensity. The 
expression of the Ub
G76V-GFP transgene appeared to have no detectable effect on the 
deposition of ubiquitinated proteins.  
 
Taken together, these results suggest that UPS dysfunction is associated with prion 
disease in vivo and support the in vitro data showing that proteasome function is directly 
compromised by the presence of PrP
Sc or its synthetic mimetic -PrP.  
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Figure 3.22 Prion infection causes specific inhibition of the UPS in GFP-proteasome reporter 
transgenic mice 
Immunohistochemical studies of UbG76V-GFP
+/- transgenic mice inoculated intracerebrally with 
the 22L strain of mouse scrapie (UbG76V-GFP
+/-/22L) (top) or normal brain homogenate (UbG76V-
GFP
+/-/NL) (middle) and  UbG76V-GFP
-/- inoculated with 22L (UbG76V-GFP
-/-/22L) (bottom). Left 
panels show low-power views of saggital sections through the hippocampus (H), third ventricle (V), 
and thalamus (T) stained with anti-PrP antiserum R30. Other panels show high-power views of the 
thalamus  stained  for  PrP,  GFAP,  and  Ub
G76V-GFP.  The  22L-inoculated  mice  exhibited  primarily 
diffuse staining for PrP and extensive astrocytosis (black arrows point to hypertrophic astrocytes). 
Collections of Ub
G76V-GFP positive cells were seen in the 22L-inoculated UbG76V-GFP
+/- mice (open 
arrows). The specificity of the anti-Ub
G76V-GFP antiserum is demonstrated by the lack of staining of 
these cells in the 22L-inoculated UbG76V-GFP
-/- mice. This experiment was performed by Dr Derek 
Dimcheff and Prof John Portis, Rocky Mountain Laboratories, USA. 
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Figure 3.23 Accumulation of the Ub
G76V-GFP reporter is not due to transcriptional upregulation 
There  was  no  significant  difference  in  expression  between  prion-infected  mice  versus  mock-
infected mice using Real-Time PCR quantified using 3 different house-keeping genes – 18S RNA, -
actin (ACTB) and GAPDH. Data are from five independent experiments + SD. This experiment was 
performed by Dr Derek Dimcheff and Prof John Portis, Rocky Mountain Laboratories, USA. 
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 Figure  3.24  Prion  infection  causes  specific 
inhibition of the UPS in GFP-proteasome reporter 
transgenic mice with accumulation of ubiquitin 
deposits 
Immunohistochemical  staining  for  ubiquitin  in 
sections  of  thalamus  from  UbG76V-GFP
+/- 
inoculated with 22L prion strain or normal brain 
homogenate.  Granular  deposits  of  ubiquitin  are 
seen  scattered  throughout  the  sections  of  the 
22L-infected brain but were rarely observed in the 
control. Arrows point to large neurone-like cells 
containing  ubiquitin  deposits  that  exhibit  a 
perinuclear  localisation.  The  lower  panel  of  a 
UbG76V-GFP
-/- inoculated with 22L demonstrates 
that the expression of the transgene appeared to 
have no effect on the deposition of ubiquitinated 
proteins. The substrate for all antisera was amino-
ethyl-carbazol  yielding  a  red  product.  Sections 
were  counterstained  with  hematoxylin.  This 
experiment was performed by Dr Derek Dimcheff 
and  Prof  John  Portis,  Rocky  Mountain 
Laboratories, USA.  
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3.3  Discussion 
While prion infection causes widespread neuronal loss in the brain, the molecular 
basis of prion neurotoxicity is unknown. Neurodegeneration cannot be explained by a loss 
of functional PrP
C, as its depletion does not trigger any gross pathology. For example, 
although PrP
C is essential
 for prion propagation and neurotoxicity (Bueler et al., 1993), 
PrP
C knockout in adult mouse brain has no overt phenotypic effect (Mallucci et al., 2002). 
In agreement, embryonic PrP
C knockout models demonstrate normal development and 
behaviour  (Bueler  et  al.,  1992;  Manson  et  al.,  1994).  Taken  together,  PrP
C  knockout 
studies effectively exclude loss of PrP
C function
 in neurones as a significant mechanism in 
prion-mediated neurodegeneration. It is widely hypothesised that an unknown toxic gain 
of function of PrP
Sc is more likely to underlie cell death. Studies have suggested that both 
full-length PrP
Sc (Hetz et al., 2003) and shorter PrP peptides are toxic to cells  in vitro 
(Forloni et al., 1993), and their relevance to in vivo pathogenesis is under debate. There is 
strong evidence that PrP
Sc itself may not be the toxic entity. For example, PrP
C-null tissue 
can be in close proximity to PrP
Sc deposits without suffering deleterious effects (Brandner 
et al., 1996; Mallucci et al., 2003), and there is no direct
 correlation between neuronal loss 
and PrP
Sc plaques in CJD brains (Parchi et al., 1996). Furthermore, prion diseases in which 
PrP
Sc  is  barely  detectable  have  been  described  (Collinge  et  al.,  1995;  Lasmezas  et  al., 
1997), and subclinical
 infection where high levels of PrP
Sc accumulate in the absence
 of 
clinical symptoms are also recognized (Hill et al., 2000; Race et al., 2001; Race et al., 2002; 
Hill  and  Collinge,  2003a).  Prion-infected  mice  expressing  PrP
C  without  a  GPI  anchor 
produce  infectious  prions,  accumulate  extracellular  PrP  amyloid  plaques,  but  do  not 
succumb to disease (Chesebro, 2005).  
Various mechanisms, all of which are not necessarily mutually exclusive, have been 
proposed to explain prion-mediated neurotoxicity. It has been suggested that during prion 
conversion a toxic intermediate (Hill et al., 2000), PrP
L , or side products may be produced 
(Hill and Collinge, 2003a; Collinge and Clarke, 2007). In such models, PrP
Sc may represent a 
moderately inert end-product, whereby the steady-state level of PrP
L determines the rate 
of neurodegeneration (Hill and Collinge, 2003a). PrP
L levels would be regulated by natural 146 | P a g e  
 
clearance  mechanisms  and  would  accumulate  when  the  concentration  of  toxic  PrP
L 
overwhelms the clearance capacity, thereby resulting in neurodegeneration. A possible 
candidate for such a toxic species could be a soluble monomeric or oligomeric conformer 
of  PrP  (Hill  and  Collinge,  2003a).  For  example,  it  has  been  shown  that,  at  acidic  pH, 
recombinant prion protein can fold into soluble -sheet-rich monomers that are protease 
resistant and prone to aggregation into fibrils (Jackson et al., 1999), suggesting such a 
conformer might exist under physiological conditions. This intermediate species may then 
only elicit
 neurotoxic effects when present at sufficient concentrations
 in particular sub-
cellular compartments.  
Alternatively, studies in which cross-linking PrP
C in vivo with specific monoclonal 
antibodies triggered rapid and marked apoptosis in hippocampal and cerebellar neurones 
via aberrant signalling, have suggested that PrP
Sc interacts with cell-surface PrP
C (Solforosi 
et  al.,  2004).  Another  explanation  is  that  PrP
Sc-induced  cellular  changes  may  lead  to 
altered  trafficking  of  PrP
C  with  its  accumulation  in  a  different  cellular  compartment 
resulting in cytotoxicity. For example, as a result of altered trafficking, PrP
C can assume 
two  different  trans-membrane  topologies  (
CtmPrP-C  trans-membrane  PrP  with  an 
extracellular  C-terminus  and 
NtmPrP-N  trans-membrane  PrP  with  an  extracellular  N-
terminus), one of which, 
CtmPrP, has been shown to confer severe neurodegeneration in 
mice with features typical of prion disease (Hegde et al., 1998). Furthermore, extensive 
PrP
C accumulation in the cytoplasm by use of proteasome inhibitors has been associated 
with
 neuronal cell death (Ma and Lindquist, 2002). However, the data is conflicting,
 with 
evidence both for (Ma et al., 2002; Heller et al., 2003; Rane et al., 2004; Wang et al., 2005; 
Rambold et al., 2006) and against (Drisaldi et al., 2003; Roucou et al., 2003; Fioriti et al., 
2005) this cytoplasmic
 accumulation of PrP
C having neurotoxic sequelae. One of the
 major 
drawbacks of many of these studies on cytosolic PrP
C is
 the high levels of proteasome 
inhibition used, which may limit
 any physiological relevance to the situation in vivo (Ding 
et al., 2003). Studies in transgenic mice expressing a PrP
C mutant lacking the N-terminal 
targeting  signal  (cytoPrP)  develop  normally,  but  are  severely  ataxic,  with  cerebellar 
degeneration and gliosis; they also accumulate an insoluble PrP
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However, a more recent study showed that accumulation of unglycosylated cytosolic PrP
C 
did not cause any overt phenotype in aged, gene-targeted mice (Cancellotti et al., 2005). 
In  vitro  and  in  vivo  experimental  evidence  presented  in this  chapter  suggest  a 
potential neurotoxic mechanism mediated by specific misfolded forms of PrP. Moreover, 
in vivo functional impairment of the UPS is also demonstrated in a neurodegenerative 
disease. Furthermore, the data describes that -sheet-rich, non-native forms of PrP inhibit 
the activity of the catalytic  subunits of the 26S proteasome, via an effect on the 20S 
proteasome, and that this occurs at stoichiometric concentrations.  
Using fluorogenic peptide assays and  subunit activity probes, the data presented 
here shows that in two prion-infected neuronal cell lines the presence of misfolded PrP 
significantly inhibits the chymotrypsin-like, caspase-like and trypsin-like activities of the 
26S  proteasome.  This  finding  was  mirrored  in  RML-prion-infected  CD-1  mouse  brain. 
These observations support previous work in mouse brain where impairment of these 
proteolytic activities was shown when infected with an alternative prion strain (Kang et 
al., 2004). Inactivation of the chymotrypsin-like sites alone is not enough to halt protein 
breakdown,  and  either  the  trypsin-like  or  caspase-like  activities  must  also  be 
compromised to achieve this effect (Kisselev et al., 2006); the data presented here are in 
close agreement with this condition. The results also demonstrate, by way of significant 
accumulation of a Ub
G76V-GFP reporter substrate (Dantuma et al., 2000), that the observed 
proteasome inhibition results in UPS impairment in live cells. This effect was abrogated by 
curing the cells of prion infection (Enari et al., 2001), demonstrating a direct link between 
prion infection and UPS impairment in live cells.  
Dose-response analysis showed that inhibition of the catalytic activity of the 26S 
proteasome by -PrP occurred at low stoichiometry. However, because the proportion of 
active  26S  proteasome  complexes  in  the  preparation  is  unknown,  it  is  impossible  to 
determine the true molecular stoichiometry for the inhibited proteasome species. Data 
presented here also supports a cytosolic localisation for a small proportion of PrP
Sc in 
prion-infected neuronal cells, in line with previous studies demonstrating toxic cytosolic 
PrP
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been reported in the cell body of neurons in CJD brain, suggesting the occurrence of intra-
neuronal  prion  aggregates  (Kovacs  et  al.,  2005).  The  very  high-affinity,  stoichiometric 
inhibition of the proteasome means that only a small amount of PrP
Sc molecules in the 
cytosol may be necessary to have a toxic effect. How aggregated -sheet-rich PrP species 
traffic  inside  neurones  and  enter  the  cytosol  and  result  in  UPS  inhibition  is  poorly 
understood.  Possible  sites  of  entry  include  retro-translocation  from  the  ER  (Ma  and 
Lindquist, 2001; Yedidia et al., 2001) or via endolysosomal membrane destabilisation and 
leakage into the cytosol, as described for diphtheria toxin and other A-B toxins (Sandvig 
and van Deurs, 2002) and A1-42 (Ji et al., 2006). Recently, Wadia et al., reported that 
some PrP can escape macropinosomes and leak into the cytosol (Wadia et al., 2008). It is 
also possible that PrP
Sc accumulation in the endolysosomal system causes dysfunction of 
this  pathway,  resulting  indirectly  in  an  increased  burden  on  the  UPS.  Constant  and 
increased  routing  of  PrP  through  ERAD  during  chronic  PrP
Sc  accumulation-induced  ER 
stress has been shown to lead to neurodegeneration (Rane et al., 2008).  
To  investigate  proteasome  inhibition  by  -sheet-rich  PrP  species  further,  an 
antibody  which  reacts  with  aggregation  intermediates,  but  not  monomeric  or  fibrillar 
forms of amyloidogenic proteins, was used (Kayed et al., 2003). Pre-incubation with this 
antibody completely abolished any inhibitory effect on the catalytic -subunits, suggesting 
that  an  ‘oligomeric’  PrP  species  may  be  responsible  for  the  inhibition  of  the  26S 
proteasome. Observations in subclinical models of prion infection have  suggested that 
prion  neurotoxicity  may  relate  not to PrP
Sc  (or  prions)  but to  critical  levels  of  a  toxic 
oligomeric  species  produced  during  prion  propagation,  PrP
L  (Hill  and  Collinge,  2003a; 
Collinge and Clarke, 2007). This hypothesis explains, amongst other things, why there are 
prion diseases (Hsiao et al., 1990; Medori et al., 1992; Collinge et al., 1995; Lasmezas et 
al., 1997) and animal models (Fischer et al., 1996) in which PrP
Sc levels are very low at 
end-stage disease. The implication is that the low PrP
Sc signal is not important in terms of 
prion-mediated  neurotoxicity  because  the  amount  of  an  intermediate  species  or  side 
product during prion conversion, such as PrP
L, is high.  149 | P a g e  
 
Taken together, the data presented here support an inhibitory effect of oligomeric 
PrP species on the 20S complex, with two possible mechanisms of inhibition (Figure 3.26). 
One possibility is that -sheet-rich PrP species have a direct inhibitory effect on the 1 and 
5 proteolytic active sites of the 20S core (Figure 3.26). However, the diameter of the 
gated channel is ~ 2 nm (Pickart and Cohen, 2004), and if the inhibitory PrP species is 
oligomeric,  it  would  be  too  large  to  traverse  the  gate  intact  and  enter  the  catalytic 
chamber. Therefore, direct inhibition would only be possible if the PrP unfolded to thread 
into the chamber. Alternatively, therefore, prions could inhibit gate-opening of the 20S 
proteasome (Figure 3.25). Entry of substrates into the catalytic chamber of the 20S is 
regulated  by  opening  of  the  gated  channel,  which  is  normally  held  closed  by  the  N-
terminal tails of the outer -ring subunits (Whitby et al., 2000; Groll et al., 2000). Studies 
of gate-opening with addition of hydrophobic peptides, use of the PA28 activator and gate 
deletion yeast mutants, all of which accelerate substrate entry, stimulate cleavage at the 
chymotrypsin-like and caspase-like sites by enhancing their Vmax, but do not stimulate the 
slower cleavage at the trypsin-like site (Kisselev et al., 2002). Therefore, an inhibitory 
effect of prions on gate-opening of the 20S proteasome would have a more severe effect 
on the chymotrypsin-like and caspase-like activities as compared to the trypsin-like site. 
The  levels  of  proteasome  inhibition  observed  (>50%  loss  in  each  caspase-like  and 
chymotrypsin-like  activity),  if  re-capitulated  in  vivo,  are  likely  to  have  serious 
consequences for neuronal viability. Moreover, the degradative capacity of the UPS is also 
known to decline with age (Lee et al., 2000), such that when combined with the effects of 
disease,  levels  of  UPS  dysfunction  and  resultant  neuronal  death  will  be  exaggerated 
(Sherman and Goldberg, 2001).  
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Figure 3.25 Possible mechanisms of proteasome inhibition by misfolded prion protein 
Abnormal aggregation-prone prion protein accumulates in cells leading to cell death. Misfolded 
prion protein inhibits the proteolytic activities of the 26S proteasome. This inhibitory effect can be 
explained by two possible mechanisms. First, the aberrant prion protein directly inhibits the active 
sites of the proteasome, which are the catalytically active  subunits. The other possibility is that 
aggregated -sheet-rich prion protein species inhibit gate-opening in the 20S particle.  
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Therefore, to ascertain whether prions exert a similar inhibitory effect on the UPS 
in vivo, Ub
G76V-GFP proteasome reporter mice were used (Lindsten et al., 2003). These 
mice enable in vivo testing of the role of the UPS in neurodegeneration and have been 
used to demonstrate that proteasome impairment does not contribute to pathogenesis in 
spinocerebellar  ataxia  7  mice  (Bowman  et  al.,  2005).  The  GFP-reporter  does  not 
accumulate by neuronal apoptosis per se and is only seen when there is significant UPS 
dysfunction.  Accumulation  of  the  Ub
G76V-GFP  reporter  occurred  only  in  prion-infected 
mice brains and was associated with neuronal loss and PrP
Sc deposition. Accumulation of 
intracellular cytosolic granular ubiquitinated deposits was also seen in the brains of prion-
infected GFP-reporter mice. These deposits may represent cytosolic ubiquitinated-protein 
conjugates  that  accumulate  as  they  are  not  degraded  by  the  failing  proteasome. 
Interestingly, similar ubiquitin-protein conjugates within neurones have been previously 
reported in the brains of prion-infected mice whereby intracellular ubiquitinated deposits 
were seen early and increased with disease progression (Lowe et al., 1992). It was also 
noted that the pathological accumulation of the intracellular ubiquitin-protein structures 
corresponded temporally with the earliest detection of PrP
Sc (Lowe et al., 1992). These 
observations may now be explained by the data presented here. Proteasome impairment 
has been suggested to be important in neurodegenerative diseases from many in vitro 
studies (Ciechanover and Brundin, 2003), but the role of the UPS in disease was unclear 
due to the lack of in vivo evidence. Recently, global changes to the UPS were shown in vivo 
in HD; using a mass spectrometry-based method it was reported that lysine 48-linked 
poly-ubiquitin chains, typically associated with proteasomal targeting, accumulate early in 
pathogenesis in both transgenic HD mouse brains and human HD patient brain (Bennett et 
al.,  2007).  Moreover,  a  conditional  Psmc1  (Rpt2)  knock-out  mouse  model  with  a 
neurodegenerative  phenotype  and  ubiquitin-positive  inclusions  displayed  26S 
proteasomal dysfunction in neurons, providing in vivo experimental support for a direct 
role of the UPS in neurodegenerative disease pathogenesis (Bedford et al., 2008).  
Collectively,  the  data  presented  here  support  the  view  that  prion  protein 
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is  growing  evidence  in  protein  misfolding  disorders  that  smaller  intermediate  protein 
species may be biologically more active than larger amyloid fibrils (Caughey and Lansbury, 
2003). In studies of prion infectivity, non-fibrillar prion particles with masses equivalent to 
14-28 PrP molecules are the most efficient initiators of prion disease (Silveira et al., 2005). 
The present observations could explain how proteasome dysfunction by aggregated -
sheet-rich PrP isoforms, but not PrP amyloid fibrils, may contribute to neurotoxicity (Rane 
et al., 2008) and are in keeping with proposals suggesting an intermediate toxic species 
produced during the conversion of PrP
C to PrP
Sc (Collinge and Clarke, 2007). Furthermore, 
proteasome inhibition by aggregated -sheet-rich PrP isoforms may account for altered 
PrP
C  trafficking  (Ma  and  Lindquist,  2001;  Yedidia  et  al.,  2001),  whereby  reduced  or 
incomplete proteasomal degradation of PrP
C may lead to the accumulation of cytosolic 
PrP
C  and lead to neurotoxicity.  
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3.4  Summary 
Work in this chapter describes a significant loss of chymotrypsin-like (5) and caspase-like 
(1)  proteolytic  activity  in  prion-infected  cells  and  prion-infected  mouse  brain,  with  a 
lesser effect on the trypsin-like (2) activity. Moreover, in vitro the catalytic subunits of 
the human 26S proteasome were found to be inhibited by the prion protein in a non-
native  -sheet  conformation.  This  inhibition  was  shown  to  occur  at  near  one  to  one 
stoichiometry  inferring  that  the  inhibitory  species  is  highly  potent  and  binds  to  the 
proteasome with high affinity. Challenge with recombinant prion and other amyloidogenic 
proteins demonstrated that it was only recombinant -sheet-rich forms of PrP, -PrP, and 
semi-purified PrP
Sc from either RML prion-infected mouse brain or mouse neuronal cells 
which  mediated  this  inhibitory  effect.  Pre-incubation  with  an  antibody  raised  against 
aggregation intermediates abrogated the inhibitory effect on the proteolytic activities, 
suggestive of an oligomeric inhibitory species. Using cell-based GFP-tagged reporters it 
was shown that they accumulate in prion-infected mouse neuroblastoma cells indicative 
of  functional  UPS  impairment.  Evidence  for  a  direct  relationship  between  prion 
neuropathology and UPS impairment in UPS-reporter transgenic mice was also presented. 
Collectively, results in this chapter suggest a possible mechanism for intracellular prion 
neurotoxicity mediated by oligomers of misfolded prion protein.  
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4  DISEASE-ASSOCIATED PRION PROTEIN INHIBITS THE UBIQUITIN 
PROTEASOME  SYSTEM  BY  BLOCKING  GATE-OPENING  IN  THE 
20S PARTICLE 
4.1  Background 
In the UPS, substrates (e.g. misfolded or regulatory proteins) are covalently linked 
to a chain of ubiquitin molecules, which leads to rapid binding and degradation to small 
peptides by the 26S proteasome (Glickman and Ciechanover, 2002). There is accumulating 
evidence  that  impaired  functioning  of  the  UPS  contributes  to  the  pathogenesis  of 
neurodegenerative diseases such as HD, PD and AD (Goldberg, 2003; Rubinsztein, 2006). 
Mutations in the E3 ubiquitin ligase, parkin, cause one of the more common inherited 
forms  of  PD  (Shimura  et  al.,  2000)  and  conditional  depletion  of  26S  proteasomes  in 
neurons of the substantia nigra or forebrain in mice results in neurodegeneration with 
inclusions resembling Lewy bodies (Bedford et al., 2008). Moreover, evidence suggests 
that in these diseases soluble micro-aggregates of misfolded proteins, rather than larger 
protein inclusions, are toxic to neurones (Rubinsztein, 2006). One hypothesis of how UPS 
dysfunction may contribute to neuronal death is that the continuous build-up of such 
aggregates eventually overwhelms the UPS, causing a functional impairment (Rubinsztein, 
2006). Protein aggregates have been reported to impair UPS functional capacity in cell 
models  (Bence  et  al.,  2001).  Proteasomes  cannot  efficiently  degrade  polyQ-rich 
aggregates  (Verhoef  et  al.,  2002)  or  polyQ  repeat-containing  proteins  (Verhoef  et  al., 
2002).  However,  there  is  conflicting  evidence  regarding  the  role  of  the  UPS  in  polyQ 
disorders  depending  on  the  particular  model  studied  (Davies  et  al.,  2007).  Therefore, 
current  experimental  evidence  suggests  that  impairment  of  the  UPS  may  play  an 
important role in neurodegenerative diseases characterised by accumulation of misfolded 
proteins but to date the biochemical mechanisms underlying the UPS dysfunction are 
unclear.    
Inactivation of any of the three active sites of the 20S slows but does not block 
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the caspase-like or the trypsin-like sites need to be inhibited in order to strongly reduce 
protein degradation (Kisselev et al., 2006). Data showing that aggregated -sheet-rich PrP 
oligomers  inhibit  predominantly  the  chymotrypsin-like  and  caspase-like  proteolytic 
activity of the 26S proteasome were presented in chapter 3 of this thesis. There are two 
possible explanations for these effects. First, the  -sheet-rich PrP species may directly 
inhibit the active sites of the 20S proteasome (Figure 3.25). This seems unlikely as the 
pore of the 20S does not exceed 2 nm in diameter (Pickart and Cohen, 2004) making it 
difficult for aggregated proteins to enter (Figure 3.25). Alternatively, the -sheet-rich PrP 
isoforms may inhibit gate-opening and entry of peptide substrates into the 20S (Figure 
3.25). Kisselev et al., 2002 showed that agents that promote gate-opening or mutations 
that disrupt the gate in yeast proteasomes primarily enhance hydrolysis of hydrophobic or 
acidic  peptides  whose  breakdown  is  limited  by  entry  into  the  particle  (unlike  basic 
peptides whose hydrolysis is limited by the low turnover rate) (Kisselev et al., 2002). An 
inhibitory effect of the aggregated PrP on gate-opening would therefore result in a more 
marked reduction in the chymotrypsin-like and caspase-like activities, as was observed.  
 
4.2  Aims of this study 
The aim of the present study was to further investigate the nature of proteasome 
inhibition  by  aggregated  -sheet-rich  PrP  isoforms  and  to  more  clearly  define  the 
biochemical mechanism of inhibition. 
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4.3  Methods 
Western blotting [used for the detection of IB- protein levels (Section 2.2.1)] and 
RT-PCR [used for the detection of IB- transcript levels (Section 2.6.1)] were performed 
by Dr Mark Kristiansen, MRC Prion Unit, UCL Institute of Neurology. The three peptidase 
activities of the 20S proteasome were monitored using fluorogenic substrates (Section 
2.4.2). The SensoLyte™ Green Protease Assay Kit was used to monitor the capacity of the 
20S  proteasome  to  degrade  fluorescent  casein  (Section  2.4.5)  and  these  experiments 
were  performed  in  collaboration  with  Dr  Kerri  Kinghorn,  Department  of 
Neurodegenerative  disease,  UCL  Institute  of  Neurology.  Co-immunoprecipitation 
experiments were performed to confirm a direct interaction between aggregated prion 
protein and the 20S proteasome (Section 2.2.2).    
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4.4  Results 
4.4.1  -sheet-rich  PrP  isoforms  inhibit  WT  but  not  the  open-gated  20S  yeast 
mutant 
The three peptidase activities of the 20S proteasome are routinely monitored in 
vitro by measuring of the rates of hydrolysis of specific fluorogenic peptides (Kisselev and 
Goldberg, 2005). To investigate whether aggregated -sheet-rich PrP isoforms may inhibit 
gate-opening  and  substrate  entry  into  the  20S  proteasome,  the  chymotrypsin-like, 
caspase-like and trypsin-like activities of WT yeast 20S were measured and compared to 
those  of  a  constitutively  ‘open-gated’  yeast  20S  mutant  (Groll  et  al.,  2000). 
Crystallographic analysis of this ‘open channel’ 20S mutant has shown that deletion of the 
nine residue tail from the N-terminus of the 3 subunit (3N strain), opens a channel 
into  the  proteolytic  chamber,  and  thus  de-represses  peptide  hydrolysis  resulting  in 
strongly enhanced basal peptidase activity levels compared to WT (Groll et al., 2000).  
 
Recombinant full-length mouse PrP in the -sheet-rich form (-PrP), which has 
similar physico-chemical properties to PrP
Sc, was used in an aggregated form (Jackson et 
al.,  1999).  The  effect  of  semi-purified  PrP
Sc  from  RML-prion-infected  hypothalamic 
neuronal (ScGT-1) cells treated with 1M lactacystin for 24h (Kristiansen et al., 2005) was 
also studied. Upon incubation with WT 20S, both aggregated -PrP
 and PrP
Sc caused a 
large reduction in chymotrypsin-like, caspase-like and trypsin-like activity (Figure 4.1). By 
contrast, no inhibition was observed when the PrP species were incubated with the 3N 
20S mutant (Figure 4.2).  
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Figure 4.1 Effect of-sheet-rich PrP on the proteolytic activities of WT yeast 20S  
Aggregated  mouse  -PrP  or  PrP
Sc  purified  from  RML  prion-infected  ScGT-1  cells  inhibit  the 
chymotrypsin-like, caspase-like and trypsin-like activities of WT yeast 20S proteasome. Peptidase 
activities of WT yeast 20S (6.25 g/ml) incubated with or without the PrP species (both at 20 
g/ml) were monitored using fluorogenic substrates specific for each activity: 100 M Suc-LLVY-
AMC  (chymotrypsin-like),  100  M  Ac-nLPnLD-AMC  (caspase-like)  and  100  M  Boc-LLR-AMC 
(trypsin-like). Following 1 h incubation with the prion species, fluorogenic substrate was added to 
the reaction and fluorescence was measured over time at 360 nm excitation and 465 nm emission. 
Data are means of three independent experiments + SEM. ***p<0.001 (compared to untreated 
20S control).  
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Figure 4.2 Aggregated -sheet rich PrP species do not inhibit the 3N 20S open-gated mutant 
Aggregated mouse -PrP or PrP
Sc purified from RML prion-infected ScGT-1 cells do not have an 
inhibitory effect on the chymotrypsin-like, caspase-like or trypsin-like activities of the open-gated 
3N yeast 20S mutant. Peptidase activities of 3N 20S (6.25 g/ml) incubated with or without 
the PrP species (both at 20 g/ml) were monitored using fluorogenic substrates specific for each 
activity: 100 M Suc-LLVY-AMC (chymotrypsin-like), 100 M Ac-nLPnLD-AMC (caspase-like) and 
100 M Boc-LLR-AMC (trypsin-like). Following 1 h incubation with the prion species, fluorogenic 
substrate  was  added  to  the  reaction  and  fluorescence  was  measured  over  time  at  360  nm 
excitation and 465 nm emission. Data are means of three independent experiments + SEM.   160 | P a g e  
 
An ‘open channel’ proteasome mutant with a double truncation of the N-termini 
of  both  3  and  7  subunits  (3/7N  strain),  which  makes  it  more  efficient  in  the 
proteolysis  of  model  proteins  when  compared  to  mutants  with  either  of  the  two 
truncations (Bajorek et al., 2003), was also studied. Upon incubation with the 3/7N 
20S,  the  PrP  isoforms  caused  a  reduction  in  the  chymotrypsin-like,  caspase-like  and 
trypsin-like activity  (Figure 4.3). The degree of inhibition by the aggregated -sheet-rich 
PrP  species  on  the  peptidase  activities  of  the  3/7N  20S  mutant  was  less  when 
compared to WT 20S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 161 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Effect of-sheet-rich PrP on the proteolytic activities of the 3/7N 20S mutant  
Aggregated mouse -PrP
 or PrP
Sc purified from RML prion-infected ScGT-1 cells moderately inhibit 
the chymotrypsin-like, caspase-like and trypsin-like activities of the 3/7N yeast 20S mutant. 
Peptidase activities of 3/7N 20S (6.25 g/ml) incubated with or without the PrP species (both 
at 20 g/ml) were monitored using fluorogenic substrates specific for each activity: 100 M Suc-
LLVY-AMC (chymotrypsin-like), 100 M Ac-nLPnLD-AMC (caspase-like) and 100 M Boc-LLR-AMC 
(trypsin-like). Following 1 h incubation with the prion species, fluorogenic substrate was added to 
the reaction and fluorescence was measured over time at 360 nm excitation and 465 nm emission. 
Data are means of three independent experiments + SEM. ***p<0.001 (compared to untreated 
3/7N 20S control). 162 | P a g e  
 
As expected, both the 3N and the 3/7N 20S mutants showed much higher 
basal chymotrypsin-like activity compared to that of WT 20S (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 The ‘open-gated’ 20S mutants have much higher basal activity than WT 20S 
The basal chymotrypsin-like activity of either the 3N or the 3/7N 20S yeast mutant is much 
higher than that of the WT 20S. The chymotrypsin-like activities of WT, 3N or 3/7N 20S (all 
at 6.25 g/ml) were monitored using 100 M Suc-LLVY-AMC. Fluorescence was measured over 
time  at  360  nm  excitation  and  465  nm  emission.  Data  are  means  of  three  independent 
experiments + SEM. ***p<0.001 (compared to WT 20S control).  
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Epoxomicin, a natural product isolated from an Actinomycetes species is an , -
epoxy-ketone tetrapeptide proteasome inhibitor, which covalently binds to the  subunits 
of the proteasome (Meng et al., 1999). To confirm that proteasome activity and not a 
contaminating activity was being measured, WT, 3N and 3/7N 20S were treated 
with  epoxomicin,  which  completely  abrogated  the  chymotrypsin-like  activity  of  all 
preparations (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Epoxomicin abolishes proteolytic activity in both the 3N and 3/7N 20S mutants 
Chymotrypsin-like activity is completely abrogated in both WT yeast 20S, 3N 20S and 3/7N 
20S proteasome after pre-treatment with 50 M epoxomicin (EPOX). Chymotrypsin-like activity of 
WT,  3N  20S,  or  3/7N  20S  (6.25  g/ml)  was  monitored  using  100  M  Suc-LLVY-AMC 
fluorogenic  substrate  following  30  min  incubation  with  50  M  epoxomicin.  Fluorescence  was 
measured  over  time  at  360  nm  excitation  and  465  nm  emission.  Data  are  means  from  five 
independent experiments +SEM. ***p<0.001 (compared to untreated control).  
 164 | P a g e  
 
4.4.2  Aggregated -sheet-rich PrP isoforms inhibit peptide hydrolysis by the 20S 
at low concentrations  
Dose-response experiments presented in chapter 3 of this thesis (Section 3.2.10) 
showed that aggregated -PrP is a highly potent inhibitor of 26S proteasome  subunit 
proteolysis. Upon incubation of cytosolic cell fractions with 50 ng/ml aggregated -PrP the 
proteolytic  subunit activity, as monitored by a proteasome activity probe (Berkers et al., 
2005), was restored to normal levels (Figure 3.14).  Furthermore, the molar ratio of -PrP 
that inhibits the 26S proteasome was shown to be essentially stoichiometric from assays 
with pure 26S proteasome with known concentrations (Figure 3.15). 
 
The above mentioned experiments were undertaken using a covalent probe  of 
proteasome activity (Berkers et al., 2005), which is less sensitive than direct fluorogenic 
enzyme  assays  for  proteasomal  activities.  These  previous  data  suggested  that  the 
inhibitory  species  are  small  aggregates  of  oligomeric  -sheet-rich  PrP.  To  define  the 
inhibitory species, the chymotrypsin-like activity of WT yeast 20S was monitored with 
fluorogenic peptides after incubation with increasing concentrations of aggregated -PrP. 
Half-maximal  inhibition  of  the  20S  (9  nM)  was  observed  between  90  and  180  nM 
aggregated  -PrP,  where  concentrations  are  based  upon  the  free  monomeric  protein 
(Figure 4.6). However, the number of -PrP molecules in the inhibitory species is unclear.  
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Figure 4.6  Aggregated -PrP
 inhibits the proteolytic activity of the 20S proteasome at low molar 
concentrations 
Half-maximal inhibition of WT yeast 20S is observed between 90 and 180 nM aggregated -PrP. 
Following incubation of WT 20S (6.25 g/ml; 9 nM) with increasing concentrations of aggregated 
-PrP (9-890 nM), the rate of hydrolysis of 100 M Suc-LLVY-AMC fluorogenic substrate by the 
chymotrypsin-like sites was measured. Fluorescence was measured over time at 360 nm excitation 
and  465  nm  emission.  Data  are  means  of  five  independent  experiments  +  SEM.  ***p<0.001 
(compared to untreated WT 20S control).  166 | P a g e  
 
4.4.3  Malate dehydrogenase does not inhibit WT 20S 
To test whether a similar inhibition of the WT yeast 20S by -sheet-rich PrP species 
is  seen  with  other  misfolded  proteins,  WT  20S  was  incubated  with  either  folded  or 
unfolded malate dehydrogenase (MDH). Unfolded MDH has been shown to bind tightly to 
the mobile outer domains of the molecular chaperonin complex of GroEL (Chen et al., 
1994; Ranson et al., 1997), which has a heptameric structure similar to that of the 20S. 
Neither folded nor unfolded MDH reduced peptide hydrolysis by the WT 20S (Figure 4.7) 
and  is  consistent  with  a  mode  of  inhibition  that  is  specific  to  the  conformation  and 
aggregation state of the -sheet-rich PrP species.  
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Figure 4.7 Unfolded malate dehydrogenase does not inhibit WT 20S  
A hydrophobic protein, malate dehydrogenease (MDH), has no inhibitory effect on the proteolytic 
activities of the WT yeast 20S proteasome. Peptidase activities of WT 20S (0.1 g/ml) incubated 
with unfolded or folded MDH (both at 3.3 g/ml) were monitored using fluorogenic substrates 
specific  for  each  activity: 100  M  Suc-LLVY-AMC  (chymotrypsin-like), 100  M  Ac-nLPnLD-AMC 
(caspase-like) and 100 M Boc-LLR-AMC (trypsin-like). Following 1 h incubation with either of the 
two proteins, fluorogenic substrate was added to the reaction and fluorescence was measured 
over time at 360 nm excitation and 465 nm emission. Folded malate dehydrogenease (MDH) was 
incubated at room temperature (RT) for 30 min in the presence of 4M GdHCl and 10mM DTT to 
unfold it. Data are means of five independent experiments +SEM.       
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4.4.4  -sheet-rich  PrP  isoforms  inhibit  the  WT,  but  partially  affect  the  open-
gated 26S yeast mutant  
To  test  whether  the  inhibitory  trend  seen  in  WT  versus  ‘open-gated’  20S 
proteasomes was also seen in the 26S proteasomes, WT or open-gated 3/7N 26S 
(Bajorek et al., 2003) were incubated with aggregated -PrP or PrP
Sc and the rates of 
hydrolysis of substrates by the chymotrypsin-like and caspase-like sites were monitored. 
Incubation  of  WT  26S  with  aggregated  -PrP  or  PrP
Sc  resulted  in  a  significant  loss  of 
chymotrypsin-like  activity  and  caspase-like  activity  (Figure  4.8).  Incubation  of  the 
3/7N open-gated 26S mutant with the prion species resulted in a moderate inhibition 
of its chymotrypsin-like activity, whereas the caspase-like activity of the mutant was not 
affected (Figure 4.9). This pattern of inhibition seen with the  3/7N 26S mutant is 
different to the one observed with the 3/a7N 20S, as there was a smaller inhibitory 
effect (Figure 4.3).  
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Figure 4.8 Effect of aggregated -sheet-rich PrP on WT and 3/7N 26S  
Aggregated  mouse  -PrP
  or  PrP
Sc  purified  from  RML  prion-infected  ScGT-1  cells  inhibit  the 
chymotrypsin-like and caspase-like activities of the WT 26S but have a partial inhibitory effect on 
the 3/7N 26S mutant. Peptidase activities of both WT and 3/7N 20S (1 g/ml) incubated 
with or without the PrP species (10 g/ml) were monitored using fluorogenic substrates specific 
for  each  activity:  100  M  Suc-LLVY-AMC  (chymotrypsin-like)  and  100  M  Ac-nLPnLD-AMC 
(caspase-like). Following 1h incubation with the prion species, fluorogenic substrate was added to 
the reaction and fluorescence was measured over time at 360 nm excitation and 465 nm emission. 
Data are means of three independent experiments + SEM. ***p<0.001, **p<0.01 (compared to 
untreated control).  170 | P a g e  
 
4.4.5  The inhibitory effect of aggregated -PrP on the trypsin-like activity of the 
26S is competitive with respect to substrate concentration 
Cleavage of substrates by the proteasome’s chymotrypsin-like or caspase-like sites 
is more sensitive to gate-opening than substrates of the trypsin-like sites because gate-
opening of latent 20S will only stimulate substrate hydrolysis if the entry rate of diffusion 
of the substrate into the 20S is slower than its cleavage rate and the trypsin-like site has 
low turnover numbers. However, the entry of such peptides can be made rate-limiting by 
lowering  the  concentration  of  a  substrate  (Kisselev  et  al.,  2002),  and  with  low 
concentrations  of  substrates,  gate-opening  also  becomes  limiting  for  the  trypsin-like 
activity.  
 
To test whether the -sheet-rich PrP species were having an inhibitory effect on 
proteasome gating, human 26S was incubated with aggregated -PrP, following which a 
range of concentrations (20-100 M) of the fluorogenic substrate Boc-LRR-AMC was used 
to  monitor  the  trypsin-like  activity.  If  the  -sheet-rich  PrP  isoforms  are  affecting  the 
cleavage of this substrate by blocking gate-opening, the aggregated -PrP should reduce 
Boc-LRR-AMC  cleavage  at  low  substrate  concentrations.  Aggregated  -PrP
  was  more 
inhibitory  at  lower  Boc-LRR-AMC  concentrations  (Figure  4.10)  where  entry  into  the 
particle  becomes  rate-limiting  (Kisselev  et  al.,  2002).  These  findings  would  therefore 
further support the conclusion that the PrP species are inhibiting the proteasome via an 
inhibition on gate-opening.  
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Figure 4.9 Boc-LRR-AMC concentration gradient in 26S incubated with -PrP 
Trend-line  representing  the  relative  %  inhibition  of  the  trypsin-like  activity  of  human  26S  by 
aggregated -PrP. Inhibition of the trypsin-like activity of the 26S increases as the Boc-LRR-AMC 
fluorogenic substrate concentration decreases. Human 26S proteasome (1 g/ml) was incubated 
with 10 g/ml aggregated -PrPbefore the addition of 20, 30, 40, 50, 60, 70, 80, 90, or 100 M 
Boc-LRR-AMC substrate in order to monitor the trypsin-like activity. Fluorescence was measured 
over time at 360 nm excitation and 465 nm emission. This experiment was repeated three times 
and each time similar results were obtained.  
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4.4.6  Aggregated -sheet-rich PrP isoforms inhibit Rpt5-mediated gate-opening 
in 20S  
When they bind ATP, C-termini of certain 19S ATPase subunits dock into inter-
subunit pockets in the 20S -ring, induce gate-opening and allow substrate entry (Smith et 
al., 2007; Rabl et al., 2008; Gillette et al., 2008) and this effect requires the presence of an 
essential HbYX amino acid motif in the C-terminus. Synthetic eight-residue peptides from 
the C-terminus of the mammalian Rpt2 and Rpt5 19S ATPase subunits have been shown to 
induce  gate-opening  in 20S  from  rabbit  muscle  (Smith et  al.,  2007)  as  well  as  bovine 
erythrocyte 20S (Gillette et al., 2008). To investigate whether aggregated -sheet-rich PrP 
isoforms can influence peptide-mediated activation of the 20S, an 8-mer synthetic peptide 
corresponding to the C-terminus of the Rpt5 subunit of the 19S (KANLQYYA) was used. 
The  Rpt5  C-terminal  peptide  (CtRpt5)  strongly  induced  gate-opening  in  human  20S 
proteasome,  since  substrate  cleavage  by  all  three  proteolytic  sites  were  markedly 
enhanced (Figure 4.10). 
 
Following the pre-incubation of 20S proteasomes with the aggregated -sheet-rich 
PrP species, their effect on CtRpt5-mediated activation 20S was tested. Although CtRpt5 
was added to the 20S/PrP sample in a fifty fold molar excess over both aggregated -PrP 
and PrP
Sc, which must represent a much higher excess over the number of aggregates, 
these -sheet-rich PrP isoforms abrogated the ability of the CtRpt5 peptide to induce 
gate-opening (Figure 4.11). They also seemed to reduce basal opening seen in the absence 
of CtRpt5 when the CtRpt5 activator was added before the aggregated -PrP
 or PrP
Sc. 
Under these conditions, the aggregated  -sheet-rich PrP species still inhibited CtRpt5-
mediated 20S activation (Figure 4.12). 
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Figure 4.10 Rpt5 peptide activates human 20S  
CtRpt5 strongly enhances the chymotrypsin-like, caspase-like and trypsin-like activities of human 
20S proteasome. Peptidase activities of pure human 20S proteasome (1 g/ml) were monitored 
using fluorogenic substrates specific for each activity: 100 M Suc-LLVY-AMC (chymotrypsin-like) 
and 100 M Ac-nLPnLD-AMC (caspase-like). CtRpt5 (Rpt5; 250M) was added to 20S. Fluorescence 
was measured over time at 360 nm excitation and 465 nm emission. Data are means of three 
independent experiments + SEM. ***p<0.001 (versus untreated control). 
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20S pre-incubation with prion protein species before addition of 
Rpt5 peptide  
 
 
Figure  4.11  Rpt5-mediated  human  20S 
proteasome activation is inhibited by -
sheet-rich PrP species-I 
Pre-incubating  human  20S  proteasome 
with the prion species before the addition 
of CtRpt5 prevents CtRpt5-mediated 20S 
activation.  Pure  human  20S  proteasome 
(1  g/ml)  was  incubated  with  the  prion 
species  (100  g/ml)  for  1  h  before 
addition of the CtRpt5 peptide (Rpt5; 250 
M). Peptidase activities were monitored 
using  fluorogenic  substrates  specific  for 
each  activity:  100  M  Suc-LLVY-AMC 
(chymotrypsin-like)  and  100  M  Ac-
nLPnLD-AMC  (caspase-like).  Reaction 
buffer (Section 2.4.2) was the vehicle for 
the  prion  species  and  was  added  to 
20S/Rpt5.  Fluorescence  was  measured 
over time at 360 nm excitation and 465 
nm  emission.  Data  are  means  of  three 
independent  experiments  +  SEM. 
***p<0.001  (versus  untreated  20S/Rpt5 
control). 
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20S  pre-activation  with  Rpt5  peptide  before  addition  of  prion 
protein species 
 
Figure  4.12  Rpt5-mediated  human  20S 
proteasome activation is inhibited by -
sheet-rich PrP species-II 
Pre-activating  human  20S  proteasome 
with  CtRpt5  before  the  addition  of  the 
prion  species  prevents  CtRpt5-mediated 
20S activation. CtRpt5 (Rpt5; 250 M) was 
added to pure human 20S proteasome (1 
g/ml)  before incubation with the prion 
species  (100  g/ml)  for  1  h.  Peptidase 
activities  were  monitored  using 
fluorogenic  substrates  specific  for  each 
activity:  100  M  Suc-LLVY-AMC 
(chymotrypsin-like)  and  100  M  Ac-
nLPnLD-AMC  (caspase-like).  Reaction 
buffer (Section 2.4.2) was the vehicle for 
the  prion  species  and  was  added  to 
20S/Rpt5.  Fluorescence  was  measured 
over time at 360 nm excitation and 465 
nm  emission.  Data  are  means  of  three 
independent  experiments  +  SEM. 
***p<0.001  (versus  untreated  20S/Rpt5 
control). 
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4.4.7  Saturating the 20S inter-subunit pockets with CtRpt5 does not prevent the 
inhibitory  effect  of  aggregated  -sheet-rich  PrP  isoforms  on  proteolytic 
activities  
To  investigate  whether  aggregated  -PrP
  and  PrP
Sc  were  competing  with  the 
CtRpt5 peptide for the same inter-subunit pockets, 20S proteasome was saturated with 
high concentrations of CtRpt5 before incubating with PrP species. Both aggregated -PrP
 
and PrP
Sc inhibited the ability of CtRpt5 to activate the 20S proteasome, as evidenced by a 
lack  of  enhancement  of  its  chymotrypsin-like  activity,  when  the  CtRpt5  peptide  was 
present at a hundred fold molar excess over the prion species (Figure 4.13).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Saturating the inter-subunit pockets of the 20S -ring does not prevent inhibition of 
CtRpt5-mediated 20S proteasome activation by the prion species 
High concentrations of the CtRpt5 peptide do not abrogate the inhibitory effect of -sheet-rich PrP 
isoforms on 20S activation. CtRpt5 (Rpt5; 500 M) was added to pure human 20S proteasome (1 
g/ml) before incubation with the prion species (100 g/ml) for 1 h. Chymotrypsin-like activity was 
monitored using 100 M Suc-LLVY-AMC. Reaction buffer (Section 2.4.2) was the vehicle for the 
prion  species  and  was  added  to  20S/Rpt5.  Fluorescence  was  measured  over  time  at  360 nm 
excitation  and  465  nm  emission.  Data  are  means  of  three  independent  experiments  +  SEM. 
***p<0.001 (versus untreated 20S/Rpt5 control). 177 | P a g e  
 
4.4.8  The inhibitory effect on CtRpt5-mediated 20S activation is conformation 
specific 
In  order  to  confirm  that  the  concentration  of  NaCl  in  the  aggregated  -PrP 
preparation  (15  mM  in  final  reaction  volume)  was  not  inhibiting  CtRp5-mediated  20S 
activation,  NaCl  was  incubated  with  human  20S  proteasome  and  the  effect  on  the 
chymotrypsin-like  activity  of  20S/CtRpt5  was  assessed.  The  addition  of  NaCl  in  the 
reaction  mixture  did  not  inhibit  the  ability  of  CtRpt5-mediated  20S  activation,  as 
evidenced by an increase in 20S chymotrypsin-like activity (Figure 4.14). Furthermore, in 
agreement  with  previous  findings  (chapter  3),  proteasomes  were  only  inhibited  by  a 
specific  conformation  of  -PrP  and  PrP
Sc,  as  neither  heat-denatured  -PrP,  denatured 
PrP
Sc nor thermally-aggregated -PrP (a recombinant PrP mimetic of PrP
C) were inhibitory 
(Figure  4.15).  Taken  together,  the  CtRpt5  series  of  experiments  suggest  that  the 
aggregated -sheet-rich PrP isoforms may interact with the gate directly or bind to the 
same inter-subunit ‘docking’ pockets in the -ring of the 20S and inactivate or block this 
action (Smith et al., 2007; Rabl et al., 2008; Gillette et al., 2008). 
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Figure 4.14 Effect of NaCl on CtRpt5-mediated 20S activation 
CtRpt5-mediated 20S proteasome activation is not inhibited by treatment with NaCl. Pure human 
20S proteasome (1 g/ml) was incubated with CtRpt5 (Rpt5; 250 M) and with 15 mM NaCl for 1h. 
Chymotrypsin-like activity was monitored using 100 M Suc-LLVY-AMC. Reaction buffer (Section 
2.4.2) was the vehicle for the proteins and was added to 20S/Rpt5. Fluorescence was measured 
over time at 360 nm excitation and 465 nm emission. Data are means of three independent 
experiments + SEM.  
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Figure  4.15  The  inhibitory  effect  on 
CtRpt5-mediated  20S  activation  is 
conformation dependent 
Non--sheet-rich  PrP  isoforms  do  not 
inhibit CtRpt5-mediated  20S proteasome 
activation.  Pure  human  20S  proteasome 
(1  g/ml)  was  incubated  with  CtRpt5 
(Rpt5;  250  M)  and  with  aggregated  -
PrP, denatured -PrP or denatured PrP
Sc 
(all  at  100  g/ml)  for  1  h.  Peptidase 
activities  were  monitored  using 
fluorogenic  substrates  specific  for  each 
activity:  100  M  Suc-LLVY-AMC 
(chymotrypsin-like),  100  M  Ac-nLPnLD-
AMC (caspase-like) and 100 M Boc-LRR-
AMC  (trypsin-like).  Reaction  buffer 
(Section  2.4.2)  was  the  vehicle  for  the 
proteins  and  was  added  to  20S/Rpt5. 
Fluorescence was measured over time at 
360 nm excitation and 465 nm emission. 
Aggregated  -PrP  was  obtained  via 
thermal  denaturation  (10  min  at  70  °C) 
whereas both aggregated -PrP and PrP
Sc 
were  denatured  by  10  cycles  of  freeze-
boiling.  Data  are  means  of  three 
independent experiments + SEM.  180 | P a g e  
 
4.4.9  UPS substrate protein accumulates in prion-infected mouse brain 
Evidence for impairment of proteasomes and the UPS in prion-infected brains of 
transgenic mice expressing a short-lived reporter protein was presented in chapter 3 of 
this thesis (Section 3.2.13). In order to further document functional impairment of the 
UPS,  IB  levels  were  assayed  in  prion-infected  mouse  brain.  IBα  is  an  important 
substrate, which inhibits the activation of the transcription factor NF-κB, the transcription 
factor involved in many pathological and inflammatory responses, and potent inhibitor of 
apoptosis (Perkins and Gilmore, 2006).  
IBα  levels  are  controlled  via  ubiquitination  and  degradation  by  the  26S 
(Palombella  et  al.,  1994).  As  IB  is  rapidly  degraded  and  accumulates  with  all  known 
proteasome inhibitors, IκB levels were therefore assayed in RML prion-infected mouse 
brain. The results shown in Figure 4.16 reveal a significant accumulation of IBα in RML 
prion-infected mouse brain compared to matched controls.  
 
 
 
 
4.4.10 -sheet-rich PrP isoforms inhibit the degradation of casein 
To determine whether the proteolytic activity of the proteasome by aggregated -
sheet-rich PrP resulted in real functional impairment, the degradation of a model protein 
was  studied.  Casein  is  degraded  in  an  ATP-dependent  manner  in  the  absence  of 
ubiquitination (Kisselev et al., 1999; Tarcsa et al., 2000; Cascio et al., 2001). Following the 
modification of casein by the fluorescent FIT2 group, it was used as a substrate in assays 
where WT yeast 20S had been pre-incubated with varying concentrations of aggregated -
PrP. Aggregated -PrP significantly reduced the degradation of this fluorescently-labelled 
casein conjugate (Figure 4.17) and this inhibitory effect depended on the concentration of 
-PrP. For reasons that are not clear, aggregated -PrP, the recombinant mimetic of PrP
C, 
had a small effect on the FITC-casein degradation (Figure 4.18). 
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Figure 4.16 Accumulation of cellular UPS substrates occurs in prion disease in vivo 
IB- levels are significantly increased in prion-infected mouse brain (RML) compared to control 
(CD-1). Four different CD-1 or RML mouse brains were homogenised and immunoblotted with an 
anti-IB- antibody. The graph represents the relative mean IB- band intensity relative to -
actin expression (p=0.0081). This experiment was performed by Dr Mark Kristiansen, MRC Prion 
Unit, UCL Insitute of Neurology.  
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Figure 4.17 FITC-casein degradation by WT 20S is inhibited by aggregated -PrP 
The  degradation  rate  of  FITC-labelled  casein  by  WT  yeast  20S  is  significantly  reduced  in  the 
presence of -PrP. 20 g of WT 20S was pre-incubated with 27, 54 or 81 M aggregated -PrP (agg 
-PrP) for 1 h before addition of FITC-labelled casein as per manufacturer’s instructions (Section 
2.4.5). FITC-casein hydrolysis was measured by fluorimetry. Fluorescence was measured over time 
at 492 nm excitation and 535 nm emission. This experiment was performed at least three times 
with similar results. This experiment was designed and analysed by myself, but was performed by 
Dr Kerri Kinghorn, MRC Prion Unit, UCL Insitute of Neurology. 
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Figure 4.18 Aggregated -PrP has a small inhibitory effect on FITC-casein degradation by WT 20S  
The  degradation  rate  of  FITC-labelled  casein  by  WT  yeast  20S  is  significantly  reduced  in  the 
presence of -PrP, but not in the presence of -PrP. 20 g of WT 20S was pre-incubated with 81 
M aggregated -PrP  (agg -PrP) or 81 M aggregated -PrP (agg -PrP) for 1 h before addition 
of FITC-labelled casein as per manufacturer’s instructions (Section 2.4.5). FITC-casein hydrolysis 
was measured by fluorimetry. Fluorescence was measured over time at 492 nm excitation and 535 
nm  emission.  This  experiment  was  performed  at  least  three  times  with  similar  results.  This 
experiment was designed and analysed by myself, but was performed by Dr Kerri Kinghorn, MRC 
Prion Unit, UCL Insitute of Neurology. 
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4.4.11 Aggregated -PrP binds directly to human 20S 
To  ascertain  whether  aggregated  -PrP  was  directly  interacting  with  the  20S 
particle, anti-PrP antibody-coated magnetic beads were used to co-immunoprecipitate the 
proteasome. Human 20S was incubated with either aggregated -PrP, or heat-aggregated 
-PrP
 or with reaction buffer (control), before incubation with anti-PrP coated beads. 20S 
subunits were precipitated in the presence of aggregated -PrP (Figure 4.18 lane 4). The 
nonpathogenic species protein, aggregated -PrP, was not co-immunoprecipated with the 
20S (lane 9). A small amount of 20S bound to the beads alone (lane 5), considerably less 
than with anti-PrP coated beads (lane 4). This result demonstrates a direct interaction 
between the -sheet-rich PrP species and the 20S proteasome. 
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Figure 4.19 Aggregated -PrP binds directly to 20S 
Aggregated -PrP
 and the 20S proteasome can be co-immunoprecipitated. Human 20S (5 g) was 
incubated with aggregated -PrP (3 g)
 for 1 h at 37
oC and then co-immunoprecipitated using anti-
PrP antibody-coated magnetic beads (ICSM18; 24 g per reaction). The complex was visualized on 
SDS-PAGE  by  immunoblotting  with  an  anti-20S  antibody  (1:1000).  Aggregated  -PrP  co-
immunoprecipitates with the 20S (lane 4). The control protein, heat-aggregated α-helical PrP (3 
g), did not co-immunoprecipitate with the 20S (lane 9). 20S alone and aggregated -PrP
 alone 
were used to demonstrate the specificities of the antibodies (lanes 2 and 7). The starting mixtures 
prior to incubation with the anti-PrP antibody-coated magnetic beads are also shown (input). The 
anti-20S antibody recognises the 5/7, 1, 5, 5i and 7
 proteasomal subunits, which run between 
22 kDa (5) and ~30 kDa (all others). Ab= antibody. 
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4.5  Discussion 
Oligomeric -sheet-rich PrP isoforms have been shown to cause an impairment of 
protein degradation by the UPS in mouse brain and cultured neurones by inhibiting the 
function of the 26S proteasome (chapter 3). These prion protein species block cleavage of 
small peptides by the proteasome, but the exact mechanism by which these species block 
its  activity  was  unclear.  The  aim  of  this  study  was  to  investigate  the  mechanism  of 
inhibition of the UPS by prion species at the biochemical and molecular level. The present 
study has demonstrated that this inhibition by prion species occurs by a novel biochemical 
mechanism, in which the -sheet-rich PrP isoforms impair the function of the 20S and 26S 
proteasomes by blocking gate-opening and substrate entry into the 20S core particle. 
-sheet-rich  PrP  species  were  shown  to  inhibit  the  hydrolysis  of  fluorogenic 
peptides  by  yeast  and  mammalian  20S,  which  can  account  for  previous  findings  that 
oligomeric non-native PrP reduces their hydrolysis by human 26S (chapter 3). However, 
PrP species did not have an inhibitory effect on the peptidase activities of the open-gated 
yeast 20S mutant (Groll et al., 2000), where peptides can freely enter the particle and are 
rapidly hydrolysed. In the 26S particle, the opening of this gated entry channel into the 
20S is regulated by the 19S ATPases. In addition, several other regulatory factors (PA28, 
P200) are known to activate the proteasome by causing gate-opening. In the latent (non-
activated) state, this gate is formed by the interactions of N-terminal tails of the seven  
subunits (Groll et al., 2000; Groll and Huber, 2003). Transient gate-opening occurs in vivo 
when the ATPases’ C-termini cause a destabilization of these interactions or when other 
proteasome activators (PA28) maintain these N-termini in the open-conformation (Smith 
et al., 2007; Rabl et al., 2008). The N-terminus of the 3 subunit comprises the structural 
support for the gate (Groll et al., 2000) and its deletion in the 3N mutant proteasomes 
studied  here  prevents  the  formation  of  the  closed-gate  conformation  and  leaves  the 
proteasome in a continually activated form. The inability of the aggregated -sheet-rich 
PrP species to inhibit the open-gated 3N mutant provides strong evidence that they act 
directly or indirectly to block gate-opening and to stabilize the closed conformation. By 
contrast, if the PrP species were able to traverse the 20S pore and to directly inhibit the 187 | P a g e  
 
active sites, which are located in the central chamber of the 20S, the magnitude of the 
inhibition of peptide hydrolysis should be  greater in the 3N mutant 20S than in WT 
particles, exactly opposite to the present findings. The aggregated -sheet-rich PrP species 
moderately inhibited the proteolytic activities of the 3/7N open-channel yeast 20S 
and 26S proteasome mutants (Bajorek et al., 2003), but did so to a much lesser extent 
when  compared  to  their  WT  counterparts.  The  deletion  of  the  N-termini  from  two 
opposing -subunits may act synergistically to relieve hindrance of protein entry into the 
20S core and thus result in a wide-open pore (Bajorek et al., 2003; Bajorek and Glickman, 
2004),  which  may  allow  for  the  entry  of  some  PrP  molecules.  Another  observation 
consistent with an effect on gating was that the PrP aggregates, like treatments that cause 
gate-opening [e.g. the 3N deletion (open-gated 20S) or treatment with SDS] or that 
favour the closed state (incubation with intracellular levels of KCl) caused larger changes 
in  the  hydrolysis  of  substrates  of  the  chymotrypsin-like  and  caspase-like  sites  than  of 
trypsin-like  site  (whose  destruction  is  slower  and  not  dependent  on  rate  of  entry). 
Together, these experiments indicate that pathogenic PrP aggregates inhibit proteasomes 
at the level of gate-opening rather than by affecting the active sites. This novel mechanism 
of inhibition thus contrasts sharply with that of the proteasome inhibitors widely used as 
research tools and in the clinic for treatment of hematological malignancies, all of which 
bind  to  the  active  sites  in  the  central  chamber,  primarily  the  chymotrypsin-like  site 
(Kisselev and Goldberg, 2001; Kisselev et al., 2006). 
There  is  growing  evidence  in  several  other  protein-misfolding  disorders  that 
soluble protein aggregates, rather than large insoluble aggregates, are the toxic species  
causing  neurodegenerative  disease  (Caughey  and  Lansbury,  2003;  Haass  and  Selkoe, 
2007). Models of subclinical prion disease (Hill and Collinge, 2003a) suggest that prion 
neurotoxicity may not be due to PrP
Sc per se but to the accumulation of a toxic oligomeric 
intermediate  produced  during  prion  conversion  or  breakdown  of  PrP
Sc  (Collinge  and 
Clarke, 2007). Accordingly, prion particles with very small masses (14-28 PrP molecules) 
appear to be the most efficient initiators of prion disease (Silveira et al., 2005; Simoneau 
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concentrations of aggregated -PrP indicated that 90 to 180 nM of the -sheet-rich PrP 
monomers  was  sufficient  to  maximally  inhibit  the  chymotrypsin-like  activity.  This 
concentration corresponds to a molar ratio of between 10 and 20 PrP per 20S, and if the 
aggregates  contain  on  the  average  2-5  molecules  of  prion  protein,  then  the  marked 
inhibition of gating occurs with only a small molar excess of aggregates over 20S. 
Structural studies of recombinant PrP have shown that its protease-resistant core 
can fold not only into amyloid fibrils, but also into β-sheet-rich oligomers (Baskakov et al., 
2002; Sokolowski et al., 2003; Govaerts et al., 2004). The size of such β-oligomers remains 
poorly defined, despite attempts to characterise their structure (Baskakov et al., 2002; 
Martins  et  al.,  2006;  Gerber  et  al.,  2007;  Gerber  et  al.,  2008).  It has  been  previously 
demonstrated that unlike aggregated -sheet-rich PrP species, PrP amyloid fibrils did not 
inhibit the 26S proteasome (chapter 3). Moreover, pre-incubation of the -sheet-rich PrP 
isoforms with an antibody raised against aggregation intermediates (Kayed et al., 2003) 
abrogated their inhibitory effect on  the 26S (chapter 3). The current observations also 
support the notion that the inhibitory species is small, although structural characterization 
at this stage is not possible due to the insoluble heterogeneous nature of PrP aggregates.  
The inhibitory effect on the proteasomal peptidase activities was not merely due 
to the hydrophobic nature of the -sheet-rich PrP species, per se, as no effect was seen 
with a hydrophobic unfolded protein, malate dehydrogenase (MDH). Unfolded MDH binds 
tightly to the mobile outer domains of the molecular chaperone complex of GroEL and 
GroES (Chen et al., 1994; Ranson et al., 1997). GroEL has two stacked heptameric subunit 
rings  analogous  to  the  20S  subunit  rings  (Hartl  and  Hayer-Hartl,  2002).  Although 
hydrophobic and able to bind to GroEL with high affinity, unfolded MDH did not inhibit the 
peptidase activities of the proteasome.  
To define further how PrP inhibits gate-opening, the effect of these aggregates on 
the  capacity  of  the  C-terminus  of  the  19S  ATPase  Rpt5  to  cause  20S  activation  was 
investigated. The present findings demonstrate that PrP isoforms inhibit Rpt5-mediated 
20S gating. In an ATP-driven reaction the 19S binds substrates, unfolds them, removes the 
poly-ubiquitin  chain,  and  translocates  the  polypeptide  into  the  20S  for  degradation 189 | P a g e  
 
(Pickart and Cohen, 2004). The C-termini of the 19S ATPases contain a conserved HbYX 
motif, which docks into the pockets between the adjacent  subunits of the 20S. Peptides 
seven residues or longer that correspond to these ATPases C-termini and also contain the  
HbYX motif, such as CtRpt5, dock into the same pockets  and induce gate-opening (Smith 
et al., 2007; Gillette et al., 2008). When the ATPases bind a nucleotide, these C-termini 
function like a ‘key in a lock’ to open the gate. Cryo-electron microscopy of the PAN/20S 
complex  indicates  that  the  HbYX  residues  in  PAN’s  C-termini  interact  with  conserved 
residues in the 20S, triggering slight rotations of the subunits that cause gate-opening 
(Rabl et al., 2008). In the present experiments, inhibition of gate-opening was observed 
irrespective of whether the PrP species were added before or after 20S activation with 
CtRpt5. These peptides have relatively low affinities for the 20S inter-subunit pockets and 
thus under these in vitro conditions must be continually binding and dissociating leading 
to  continual  opening  and  closing  of  the  gate.  Three  possible  modes  of  action  could 
account for these results: 1) the binding of the -sheet-rich PrP species to the -ring may 
block binding of the Rpt5 C-terminus to the inter-subunit pockets; 2) the prion aggregates 
may alter the structure of the -ring, such that Rtp5 binding no longer leads to subunit 
rotation and gate-opening; 3) it may directly interact with the gating residues to favor the 
closed-gate conformation. Unfortunately, it is unclear whether the CtRpt5 peptide binds 
to a specific inter-subunit pocket in the -ring. Some insight into possible binding sites for 
the ATPases’ C-termini comes from archaebacterial 20S-PAN gate-opening studies (Rabl et 
al., 2008). However, the eukaryotic 26S proteasome differs from the 20S-PAN complex in 
having seven different inter-subunit pockets and six different ATPases. Only three of the 
six 19S ATPases contain the HbYX motif (Smith et al., 2007) and out of the seven inter-
subunit pockets in the 20S -ring (Groll et al., 1997; Whitby et al., 2000) only six contain 
the  conserved  Lys66,  which  is  essential  for  gate-opening.  Moreover,  all  inter-subunit 
pockets contain a hydrophobic residue in place of Leu81, one more residue essential for 
gate-opening. In the 26S, the C-termini of the different ATPase subunits probably bind into 
specific inter-subunit pockets and most likely occupancy of only one or a two key pockets 
is sufficient to cause gate-opening (Smith et al., 2007; Rabl et al., 2008; Gillette et al., 190 | P a g e  
 
2008).  In  agreement,  cross-linking  studies  of  CtRpt2  and  CtRpt5  peptides  to  the  20S 
proteasome  have  revealed  different  binding  locations  for  the  two  different  ATPases 
(Gillette et al., 2008).  
Complete unfolding of polypeptides is a pre-requisite for entry through the pore of 
the proteasome (Wenzel and Baumeister, 1995). For example, EM studies have shown 
that when the insulin B-chain, which is otherwise easily degraded by the proteasome, is 
attached to a 2 nm wide Nanogold™ particle it cannot pass through the 20S opening and 
sits at the center of the -ring (Wenzel and Baumeister, 1995). Also, when a substrate of 
the archaebacterial 20S-PAN ATPase complex is linked to a very large avidin molecule, so 
that it can’t be translocated through the narrow pores in the ATPase and the 20S, it 
becomes a dominant inhibitor preventing the degradation of other substrates (Navon and 
Goldberg, 2001). Similarly, the aggregated -sheet-rich PrP species could be acting like a 
‘plug’;  i.e.  a  dominant  inhibitor  that  prevents  peptide  entry  into  the  20S.  Such  PrP 
aggregates by associating with the outer ring of the 20S may also block the association of 
the 19S ATPase C-termini with the inter-subunit pockets on the -ring, thereby inhibiting 
26S  assembly  and  protein  degradation.  Interestingly,  it  was  recently  reported  that  a 
conditional Psmc1 (Rpt2) knock-out mouse shows not only 26S proteasomal dysfunction 
but also ubiquitin-positive inclusions and neurodegeneration  (Bedford et al., 2008). As all 
six ATPases are functionally non-redundant, deletion of Rpt2 prevents formation of the 
hexameric ring in the base of the 19S thereby disrupting 26S assembly, gate-opening and 
protein degradation (Bedford et al., 2008). Presumably the PrP aggregates by inhibiting 
Rpt5-mediated 20S activation could be neurotoxic via similar mechanisms (Bedford et al., 
2008). 
Data presented in chapter 3 indicate a large impairment of protein degradation by 
the UPS in prion-infected cells and mouse brain, such as the accumulation of ubiquitinated 
proteins and of the model substrate, Ub
G76V-GFP (Dantuma et al., 2000; Lindsten et al., 
2003),  which  is  rapidly  degraded  by  the  proteasome  after  ubiquitination  by  the  UFD 
pathway.  To  define  this  further  at  the  biochemical  level  the  degradation  of  casein,  a 
model UPS substrate protein, which is a useful measure of protease activity was studied. 191 | P a g e  
 
By  directly  monitoring  the  degradation  of  fluorescently  labeled  casein  conjugate,  the 
present  data  demonstrate  that  aggregated  -PrP
  functionally  impairs  20S-mediated 
degradation of FITC-linked casein.  
One critical  consequence of  proteasome inhibition in cells is a failure to degrade 
the key inhibitor of the inflammatory response, IB In many disease states, it is rapidly 
degraded by the proteasome following its phosphorylation and ubiquitination (Palombella 
et al., 1994; Alkalay et al., 1995). The increased levels of IB in prion-infected mouse brain 
shown here provide further evidence for a general inhibition of proteasomal function. 
Normally, IB prevents the activation of the  transcription factor NF-B (Alkalay et al., 
1995), and its level falls due to rapid proteolysis in  many different pathophysiological 
processes including neurodegeneration (Mattson and Camandola, 2001). If gating in the 
20S  particle  is  inhibited,  a  vast  number  of  critical  short-lived  proteins  that  regulate 
fundamental  cellular  processes  are  likely  to  accumulate  and  this  accumulation  of  key 
proteins destined for degradation by the UPS would impair neuronal function and may 
contribute  to  prion  neurotoxicity  in  vivo.  In  this  regard,  the  accumulation  of  IB  by 
preventing activation of NF-B should be particularly important, since NF-B is critical in 
prolonging  viability  (i.e.  inhibiting  apoptosis)  and  inducing  host  (immune)  defence 
mechanisms. These data also support the biochemical evidence of functional impairment 
of degradation of a model protein in vitro (i.e. FITC-casein). The UPS is involved in the 
turnover  of  a  vast  number  of  critical  proteins  participating  in  fundamental  biological 
processes such as cell growth, cell differentiation, apoptosis and inflammation (Goldberg, 
2003). Consequently, accumulation of ubiquitinated substrates destined for degradation 
by the UPS would impair cellular function and contribute to prion neurotoxicity in vivo.  
Inhibition  of  proteasomal  function  has  often  been  proposed  as  a  mechanism 
contributing to neurodegenerative disease (Goldberg, 2003). However, direct evidence for 
such  an  inhibition  or  a  specific  mechanism  has  been  generally  lacking.  The  various 
observations presented here together demonstrate that prions can act at the level of the 
20S  gate,  leading  to  functional  impairment  of  its  degradative  capacity.  The  co-
immunoprecipitation  studies demonstrate that  there  is  a  direct  and  stable  interaction 192 | P a g e  
 
between aggregated -PrP
 and the 20S proteasome. The inhibitory species binding to this 
site is likely to be small, in view of the relatively low stoichiometry, and  the previous 
finding  that  an  antibody  raised  against  aggregation  intermediates  can  abrogate  the 
inhibitory effect of prions on the 26S (chapter 3). These findings serve as a model for 
understanding the more general unanswered question in the field of neurodegenerative 
diseases  as  to  how  misfolded  -sheet-rich  proteins  impair  UPS  function.  The  present 
findings  may  therefore  have  relevance  for  understanding  the  pathogenesis  of  other 
neurodegenerative diseases that are also characterized by the accumulation of -sheet-
rich proteins. Such aggregates may act similarly to aggregated prion protein to prevent 
gate-opening  and  function  as  a  dominant  inhibitors  of  protein  degradation,  which  is 
essential for cellular homeostasis and viability.   
 
4.6  Summary 
Pathogenesis in prion disease is associated with the conversion of mainly -helical PrP
C to 
a -sheet dominant isoform (PrP
Sc) and previous studies suggest a role for the UPS in prion 
disease  pathogenesis.  Data  presented  here  demonstrate  a  novel  mechanism  of 
proteasome  inhibition  by  aggregated  -sheet-rich  prion  protein  (PrP)  via  an  effect  on 
gate-opening in the 20S particle. Direct binding of low concentrations of PrP is sufficient to 
inhibit  the  proteasome.  Incubation  with  other  hydrophobic  proteins  or  PrP  in  other 
conformational  states  had  little  effect,  demonstrating  that  inhibition  is  specific  and 
depends on sequence, conformation and aggregation state. Moreover, -sheet-rich PrP 
isoforms cause functional impairment of proteasome-mediated protein degradation and 
lead  to  accumulation  of  a  key  UPS  substrate  in  prion-infected  mouse  brain.  Findings 
presented here suggest a mechanism for proteasome inhibition that may be relevant to 
other diseases characterized by accumulation of misfolded -sheet-rich proteins.  
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5  AUTOPHAGY AND CLEARANCE OF DISEASE-ASSOCIATED PRION 
PROTEIN 
5.1  Background 
Dysfunction  of  either  of  the  two  principal  intracellular  protein-degradation 
pathways,  UPS  and  autophagy,  may  contribute  to  the  pathology  of  various 
neurodegenerative  disorders  (Rubinsztein,  2006;  Kundu  and  Thompson,  2008).  Recent 
studies  have  suggested  a  clear  role  for  UPS  dysfunction  in  the  pathogenesis  of  prion 
disease, whereby mild proteasome impairment invokes a neurotoxic mechanism involving 
the intracellular formation of cytosolic PrP
Sc aggresomes that trigger caspase-dependent 
neuronal apoptosis (Kristiansen et al., 2005). Furthermore, data presented in chapters 3 
and 4 of this thesis demonstrate that aggregated -sheet-rich PrP isoforms inhibit the 26S 
proteasome  by  blocking  gate-opening  in  the  20S  particle,  and  thereby  interfere  with 
substrate accessibility to the proteolytic chamber.  
In contrast to the UPS, which predominantly degrades short-lived cytosolic and 
nuclear  proteins,  autophagy  can  degrade  much  larger  substrates,  including  protein 
aggregates  and  whole  organelles  (Kundu  and  Thompson,  2008).  Although  autophagy 
occurs  at  basal  levels  during  growth  and  development,  it  can  be  induced  under 
physiological  stress  conditions;  increased  numbers  of  autophagosomes  have  been 
observed in a range of neurological diseases as well as after neuronal injury (Rubinsztein 
et al., 2005; Kundu and Thompson, 2008; Mizushima  et al., 2008). However, it is not 
always  clear  whether  this  accumulation  is  due  to  increased  autophagy  or  reduced 
autophagosome-lysosome fusion, and the precise  relationship between autophagy and 
neuronal cell death remains unclear. All published studies to date have demonstrated 
autophagy to have a neuroprotective role in the context of disease (Kundu and Thompson, 
2008; McCray and Taylor, 2008). Furthermore, two studies published in Nature showed 
that the KO of two Atg genes, Atg5 and Atg7, which are essential for autophagy, causes 
early postnatal lethality in mice (Komatsu et al., 2006; Hara et al., 2006). Even in the 
absence of the expression of aggregate-prone proteins, autophagy defects, specifically in 194 | P a g e  
 
the neurones of these mice, resulted in the formation of intracellular inclusions in the 
brain and development of neurodegenerative symptoms (Komatsu et al., 2006; Hara et al., 
2006). 
Ultra-structural studies demonstrating the presence of autophagic vacuoles in the 
cortical neurones of scrapie and CJD rodent experimental models (Boellaard et al., 1989; 
Boellaard et al., 1991; Liberski et al., 1992a), as well as in naturally-occurring BSE (Liberski 
et al., 1992b), have suggested a role for autophagy in prion disease. These autophagic 
vacuoles have been shown to be accompanied by increased membrane proliferation and 
sequestering of neuronal cytoplasm (Liberski et al., 2002). Human prion diseases (Sikorska 
et al., 2004) and experimental models of BSE (Jeffrey et al., 1992b) and scrapie (Sikorska 
et  al.,  2007)  have  demonstrated  such  vacuoles  throughout  the  neuronal  cell,  but 
especially  at  synaptic  endings.  This  suggests  a  possible  link  between  autophagosome 
formation and synaptic dysregulation in prion disease and in vivo evidence has shown that 
autophagic vacuoles are closely associated with the protein product encoded by scrapie-
responsive gene (Scrg)1 (Dron et al., 2005). This gene’s transcript is markedly increased in 
a variety of prion diseases (Dandoy-Dron et al., 1998; Dron et al., 1998; Dandoy-Dron et 
al., 2000). Whether increases in autophagosome numbers by PrP
Sc formation correlates 
with enhanced autophagy or delayed autophagosome clearance, and how this relates to 
prion disease pathogenesis, remains unclear. However, autophagy may have an important 
role in the normal degradation of PrP
Sc in prion-infected cells, as suggested by reports of 
the use of the tyrosine kinase inhibitor, immatinib mesylate (also known as ST1571 or 
Gleevec), to induce lysosomal degradation of cellular PrP
Sc (Ertmer et al., 2004). Ertmer et 
al.,  have  recently  suggested  that  this  probably  occurs  via  autophagy  as  lysosomal 
inhibition increases basal levels of PrP
Sc (Ertmer et al., 2007).  
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5.1.1  Aims 
The aims of this study were to correlate markers of autophagosome formation with prion 
infection and to evaluate the role of autophagy in prion disease pathogenesis, both in 
vitro and in vivo. 
 
5.1.2  Methods 
Western blotting was used for the detection of LC3I and LC3II protein levels in cell 
lysates  and  brain  homogenates  (Section  2.2.1).  Following  RNA  extraction  and  cDNA 
synthesis,  SYBR  Green  reverse  transcriptase  real-time  PCR  was  undertaken  to  assess 
beclin1, Atg12L and Atg16L mRNA levels in uninfected and prion-infected mouse GT-1 
cells (Section 2.6). The scrapie cell assay (SCA) was used to monitor PrP
Sc clearance after 
treatment with an autophagy inducer (Section 2.1.3). The LDH assay was used to monitor 
amelioration or exacerbation of cell death following treatment with proteasome inhibitors 
and  autophagy  inducers/inhibitors  (Section  2.5.1).  Experiments  were  performed  in 
collaboration with Mrs Christine Butler-Cole, MRC Prion Unit, UCL Institute of Neurology.  
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5.2  Results 
5.2.1  Enhanced LC3II levels in prion-infected GT-1 cells 
It has been difficult to differentiate autophagosomes from other vesicles in the 
absence  of  specific  markers.  The  identification  of  LC3II,  which  is  associated  with 
mammalian autophagosomes simplified this problem (Kabeya et al., 2000). LC3 lipidation 
is  measured  on  a  Western  blot,  and  may  reflect  either  enhanced  autophagosome 
formation  due  to  increases  in  autophagic  activity,  or  to  a  reduced  autophagosome 
turnover  (Klionsky  et  al.,  2008).  Autophagic  flux  can  be  measured  by  inferring  LC3II 
turnover by Western blot in the presence and absence of lysosomal degradation, which 
can be achieved by using drugs such as bafilomycin A1 that alter the lysosomal pH (Fass et 
al., 2006).  
In order to investigate whether prion infection affects autophagy flux, LC3II levels 
were assessed in uninfected and prion-infected GT-1 cells, in the presence or absence of 
bafilomycin. Mouse hypothalamic neuronal GT-1  were infected with 0.1 % RML prion-
infected mouse brain homogenate. Uninfected or RML-infected GT-1 cells (ScGT-1) were 
treated  with  bafilomycin.  Furthermore,  to  investigate  autophagy  flux  following 
proteasome inhibition, lactacystin, a proteasome inhibitor, was used in the presence or 
absence of bafilomycin in prion-infected GT-1 (ScGT-1) and uninfected GT-1 cells. LC3I and 
LC3II levels were measured by Western blot (Figure 5.1).  
The  use  of  bafilomycin  demonstrates  that  LC3II  levels,  which  correlate  with 
autophagosome numbers, were significantly enhanced in the prion-infected GT-1 (ScGT-1) 
cells compared to uninfected controls (Figure 5.1; lanes 8 and 4 respectively). ScGT-1 cells 
treated  with  lactacystin  and  bafilomycin  showed  increased  LC3II  levels  compared  to 
uninfected GT-1 cells (Figure 5.1; lanes 7 and 3 respectively). Conversely, prion-infected 
(ScGT-1) cells that were not bafilomycin-treated showed lower LC3II levels compared to 
controls (Figure 5.1; lanes 5 and 1 respectively). This was mirrored in the lactacystin-
treated prion-infected cells compared to uninfected GT-1 cells (Figure 5.1; lanes 6 and 2 
respectively). 
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Figure 5.1 Up-regulation of the autophagosome marker LC3II in prion-infected GT1 cells 
RML-infected ScGT-1 and control uninfected GT-1 cells were treated with 1 μM lactacystin (LAC) 
and/or 100 nM bafilomycin (BAF) for 24 h. Levels of LC3II and LC3I were assessed by Western 
blotting using an anti-LC3 antibody (1:1000; Novus Biologicals). The use of bafilomycin clearly 
demonstrates  that  levels  of  LC3II,  correlating  to  autophagosome  numbers,  are  significantly 
increased in prion-infected cells. 30 g of total protein from cell lysates were loaded per lane. 
Levels of an endogenous mouse protein, -actin, were assessed by immunoblotting to confirm 
equal protein loading. Image is representative of two independent experiments. 
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5.2.2  Up-regulation of Atg gene transcript markers in prion-infected cells when 
the proteasome is inhibited 
Mild proteasome inhibition in prion-infected neuronal cells has been shown to 
result in the formation of large, cytosolic PrP
Sc-containing aggresomes (Kristiansen et al., 
2005). The autophagy-lysosomal system relies on the expression of over twenty essential 
autophagy-related  genes  (Atg),  which  are  responsible  for  the  formation  of  the 
autophagosomal  membrane  in  eukaryotes  (Reggiori,  2006).  In  order  to  investigate  a 
putative induction of autophagy as a response to proteasome inhibition and aggresome 
formation  in  prion-disease,  mRNA  transcript  levels  of  three  Atg  genes  essential  for 
autophagosome formation were measured.  
 
GT-1  cells  were  either  mock-infected  with  CD-1  mouse  brain  homogenate,  or 
infected with RML prions. Both mock-infected (GT-1) and RML prion-infected (ScGT-1) 
cells  were  treated  with  the  proteasome  inhibitor  lactacystin  for  24  h.  Following  RNA 
isolation,  cDNA  was  synthesised  in  the  presence  of  reverse  transcriptase  and  mRNA 
transcript levels were detected using the SYBR Green PCR system. Figure 5.2 shows that 
beclin1, Atg12L and Atg16L mRNA transcripts are significantly enhanced in prion-infected 
(ScGT-1) cells compared to controls (GT-1), suggesting that autophagy is up-regulated in 
response to proteasome inhibition and aggresome formation.  
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Figure 5.2 Up-regulation of Atg genes in prion-infected cells 
Mock-infected and RML prion-infected GT-1 cells (ScGT-1) were treated with 1 μM lactacystin for 
24 h, following which levels of the mRNA transcripts for (A) beclin1, (B) Atg12L and (C) Atg16L 
were  assessed  by  real-time  SYBR-green  quantitative  RT-PCR.  Each  gene  is  significantly  up-
regulated in prion-infected cells compared to uninfected controls. Values expressed relative to the 
expression of β-actin. Data are the mean + SEM of five independent samples. ***p <0.001 (versus 
uninfected controls). 
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5.2.3  Induction  of  autophagy  partially  rescues  prion-infected  cells  from  cell 
death when the proteasome is inhibited 
Following  proteasome  inhibition  prion-infected  cells  have  been  shown  to  form 
PrP
Sc-containing aggresomes, which in turn trigger caspase 3 and 8 activation leading to 
cell  death  (Kristiansen  et  al.,  2005).  Rapamycin,  a  lipophilic  antibiotic  has  been 
demonstrated to induce autophagy by inactivating the mammalian target of rapamycin 
(mTOR),  and  as  such  serves  as  an  autophagy  enhancer  (Berger  et  al.,  2006).  Several 
studies have shown that rapamycin has protective effects in cell and animal models of 
neurodegenerative diseases such as polyQ and AD (Sarkar et al., 2009). Therefore, it was 
interesting to test in vitro if induction of autophagy, by means of rapamycin treatment, 
ameliorates  the  cell  death  observed  in  prion-infected  cells  when  the  proteasome  is 
challenged by the proteasome inhibitor lactacystin.  
 
Both uninfected (GT-1 and N2aPK-1) and prion-infected (ScGT-1 and ScN2aPK-1) 
cells were treated with a low concentration of lactacystin for 24 h, in the presence or 
absence of rapamycin. LDH assays, which are used to measure cell death, showed that 
prion-infected  cells  (ScGT-1  and  ScN2aPK-1)  displayed  significant  levels  of  cell  death 
following lactacystin treatment compared to uninfected controls (Figures 5.3 and 5.4), in 
agreement with previous findings (Kristiansen et al., 2005). However, in the concomitant 
presence of rapamycin, ScGT-1 (Figure 5.3) and ScN2aPK-1 (Figure 5.4) cells were partially 
rescued from the deleterious effects of the proteasome inhibitor, suggesting that, in part, 
autophagy could be conferring a compensatory degradative mechanism in these cells. 
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Figure 5.3 Induction of autophagy partially rescues prion-infected GT-1 cells from cell death 
RML-infected ScGT-1 and control uninfected GT-1 cells were treated with 1 μM lactacystin and/or 
0.2 μM rapamycin to induce autophagy for 24 h. Rapamycin significantly reduces prion-induced 
cytotoxicity  in  cells  in  which  the  proteasome  is  mildly  impaired.  Values  are  expressed  as 
percentage LDH release relative to maximal cell death obtained from lysing untreated cells with 1 
% (v/v) Triton X-100. Data are the mean + SEM of eight independent samples. ***P <0.001. 
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Figure 5.4 Induction of autophagy partially rescues prion-infected N2aPK-1 cells from cell death 
RML  prion-infected  N2aPK-1  and  control  uninfected  N2aPK-1  cells  were  treated  with  1  μM 
lactacystin  and/or  0.2  μM  rapamycin  to  induce  autophagy  for  24  h.  Rapamycin  significantly 
reduces prion-induced cytotoxicity in cells in which the proteasome is mildly impaired. Values are 
expressed  as  percentage  LDH  release  relative  to  maximal  cell  death  obtained  from  lysing 
untreated  cells  with  1  % (v/v)  Triton  X-100.  Data  are  the  mean  +  SEM  of  eight  independent 
samples. ***P <0.001. 
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5.2.4  Inhibition of autophagy exacerbates cell death in prion-infected cells  
3-methyladenine (3-MA) inhibits the sequestration stage of autophagy, where a 
double membraned structure, the autophagosome, forms around a portion of the cytosol 
(Klionsky and Ohsumi, 1999). 3-MA was used to further investigate a role for autophagy in 
prion disease.  
 
Both uninfected (GT-1 and N2aPK-1) and prion-infected (ScGT-1 and ScN2aPK-1) 
cells were treated with 3-MA for 24 h. LDH assays, which are used to measure cell death, 
showed  that  both  uninfected  (GT-1  and  N2APK-1)  and  prion-infected  (ScGT-1  and 
ScN2aPK-1)  cells  displayed  significant  levels  of  cell  death  following  3-MA  treatment 
(Figures 5.5 and 5.6). However, ScGT-1 (Figure 5.5) and ScN2aPK-1 (Figure 5.6) were less 
able to tolerate the 3-MA treatment compared to uninfected controls (GT-1 and N2aPK-1). 
Cell  death  in  cells  cured  of  prion-infection,  by  means  of  treatment  with  an  anti-PrP 
antibody (ICSM18; ScGT-18 and ScN2aPK-1-18), was similar to that of uninfected controls. 
Together  these  results  suggest  that  autophagy  could  have  some  importance  in  PrP
Sc 
clearance and thereby cell viability. 
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Figure 5.5 Autophagy inhibition exacerbates cell death in prion-infected GT-1 cells 
RML-infected ScGT-1 and control uninfected GT-1 cells were treated with or without 10 mM 3-MA 
to inhibit autophagy. 3-MA significantly induces cell death in both uninfected (GT-1) and prion-
infected (ScGT-1) cells, however there is significantly more cell death observed in ScGT-1 cells 
compared to controls. In cells cured of prion infection (ScGT-1-18), by treatment with an anti-PrP 
antibody (ICSM18), cell death is restored to levels seen in uninfected (GT-1) cells. Values are 
expressed  as  percentage  LDH  release  relative  to  maximal  cell  death  obtained  from  lysing 
untreated  cells  with  1  % (v/v)  Triton  X-100.  Data  are  the  mean  +  SEM  of  eight  independent 
samples. ***P <0.001. This experiment was designed by myself, but was performed and analysed 
by Mrs Christine Butler-Cole, MRC Prion Unit, UCL Institute of Neurology. 
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Figure 5.6 Autophagy inhibition exacerbates cell death in prion-infected N2aPK-1 cells 
RML-infected ScN2aPK-1 and control uninfected N2aPK-1 cells were treated with or without 10 
mM 3-MA to inhibit autophagy. 3-MA significantly induces cell death in both uninfected (N2aPK-1) 
and prion-infected (ScN2aPK-1) cells, however there is significantly more cell death observed in 
ScN2aPK-1 cells compared to controls. In cells cured of prion infection (N2aPK-1-18), by treatment 
with an anti-PrP antibody (ICSM18), cell death is restored to levels seen in uninfected (N2aPK-1) 
cells. Values are expressed as percentage LDH release relative to maximal cell death obtained from 
lysing untreated cells with 1 % (v/v) Triton X-100. Data are the mean + SEM of >eight independent 
samples. ***P <0.001. This experiment was designed by myself, but was performed and analysed 
by Mrs Christine Butler-Cole, MRC Prion Unit, UCL Institute of Neurology. 
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5.2.5  Induction of autophagy clears PrP
Sc from prion-infected cells 
In vitro studies, by use of pharmacological means to induce or inhibit autophagy, 
have demonstrated that certain neurodegenerative disease-causing proteins are degraded 
by  autophagy  (Ravikumar  et  al.,  2002;  Webb  et  al.,  2003).  Furthermore,  the  tyrosine 
kinase  inhibitor  immatinib  has  been  shown  to  induce  the  cellular  clearance  of  prion-
infected  cells  from  PrP
Sc  by  activating  its  lysosomal  degradation  (Ertmer  et  al.,  2004; 
Ertmer et al., 2007). 
 
To test the role of autophagy on PrP
Sc clearance in prion-infected neuronal cells 
(ScGT-1 and ScN2aPK-1), they were induced for 24 h, by means of 0.2 M rapamycin 
treatment.  Following  this,  the  scrapie  cell  assay  (SCA)  was  used  to  calculate  the 
percentage of PrP
Sc-positive spots in the prion-infected (ScGT-1 and ScN2aPK-1) and in 
uninfected cells (GT-1 and N2aPK-1), which were used as negative controls. All cell lines 
were plated at 5000 cells per well in a 96 well plate. 
 
Rapamycin increased clearance of PrP
Sc in both ScN2aPK-1 and ScGT-1 cells (Figure 
5.7  A  and  B).  Rapamycin-treated  ScN2aPK-1  cells  had  50%  less  PrP
Sc-positive  spots 
compared  to  untreated  ScN2aPK-1  cells  (Figure  5.7  A).  ScGT-1  cells  treated  with 
rapamycin also showed a decrease in PrP
Sc-positive spot number (30% less than untreated 
ScGT-1) (Figure 5.7 B). These results suggest that inducing autophagy allows for some 
PrP
Sc clearance in prion-infected cells. 
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Figure 5.7 Induction of autophagy clears PrP
Sc from prion-infected cells 
RML prion-infected ScN2aPK-1 (A) or ScGT-1 (B) and were treated with 0.2 μM rapamycin for 24 h. 
PrP
Sc levels were measured by the SCA assay. 5000 cells were plated in individual wells of 96 well 
plates. Values are expressed as the number of PrP
Sc-positive cells compared to control (A-N2aPK-1 
and B-GT-1). Data are the mean + SEM of 8 independent samples. ***P <0.001 as compared to 
controls. These experiments were designed, performed and analysed by myself, apart from B which 
was  performed  and  analysed  by  Mrs  Christine  Butler-Cole,  MRC  Prion  Unit,  UCL  Institute  of 
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5.2.6  Up-regulation of LC3II in vivo in prion-infected mouse brain  
Levels of LC3II on a Western blot correspond to autophagosome numbers and can 
be used to assess autophagy flux (Tanida et al., 2005). Figure 5.1 shows that bafilomycin-
treated prion-infected cells have higher levels of LC3II compared to bafilomycin-treated 
uninfected controls, suggesting that prion infection results in an increased autophagy flux. 
In order to investigate whether this also occurred in vivo, LC3II levels were measured by 
Western blotting using an anti-LC3 antibody. Four FVB and four RML-infected FVB mouse 
brains (both groups at end-stage disease) were homogenised and run on SDS-PAGE. LC3II 
levels, which correlate with autophagosome numbers, were higher in RML-infected FVB 
mice compared to uninfected control mouse brains (Figure 5.8; arrow).     
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Up-regulation of LC3II in vivo in prion-infected FVB mouse brain 
FVB mice were inoculated with RML or control-infected CD-1 mouse homogenate and culled at 
end-stage clinical disease. Brain tissue was then homogenised and analysed for the presence of 
LC3II  by  immunoblotting using  an  anti-LC3  antibody  (1:1000;  Novus  Biologicals).  Image  shows 
results for four individual mice in each group and demonstrates that LC3II levels are increased in 
the brains of RML-prion-infected FVB mice (arrow). Levels of an endogenous mouse protein, -
actin, were assessed by immunoblotting to confirm equal protein loading. 
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5.3  Discussion 
Accumulation  of  misfolded  protein  deposits  in  affected  brain  regions  is  a 
characteristic  feature  of  many  neurodegenerative  diseases,  suggesting a  failure  in the 
cell’s degradative capacity. Experimental evidence suggests that neuronal death may be 
associated with UPS impairment, although whether this is a cause or consequence of 
neurodegeneration is still unclear. UPS impairment is thought to be important in prion 
disease (Ma and Lindquist, 2002; Ma et al., 2002; Kang et al., 2004; Kristiansen et al., 
2005), also evidenced by data presented in chapters 3 and 4 of this thesis. In contrast, the 
role, if any, of the alternative major protein degradation pathway, autophagy, in prion 
disease is still unclear as data to date are confined to a few electron-microscopy papers 
(Liberski et al., 1989; Liberski et al., 1992a; Liberski et al., 2005). Autophagosome-like 
structures have been described using EM (Kopnika  et al., 2008), however biochemical 
evidence  for  a  role  in  prion  pathogenesis  is  lacking.  The  aim  of  this  study  was  to 
investigate the role of autophagy in prion-mediated neurodegeneration by biochemical 
analysis. Results presented in this chapter indicate that autophagy, by measurement of 
LC3II  levels,  is  up-regulated  in  prion-infected  cells  and  in  vivo  at  end-stage  disease. 
Furthermore,  data  presented  here  show  that  interference  with  autophagy  by 
pharmacological induction or inhibition, alters levels of PrP
Sc and cell viability patterns in 
prion-infected cells where the UPS is inhibited. An up-regulation of three key Atg genes, 
which are required for autophagosome formation, was also demonstrated. 
Autophagy involves the delivery of cytoplasmic cargo randomly sequestered inside 
double-membraned  vesicles,  or  autophagosomes,  to  the  lysosome  (Figure  5.9).  Under 
normal  conditions,  autophagy  occurs  at  low  basal  levels  to  perform  homeostatic 
functions.  Autophagy  can  be  readily  enhanced  during  stress,  such  as  during  birth  or 
nutrient  starvation,  or  when  pharmacologically  manipulated  (Figure  5.9).  There  are 
various  methods  for  monitoring  autophagy  (Klionsky  et  al.,  2008),  however  as  the 
molecular mechanisms regulating this process are not fully understood at present, there 
are a number of limitations in interpreting results (Klionsky et al., 2008).  
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Figure 5.9 The cellular, molecular and physiological aspects of autophagy
15 
The cellular events during autophagy follow distinct stages: vesicle nucleation (formation of the 
isolation membrane/phagofore), vesicle elongation and completion (growth and closure), fusion of 
the double-membraned autophagosome with the lysosome to form an autolysosome, and lysis of 
the autophagosome inner membrane and breakdown of its contents inside the autolysosome. This 
process occurs at a basal level and is regulated by numerous different signalling pathways. Shown 
here  are  only  the  regulatory  pathways  that  have  been  targeted  pharmacologically  for 
experimental or clinical purposes. Inhibitors and activators of autophagy are shown in red and 
green, respectively. At the molecular level, Atg proteins form different complexes that function in 
distinct  stages  of  autophagy.  Shown  here  are  the  complexes  that  have  been  identified  in 
mammalian cells, with the exception of Atg13 and Atg17 that have only identified in yeast. Shown 
here are functions revealed by in vivo studies of mice that cannot undergo autophagy. 
                                                      
15 Reprinted from Cell, Vol 132, Levine, B., and Kroemer, G., Autophagy in the pathogenesis of disease, pp 
27-42, © 2008, with permission from Elsevier.  211 | P a g e  
 
For example, increased levels of the autophagosomal marker LC3II may reflect enhanced 
autophagosome formation due to a) increases in autophagic activity, or b) to reduced 
turnover  of  autophagosomes  by  fusion  with  lysosomes.  In  particular,  enhanced  LC3II 
levels are not a measure of autophagic flux per se, which includes the final step of cargo 
delivery to lysosomes. Autophagic flux is measured by analysing LC3II levels by Western 
blot (Tanida et al., 2005) in the absence of lysosomal  fusion and degradation. The use of 
bafilomycin, which prevents lysosomal degradation, and which resulted in enhanced LC3II 
levels in prion-infected cells, suggests that prion infection leads to increased autophagic 
flux.  In  sharp  contrast,  steady-state  measurement  of  autophagosome  formation,  by 
inferring LC3II levels in the absence of bafilomycin, showed less LC3II in prion-infected 
cells compared to uninfected controls. This infers that increased LC3II levels as a marker of 
increased  autophagic  flux  are  matched  by  increased  degradation  via  rapid  lysosomal 
turnover. Therefore, LC3II turnover in the presence of bafilomycin is more relevant when 
investigating the role of autophagy in any system (Klionsky et al., 2008).  
At present there are no ideal methods to monitor autophagic flux  in vivo or in 
organs.  Some  of  the  most  useful  methods  include  GFP-LC3  analysis,  morphological 
detection  of  autophagosomes  using  fluorescence  or  electron  microscopy,  and 
immunohistochemical staining, however in vivo analyses have proven relatively complex 
(Klionsky et al., 2008). Data here shows that there are enhanced LC3II levels in prion-
infected,  end-stage  mouse  brains,  indicating  increased  autophagosome  numbers.  To 
obtain  autophagy  flux  data  in  vivo  it  would  be  necessary  to  include  a  bafilomycin 
treatment regime. However, the ability of bafilomycin to cross the blood-brain barrier is 
still unknown. Furthermore, in order to obtain flux data a time course would also need to 
be included to follow changes in substrate accumulation (including LC3II). Such a time 
course would also test whether induction of autophagy is an early or late phenomenon in 
prion disease.  
Mild  proteasome  inhibition  in  prion-infected  neuronal  cells  leads  to  PrP
Sc-
aggresome formation, caspase 3 and 8 activation and subsequent apoptosis (Kristiansen 
et al., 2005). Experiments were carried out to determine whether inducing autophagy 
conferred neuroprotection in prion-infected cells when the proteasome is inhibited. Co-212 | P a g e  
 
treatment with rapamycin and the proteasome inhibitor lactacystin resulted in a partial 
rescue of cell death in prion-infected cells. Conversely, inhibition of autophagy by 3-MA 
exacerbated  cell  death.  These  results  suggest  that  autophagy  could  be  acting  as  a 
compensatory degradative mechanism when the UPS is impaired in prion-infected cells. 
Indeed, proteasome inhibition has been demonstrated to lead to the accumulation of 
various critical molecules that need to be tightly regulated, such as p53, and is toxic (Chen 
et al., 2005). In addition, global proteasome inhibition may lead to intra-cellular aggregate 
formation (Rideout et al., 2001). More recently it was shown that proteasome inhibition is 
toxic  to  Drosophila  eyes,  as  illustrated  by  retinal  degeneration,  and  that  this  can  be 
rescued by induction of autophagy, by means of rapamycin treatment or HDAC6 over-
expression (Pandey et al., 2007). HDAC6 is a microtubule- and dynein-associated protein; 
microtubules and dynein are both involved in autophagosome transport for lysosomal 
delivery  (Rubinsztein,  2006).  Pandey  et  al.  suggested  that  HDAC6  is  an  essential  link 
between the two degradation pathways, rescuing toxicity caused by UPS inhibition by 
providing  an  alternative  route  for  substrate  clearance  (autophagy).  Further  work  is 
needed in the prion cell model used here to elucidate whether HDAC6 also functions as a 
mechanistic link between prion-induced proteasome inhibition and an up-regulation of 
autophagy, leading to the partial rescue of the deleterious phenotype. Data presented in 
this  chapter  are  also  in  agreement  with  studies  in  other  neurodegenerative  diseases 
characterised  by  the  accumulation  of  aggregation-prone  proteins,  in  which  rapamycin 
treatment has been shown to attenuate toxicity (Ravikumar et al., 2002; Webb et al., 
2003; Ravikumar et al., 2004; Berger et al., 2006). Rapamycin may therefore be beneficial 
in  prion  disease  and  could  be  used  as  a  potential  therapeutic.  Indeed,  a  rapamycin 
analogue, CCI-779, has been shown to improve performance in various behavioural tasks 
and decrease aggregate formation in a mouse model of HD (Ravikumar et al., 2004).  
Stimulation  of  autophagy  resulted  in  some  clearance  of  PrP
Sc  in  prion-infected 
neuronal  cell  lines.  This  result  suggests  that  PrP
Sc,  is  at  least  in  part,  degraded  by 
autophagy. This is in agreement with previously published studies, where the use of the 
tyrosine kinase inhibitor immatinib, which was subsequently shown to be an inducer of 
autophagy, activated the lysosomal degradation of PrP
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and dose-dependent manner (Ertmer et al., 2004). Prion-infected GT-1 (ScGT-1) and N2a 
(ScN2a) cells were both almost equally sensitive to the autophagy inducer, with PrP
Sc 
levels undetectable following 3 days of immatinib treatment (Ertmer et al., 2004). The 
current data confirm these observations in that an inducer of autophagy results in PrP
Sc 
clearance.  However,  the  data  presented  here  indicate  that  prion-infected  N2aPK-1 
(ScN2aPK-1) and GT-1 (ScGT-1) cells display slightly different sensitivities to the autophagy 
inducer rapamycin in terms of the amount of PrP
Sc cleared. This could be due to signalling 
differences  between  the  two  cell  lines,  as  well  as  due  to  differences  in  protein 
composition in either cell line. However, there are several other possible explanations for 
this. First, this study used a different autophagy inducer, namely rapamycin instead of 
immatinib. Rapamycin acts by inactivating the mTOR (Noda and Ohsumi, 1998), which 
normally inhibits autophagy, and although the details of this regulatory mechanism are 
still unclear, the mode of autophagy induction is different to that of immatinib (Ertmer et 
al.,  2007).  Second,  the  method  of  quantification  of  PrP
Sc  levels  in  the  previous  study 
depended on Western blot analysis for PK-resistant PrP, whereas in this study the much 
more sensitive SCA was used (Klohn et al., 2003). This may be the reason why the present 
data shows clearance of PrP
Sc in cells in as little as 24 h post-autophagy induction, as 
compared to day 2 of drug treatment. Finally, the differences can also be attributed to the 
cell lines used, for example Ertmer et al. used N2a cells, whereas this study used N2aPK-1 
cells, which propagate prions more readily.   
Autophagy  induction  is  sometimes  accompanied  by  enhanced  mRNA  levels  of 
some autophagy genes, such as Atg12L (Kouroku et al., 2007). The present study showed 
that three key Atg genes, beclin1, Atg12L and Atg16L, were significantly up-regulated in 
prion-infected  cells  when  the  proteasome  was  inhibited.  This  finding  supports  the 
experiments described above, and further suggests that autophagy could be induced as a 
compensatory  mechanism  when  the  proteasome  is  inhibited.  However,  it  is  not  clear 
whether changes in mRNA transcripts are sufficient to induce autophagy, and therefore 
such measurements alone are not sufficient. Additional follow-up of protein levels would 
be necessary, as that is the definitive readout with respect to initiation and completion of 
autophagy (Klionsky et al., 2008).  214 | P a g e  
 
Autophagy  probably  acts  to  clear  monomeric  and
  oligomeric  precursors  of 
aggregates, rather than the aggregates
 themselves. In support of this, no study has yet 
reported inclusions that
 are membrane-bound and the size of inclusions is often much 
larger  than  mammalian
  autophagosomes  (Rubinsztein  et  al.,  2005).  Chapters  3  and  4 
suggest that small, oligomeric -sheet-rich PrP isoforms inhibit the proteolytic activities of 
the  26S  proteasome  by  blocking  gate-opening  in  the  20S  particle  and  subsequent 
substrate accessibility. Furthermore, the most infectious PrP molecules has been shown to 
have very small masses (14-28) (Silveira et al., 2005; Simoneau et al., 2007). Therefore, 
further work is required to elucidate whether induction of autophagy in prion disease 
allows  for  the  partial  rescue  of  the  deleterious  phenotype  (conferred  by  proteasome 
inhibition)  (Kristiansen  et  al.,  2005)  by  clearing  PrP
Sc-aggresomes  themselves,  or  by 
clearing small oligomeric precursors of PrP
Sc. This could be achieved by treating cells with 
rapamycin  or  3-MA,  after  treatment  with  proteasome  inhibitors,  and  conducting 
immunofluorescence studies to check for alterations in the presence of PrP
Sc-aggresomes. 
If autophagy is neuroprotective by clearing PrP
Sc-aggresomes themselves, then rapamycin 
treatment should reduce their number. On the other hand, if inhibition of autophagy 
results in increased numbers of PrP
Sc-aggresomes, then this would suggest that normally 
autophagy could be clearing some of the small PrP precursors that are sequestered into 
PrP
Sc-aggresomes. Under normal circumstances autophagy could be reducing the amount 
of PrP precursors available for the formation of PrP
Sc-aggresomes and thereby conferring 
some level of neuroprotection.  
  The  key  questions  concerning  autophagy  in  neurodegenerative  disease  remain 
unanswered. It remains unclear as to whether autophagosome numbers increase due to 
enhanced  autophagy  or  decreased  autophagosome  clearance,  and  of  course  whether 
autophagy is beneficial or not. These questions will most probably be answered when the 
molecular aspects of mammalian autophagy are better understood, which would provide 
valuable tools in answering these questions in prion disease and other clinical conditions 
characterised by protein misfolding. 
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5.4  Summary 
Results presented in this chapter show that autophagosome numbers appear to 
increase in prion-infected cells. Furthermore, induction of autophagy by use of rapamycin 
is able to rescue cells from the deleterious effects of proteasome inhibition, implying a 
degree  of  compensation  between  the  two  protein  degradation  pathways.  Moreover, 
transcripts  of  markers  of  early  autophagosome  formation,  including  the  tumour-
suppressor  gene  beclin1  and  components  of  the  Atg12-Atg5-Atg16L  ubiquitin-like 
conjugation system are rapidly up-regulated in prion-infected neuronal cells, and levels of 
LC3II, a membrane marker of mature autophagosomes, are similarly elevated. Induction of 
autophagy is able to clear cellular PrP
Sc from infected cells. Finally, it was also shown that 
autophagosome formation is elevated in vivo at end-stage prion disease. Taken together, 
these data demonstrate that autophagy is up-regulated in prion disease and suggest a 
mechanistic insight into interactions between the major protein degradation pathways 
during prion-mediated cellular neurotoxicity.    
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6  CONCLUSIONS AND FUTURE WORK 
6.1  Thesis summary and conclusions 
The work presented in this thesis aimed to investigate the cellular mechanisms 
involved in prion-mediated neurodegeneration. Specifically, it aimed to define the role of 
the two major degradation systems, namely the UPS and autophagy, in prion disease 
pathogenesis. Studies have previously suggested a role for the UPS in prion disease (Ma et 
al., 2002; Kang et al., 2004; Kristiansen et al., 2005), whereas the role of autophagy in 
prion disease pathogenesis is not well characterised. 
Work presented here indicates that -sheet-rich PrP molecules specifically inhibit 
the proteolytic  subunits of the 26S proteasome via a novel inhibitory effect on gate-
opening and subsequent substrate entry into the 20S proteolytic core. This effect was 
demonstrated in purified proteasome incubated with recombinant -sheet-rich PrP and 
with  semi-purified  PrP
Sc  (from  prion-infected  cells  and/or  mouse  brain),  as  well  as  in 
scrapie-infected cell lines. The inhibitory effect was only seen when PrP was in a non-
native, -sheet conformation, as other amyloidogenic proteins and recombinant -helix-
dominant PrP were not inhibitory. Only aggregated -sheet-rich PrP directly binds to the 
20S  proteasome,  but  not  aggregated  -helix-dominant  PrP,  further  suggesting  the 
inhibitory effect depends on conformation. Pre-incubation with an antibody raised against 
aggregation intermediates abrogated the inhibitory effect, consistent with an oligomeric 
species  mediating  this  effect.  Indeed,  assaying  various  molar  concentrations  of 
aggregated,  recombinant  -sheet-rich  PrP,  where  calculations  are  based  on  the 
monomeric protein, show that half-maximal inhibition of the proteasome occurs when 
there are 10 to 20 PrP molecules present. Inhibition of the proteasome so that it can no 
longer  degrade  proteins,  such  as  casein  and  IB  shown  here,  indicates  functional 
impairment of the UPS. Therefore, considering the wide range of physiological functions 
the UPS is involved in, UPS inhibition can be deleterious. A direct relationship between 
prion  neuropathology  and  UPS  impairment  was  demonstrated  in  scrapie-infected 
proteasome-reporter mice. Autophagy was also shown to be induced in prion disease, 217 | P a g e  
 
both  in  vitro  and  in  vivo,  and  to  ameliorate  cell  death  associated  with  proteasome 
inhibition  by  clearing  some  PrP
Sc,  suggesting  it  acts  as  a  compensatory  mechanism 
following UPS inhibition.  
  The pathogenesis of prion disease  is  likely  to be  multifactorial, but the potent 
inhibition  of  the  proteasome  by  pathogenic  PrP,  by  blocking  gate-opening  in  the  20S 
particle,  is  likely  to  result  in  neuronal  perturbation  and  contribute  to  the  widespread 
neuronal loss. Data presented here also help explain how cytosolic PrP
c may accumulate in 
the cytosol, with UPS inhibition leading to cytosolic accumulation of PrP
C destined for 
ERAD (Ma and Lindquist, 2002). Impairment of the UPS leads to cellular dysfunction and 
apoptosis  through  various  mechanisms  (Goldberg,  2003).  Induction  of  autophagy  may 
help clear some disease-related PrP, and by doing so will slightly decrease UPS burden and 
ameliorate the deleterious phenotype linked to proteasome inhibition. However, the key 
feature of prion disease, the autocatalytic conversion of PrP
C to PrP
Sc, will form a positive 
feedback loop by inhibiting the UPS, thereby further reducing the rate of clearance of 
PrP
Sc and thus stimulating the formation of more PrP
Sc, until the levels of proteasome 
function are too low for cell survival. A key question that arises is whether the findings 
described  here  are  relevant  to  other  neurodegenerative  diseases  where  protein 
misfolding occurs, or a unique property to prion diseases.  
6.2  Suggestions for future work 
6.2.1  Development of model cell system to study PrP
Sc trafficking 
At present, cellular PrP
Sc trafficking is poorly understood, as studies are hindered by 
the lack of PrP
Sc-specific antibodies. Research suggests PrP
Sc localisation at the plasma 
membrane and in the endolysosomal compartment (Caughey and Raymond, 1991; Arnold 
et  al.,  1995),  whereas  the  site  of  conversion  of  PrP
C  to  PrP
Sc  remains  controversial 
(Campana et al., 2005). Once PrP
Sc is formed, it has been shown to accumulate on the cell 
surface, lysosomes and autophagosomes (Caughey and Baron, 2006). The work presented 
in  this  thesis  indicates  that  aggregated,  -sheet-rich  PrP  molecules  inhibit  the  UPS. 
However, it is unclear how PrP
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Studies with WT and mutant PrP
C forms have suggested that it is retro-translocated from 
the  ER  (Ma  and  Lindquist,  2001;  Yedidia  et  al.,  2001).  Another  possibility  comprises 
destabilisation of endolysosomal membranes and leakage into the cytosol, as shown for 
A1-42 (Ji et al., 2006). The accumulation of PrP
Sc in the endolysosomal system could be 
causing UPS dysfunction and imposing an increased burden on the degradative pathway. 
To  answer  many  of  these  questions  and  try  to  establish  the  exact  details  of  PrP
Sc 
trafficking, PrP
C could be tagged with a GFP construct. Although this method would, in 
principle,  allow  for  tracking  the  formation  of  newly-converted  PrP
Sc  and  its  cellular 
trafficking, the major drawback however, is the size of the GFP tag. It is quite possible that 
the attachment of such a big protein, approximately 28 kDa, to PrP
C will probably block 
the  conversion  of  PrP
C  to  PrP
Sc.  Indeed,  several  groups  have  failed  to  demonstrate 
successful prion propagation using GFP-PrP
C constructs (Negro et al., 2001; Ivanova et al., 
2001; Lee et al., 2001b; Lorenz et al., 2002; Hachiya et al., 2004). Conversely, Bian et al. 
have been able to show compromised prion replication in transgenic mice using GFP-
tagged PrP, but with the mice manifesting atypical neuropathology and increased disease 
onset,  and  the  tagged  PrP  lacking  the  full  spectrum  of  PrP
Sc-associated  biochemical 
properties (Bian et al., 2006). Therefore, alternative detection methods, such as by use of 
c-myc or FLAG tags, would be the preferential means by which to study prion protein 
trafficking. In fact, FLAG-tagged PrP constructs have been successfully used in transgenic 
mice in the past, without loss of prion propagation (Telling et al., 1997). Accordingly, the 
expression of a c-myc- or FLAG-tagged PrP construct in KO neuroblastoma cells, alongside 
the use of anti c-myc or anti-FLAG antibodies, can track de novo PrP
Sc production. Once 
this system is established, antibodies to various cellular compartments can be used to 
define PrP
Sc localisation and trafficking. Furthermore, a time-course study may also be 
undertaken to track intracellular PrP
Sc at serial time-points following UPS inhibition (by 
low  dose  of  proteasome  inhibitor)  to  assess  its  route  into  the  cytosol  to  form  PrP
Sc 
aggresomes (Kristiansen et al., 2005).  219 | P a g e  
 
6.2.2  Development of a human cell model to study the UPS in the context of 
human prion disease 
Cell models of prion disease are in principle good systems in which to study and 
analyse prion propagation as well as potential therapeutic targets. Such models are now 
as  sensitive  as  bioassays  and  can  replace  the  latter  in  some  instances  (Bosque  and 
Prusiner,  2000;  Klohn  et  al.,  2003).  Nonetheless,  research  into  PrP
Sc  cell  biology  is 
hindered by the sparse number of cell lines able to propagate PrP
Sc. Prion-propagating cell 
lines to date include rat PC12 cells (Rubenstein et al., 1984), murine N2a cells (Butler et 
al., 1988) and murine GT-1 cells (Schatzl et al., 1997) and these are susceptible to mouse- 
adapted,  hamster-adapted,  or  sheep  scrapie  strains.  However,  at  present  there  is  no 
known cell line documented to propagate human prions. The development of such a cell 
line, particularly of neuronal origin, is critical to facilitate studies on the pathophysiology 
of human prion diseases, which currently rely on the use of transgenic mice. The use of 
animal  models  is  both  time-consuming  (incubation  time  of  prion  disease)  and  costly. 
Furthermore, mouse models do not always represent the optimal system, for example 
when  studying  mechanisms  at  the  molecular  and  cellular  level.  One  possible  way  to 
propagate human prions into cells would be to use a human neural stem cell line. Stem 
cells  from  human  foetal  ventral  mesencephalon  are  available  from  ReNeuron,  and 
following growth factor removal, they can be differentiated into mature human neurones. 
These  cells  express  high  levels  of  PrP
C  and  are  129MM,  which  is  the  PRNP  genotype 
associated with vCJD. Therefore, vCJD infection of these cells at various stages of their 
differentiation could lead to the propagation of human prions  in vitro. Such a human 
neuronal model can be used to study the pathobiology of human prion disease, including 
PrP
Sc accumulation, and also to screen prion therapeutics. Furthermore, these cells could 
be stably transfected with the Ub
G76V-GFP UPS reporter substrate (chapter 3) at the stem 
cell stage. Following their differentiation and subsequent prion-infection, levels of the UPS 
reporter could be directly assessed to ascertain its accumulation and whether there is 
progressive UPS dysfunction. This could potentially allow for understanding the temporal 
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This human cell system could also be used to define the temporal relationship 
between UPS function and ER stress in human prion disease. ER stress has been implicated 
in prion disease pathogenesis, but it is not yet know whether it is primary or secondary to 
UPS dysfunction (Hetz et al., 2003; Hetz et al., 2007). Studies have linked UPS impairment 
with ER stress, showing it has a general inhibitory effect on UPS function (Menendez-
Benito et al., 2005). Alternatively, work presented here suggests that UPS impairment, as 
a result of prion infection, may result in the accumulation of misfolded proteins in the ER, 
which  would  otherwise  be  degraded  by  ERAD,  and  result  in  ER  stress.  Constant  and 
increased routing of PrP through ERAD may thus contribute to neurodegeneration in prion 
disease. This raises two hypotheses: 1) accumulation of PrP
Sc may lead to ER stress and 
reduced  translocation  of  nascent  PrP  into  the  ER  lumen;  2)  at  least  a  subset  of  the 
neurodegenerative sequelae of prion infection may be directly inducible, even when PrP
Sc 
or misfolded PrP aggregates are absent, just by changing the PrP
C metabolism to that 
occurring  during  chronic  ER  stress.  Interestingly,  evidence  of  ER  stress  and  decreased 
translocation of native PrP to the ER during prion infection was recently presented (Rane 
et al., 2008). Furthermore, the authors showed that the expression of a mutant PrP (with 
reduced  translocation  at  levels  expected  during  ER  stress)  in  transgenic  mice  was 
sufficient  to  cause  various  mild,  age-dependent  manifestations  of  PrP-mediated 
neurodegeneration, and thereby provided a link between PrP
Sc-induced ER stress with 
neuronal cell death.  
6.2.3  In vivo time-course pathogenesis study in UPS reporter transgenic mice 
Results  presented  in  this  thesis  show  that  the  proteolytic  activities  of  the  26S 
proteasome are significantly inhibited in  prion-infected cells and prion-infected mouse 
brain. However, the mice used to study UPS inhibition were culled at the end-stage of 
prion disease. Therefore, from these experiments alone it is unclear whether in vivo UPS 
inhibition is an early or late phenomenon. Hence, in addition to the human cell model 
described  above,  an  in  vivo  pathogenesis  study  using  the  Ub
G76V-GFP  UPS  reporter 
construct would also help clarifying the temporal and spatial relationship between UPS 
dysfunction  and    prion  disease  pathogenesis.  Such  an  experiment,  where  Ub
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expressing transgenic mice are culled at different time points following prion infection, 
would  provide  information  as  to  how  critical  UPS  dysfunction  is  to  the  neuronal  loss 
associated  with  prion  disease.  Various  experimental  techniques,  such  as 
immunohistochemistry, Western blotting, RT-PCR and co-immunoprecipitation, could be 
used to assess different aspects of prion neurobiology and the role of degradation systems 
(UPS and autophagy) in prion pathogenesis.   
The  ubiquitosome,  a  marker  of  early  proteasome  dysfunction,  should  also  be 
investigated by looking at the accumulation of lys 48-linked ubiquitinated peptides in the 
UPS  reporter  mice  and in  WT  mice,  again by  culling  at  serial time  points.  Most  poly-
ubiquitinated substrates targeted for proteasomal degradation are lys 48-linked (Pickart 
and Fushman, 2004), and thus their steady-state cellular levels should reflect proteasome 
function. Recently, Bennett et al. exploited a mass-spectrometry method to quantify poly-
ubiquitin chains (Kirkpatrick et al., 2006) and demonstrated that the abundance of these 
chains is a faithful endogenous biomarker of UPS function  (Bennett et al., 2007). The 
authors found that lys 48-linked poly-ubiquitin chains accumulate early in pathogenesis in 
brains from transgenic mouse models of HD and from human HD patients, establishing 
UPS dysfunction as a consistent feature of HD pathology. Therefore, this method, both in 
prion-infected WT and UPS reporter transgenic mice, should allow for an evaluation of the 
function of the UPS in prion disease. 
Recently Wang et al. used adenoviral fluorescent reporters to measure synaptic 
UPS activity in vitro and in vivo and observed a significant decrease in synaptic UPS activity 
in  HD  mice  (Wang  et  al.,  2008).  Therefore,  these  reporters  can  serve  as  a  tool  for 
measuring  the  function  of  the  synaptic  UPS  and  its  regulation  under  physiological  or 
pathological  conditions.  Synaptic  dysfunction  is  well  documented  in  other 
neurodegenerative  diseases  such  as  AD  and  PD  (Klyubin  et  al.,  2005),  where  UPS 
impairment is also thought to be involved (Ross and Pickart, 2004). Earlier studies and 
work  presented  in  this  thesis  suggest  that  UPS  impairment  may  be  involved  in  prion 
disease pathogenesis. Specifically, total lysates from prion-infected mouse brain showed 
reduced  proteolytic  activities  compared  to  uninfected  controls.  Considering  the 
localisation of PrP
C as a GPI-anchored protein and its putative role in cellular signalling, as 222 | P a g e  
 
well  as  the  possibility  that  the  site  of  conversion  of  PrP
C  to  PrP
Sc  is  at  the  plasma 
membrane (Caughey and Baron, 2006), it would be interesting to investigate whether 
misfolded PrP can affect synaptic UPS function in prion disease. This could be done by 
comparing UPS proteolytic activities of synapses with those in total lysates.  
6.2.4  Defining cross-talk between UPS and autophagy in prion disease 
The UPS and autophagy have been viewed as independent, parallel degradation 
systems with no point of intersection. However, increasing evidence now suggests that 
these two pathways are functionally interrelated (Rideout et al., 2001; Iwata et al., 2005b; 
Pandey et al., 2007) and demonstrate co-ordinated, occasionally compensatory, function. 
Furthermore, in contrast to the notion that the UPS degrades short-lived proteins whereas 
autophagy  degrades  long-lived  polypepides,  studies  have  demonstrated  that  some 
proteins may be degraded by either pathway (Webb et al., 2003; Fuertes et al., 2003a; 
Fuertes et al., 2003b; Li, 2006). Links between the two systems have also been illustrated 
in  studies  of  the  Atg5  and  Atg7  KO  mice,  as  they  display  neurodegeneration  with 
ubiquitin-positive pathology (Komatsu et al., 2006; Hara et al., 2006).  
Following UPS inhibition, either by accumulation of misfolded proteins or use of 
pharmacological inhibitors, ubiquitinated, misfolded proteins are actively transported to 
aggresomes  (Johnston  et  al.,  1998).  At  present,  evidence  indicates  that  clearance  of 
misfolded proteins from aggresomes is mediated at least in part by autophagy, suggesting 
that autophagy may act as a compensatory mechanism for degrading misfolded proteins 
when the proteasome is impaired (Taylor et al., 2003; Iwata et al., 2005a; Iwata et al., 
2005b; Yamamoto et al., 2006). Work presented here shows that in prion-infected mouse 
cells,  induction  of  autophagy  ameliorates  the  deleterious  effects  caused  by  the 
proteasome  inhibitor  lactacystin.  Indeed,  induction  of  autophagy  following  UPS 
impairment appears to be cytoprotective since degenerative phenotypes associated with 
proteasome  impairment  in  Drosophila  are  enhanced  in  an  autophagy-deficient 
background,  but  suppressed  when  autophagy  is  induced  by  means  of  rapamycin 
treatment (Pandey et al., 2007). Recently, pre-treatment of PC12 cells with rapamycin 
showed that it attenuates lactacystin-induced apoptosis and reduces lactacystin-induced 223 | P a g e  
 
ubiquitinated protein aggregation (Pan et al., 2008). Therefore, induction of autophagy 
may be a compensatory mechanism for PrP
Sc clearance when the proteasome is impaired. 
In agreement with other studies (Ertmer et al., 2004), induction of autophagy resulted in 
some PrP
Sc clearance in prion-infected neuronal cells, suggesting this pathway is involved 
in PrP
Sc degradation.  
However, at present there are difficulties in the use and interpretation of assays to 
monitor autophagy (Klionsky et al., 2008) making it hard to define whether induction of 
autophagy has a role in prion pathogenesis, and whether it is associated with enhanced 
autophagic flux or delayed autophagosome clearance. Furthermore, the mechanism by 
which autophagy and UPS are co-ordinated is unclear, but there are several regulators 
that are thought to be key players in mediating this cross-talk and include: HDAC6 (Iwata 
et  al.,  2005b;  Pandey  et  al.,  2007),  p62  (Bjorkoy  et  al.,  2005)  and  the  FYVE-domain 
containing protein Alfy (Simonsen et al., 2004). Future experiments to establish whether 
there is an increase in autophagy flux in prion disease should include: monitoring the 
turnover  of  long-lived  proteins  and  use  of  a  GFP-LC3  construct  to  assess  lysosomal 
delivery and proteolysis (to generate free GFP). Furthermore, cross-talk between the UPS 
and autophagy in prion disease should also be investigated. One possibility would be to 
assess p62 levels, as it has been shown to serve as a link between LC3 and ubiquitinated 
substrates  (Bjorkoy  et  al.,  2005)  when  it  becomes  incorporated  into  the  completed 
autophagosome  and  degraded  in  autolysosomes  (Mizushima  and  Yoshimori,  2007). 
Recently,  it  was  demonstrated  that  inhibition  of  autophagy  correlates  with  increased 
levels of p62, implying that steady state levels of this protein reflect the autophagic status 
(Wang et al., 2006; Komatsu et al., 2007). Additional evidence for UPS/autophagy cross-
talk in prion disease could be obtained by assessing the role of HDAC6. HDAC6 activity is 
thought to be important for trafficking ubiquitinated proteins and lysosomes, proposing 
that it co-ordinates substrate delivery to the autophagic machinery (Iwata et al., 2005b; 
Pandey et al., 2007). Specifically, HDAC6 over-expression in Drosophila  has been shown to 
suppress  degeneration  associated  with  UPS  dysfunction  and  caused  by  toxic  polyQ 
expression (Pandey et al., 2007). Investigating the role of autophagy in the pathogenesis 224 | P a g e  
 
of human prion disease may have therapeutic implications as modulators of autophagy 
are already in clinical trials for human cancers.  
6.2.5  Site of PrP binding on the 20S core particle 
As evidenced here (chapter 4), aggregated -sheet-rich PrP co-immunoprecipitates 
with the 20S proteasome, indicating a direct binding interaction between the two. The 
disease-related  PrP  isoform  inhibits  the  UPS  by  blocking  gate-opening  and  substrate 
accessibility in the 20S proteasome (chapter 4). The aggregated -sheet-rich PrP species 
inhibited the WT yeast 20S proteasome, but not the open-gated 20S mutant (3N), and 
abrogated the ability of a synthetic octamer from the C-terminus of the 19S ATPase Rpt5 
to mediate 20S activation. Taken together, these results suggest that these PrP species 
inhibit the 20S at the level of the gate. However, the exact binding location of the C-
termini of the 19S ATPases is unknown, and therefore it is not clear if the aggregated -
sheet-rich  PrP  species  bind  to  the  same  inter-subunit  pocket  as  the  ATPases  or  to  a 
different location on the 20S particle to exert their inhibitory effect. This could be further 
investigated  using  an  EM  approach  and/or  chemical  cross-linking.  Specifically,  single-
particle cryo-EM would be very useful in elucidating the exact binding location, and could 
also provide some structural information on the inhibitory species itself, studies on which 
are currently hindered due to its highly aggregated nature. The other possible way to 
investigate where -sheet-rich PrP binds on the 20S is to use a cross-linker to bind the PrP 
and the 20S. Recently, a study using gluteraldehyde to cross-link various 20S subunits 
demonstrated  the  existence  of  a  previously  poorly  described  unit  within  the  20S, 
comprising non-ATPases Rpn1 and Rpn2 (Rosenzweig et al., 2008). The authors used mass 
spectroscopy, amino acid sequencing, and AFM to elucidate the binding locations of their 
cross-linked subunits on the 20S proteasome and established that both Rpn1-Rpn2 and 
the ATPases of the 19S appear to be required for substrate translocation and gating of the 
proteolytic channel. Such methods should also be used to define the precise location of 
the -sheet-rich PrP species on the 20S.   225 | P a g e  
 
6.2.6  Effect of other oligomeric proteins on the activity of the proteasome 
The  ability  of  aggregated,  oligomeric  -sheet-rich  PrP  isoforms  to  block  gate-
opening and substrate entry into the proteasome (chapter 4) may have relevance to other 
neurodegenerative  diseases  where  there  is  an  accumulation  of  misfolded  -sheet-rich 
proteins  and  impairment  of  protein  degradation  by  the  UPS.  Therefore,  it  will  be 
interesting  to  investigate  whether  such  -sheet-rich  proteins  associated  with  other 
neurodegenerative diseases, such as AD and PD, can also inhibit the UPS. The species used 
here (chapter 3) did not inhibit the proteasome, most probably because they were in a 
fibrillar  form.  There  is  growing  evidence  in  several  protein-misfolding  disorders  that 
soluble protein aggregates, rather than large insoluble aggregates, are the toxic species  
causing  neurodegenerative  disease  (Caughey  and  Lansbury,  2003;  Haass  and  Selkoe, 
2007). For example, in AD, A40 and A42 are particularly toxic to cells when they are in 
the form of small oligomers at the early stage of peptide aggregation before they form A 
fibrils  (Hardy  and  Selkoe,  2002).  Given  that  oligomeric,  -sheet-rich  PrP  isoforms  are 
potent inhibitors of the proteolytic activity of the 20S proteasome, the effect of other 
aggregate-prone proteins in an oligomeric state on the function of the UPS should also be 
assessed. This would help understand whether the effects seen here are unique to prion 
disease.  
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